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Abstract 
Heterotaxy is a congenital disorder that occurs due to the defective establishment of the left-right (L-
R) body axis during early embryo development. The disorder affects 1/10,000 live births, results in the 
abnormal alignment of internal organs with respect to the L-R axis, and is often accompanied by severe 
cardiac malformations. The most commonly mutated gene in human cases of Heterotaxy is the X-
linked ZIC3, which was first associated with the condition in 1997. ZIC3 belongs to a family of 
multifunctional transcriptional regulator proteins (ZIC family) all characterised by a C2H2 type zinc 
finger domain (ZFD). This domain is implicated in the transactivation (DNA binding) and co-factor 
(protein binding) function of the proteins. However, despite both capabilities, it is still not known 
when during development the co-factor role of ZIC3 is necessary over the transcription factor role. 
Consequently, the exact cellular and molecular causes underlying ZIC3-associated Heterotaxy remain 
unknown.  
Mouse models of Zic3 loss-of-function reveal phenotypes that resemble human Heterotaxy and 
exhibit a defective node (the structure that confers the left-right axis during development). More 
recently, studies have shown murine Zic3 alleles lead to incompletely penetrant, partial (posterior) 
axis duplications and anterior truncation, phenotypes characteristic of elevated canonical Wnt 
signalling. The expression pattern of Zic3 during mammalian gastrulation overlaps with a known 
repressor of the canonical Wnt pathway, Tcf7l1 and it has also been shown that a related ZIC protein 
(ZIC2) can interact with TCF proteins to co-repress Wnt/β-catenin mediated transcription when 
overexpressed in cell lines. Overall, this leads to the novel hypothesis that ZIC3 controls the 
establishment of the L-R axis by interacting with TCF7L1 to repress Wnt signalling during mammalian 
gastrulation. In this thesis I examine the molecular role of ZIC3 in the Wnt pathway and investigate 
the functional consequences of ZIC3 Heterotaxy-associated protein variants.  
A physical interaction between ZIC3 and TCF7L1 was demonstrated by several molecular assays. 
Additionally, 17 Heterotaxy-associated human ZIC3 variants were functionally assessed in well-
established cell-based assays. Four of the human protein variants exhibit non-pathogenic properties 
as they retain wildtype ZIC3 function in these assays. The remaining variants, which affect key residues 
within the ZFD or contain a premature termination codon, display impaired transcription factor and 
co-factor functions: they can no longer activate transcription at a ZIC responsive element and have 
reduced ability to inhibit β-catenin-mediated Wnt transcription. Loss of Wnt inhibition did not always 
correlate with loss of TCF7L1 interaction, suggesting ZIC3 and/or TCF7L1 must interact with additional 
co-repressors or repressive chromatin complexes to mediate transcriptional repression in the Wnt 
pathway. Additionally, in this thesis I identified several evolutionary conserved domains implicated in 
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transactivation, including the newly annotated SANC and SACC domains, enhancing our understanding 
of the structural domains required for ZIC3 molecular function. Overall, this thesis supports a new 
model of ZIC3 molecular function: ZIC3 interacts with TCF7L1 to inhibit canonical Wnt signalling during 
mammalian gastrulation and correctly establish the L-R axis. Ultimately, ZIC3-associated Heterotaxy 
arises when ZIC3 is unable to function as a Wnt co-repressor.  
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Chapter 1: Introduction 
This chapter contains text and figures from the paper Diamand, K.E.M., Barratt, K.S. & Arkell, R.M 
(2017) Chapter 10: Overview of rodent Zic genes, “Zic family - Evolution, Development and Disease”, 
Springer 
1.1 Heterotaxy 
The exterior of the vertebrate body plan is bilaterally symmetrical, with a mirror image along the 
sagittal plane of the body that creates an identical left and right. Interiorly, however, some organs are 
placed in a specific, yet asymmetrical, position along the left-right (L-R) axis of the body. For example, 
organs such as the heart, spleen and pancreas are situated on the left of the body, while the liver and 
gallbladder are positioned along the right. Paired organs such as the lungs also demonstrate 
asymmetries, for example, the right lung has three lobes, whilst the left has two. This normal 
organisation of the internal organs is called situs solitus (Figure 1.1) and arises because of an initial 
symmetry-breaking event during early embryogenesis, which subsequently allows the development 
of a distinct left and right. Failure to establish the correct L-R axis results in laterality disorders and 
severe congenital defects. Complete reversal of the L-R axis is termed situs inversus, characterised by 
a mirror image of the internal asymmetries. Although, as the organs are still in a functional 
arrangement with respect to each other, situs inversus is not normally associated with developmental 
disorders. Heterotaxy, otherwise known as situs ambiguous, falls somewhere between situs solitus 
and situs inversus as it defines the abnormal positioning of the thoraco-abdominal organs along the L-
R body axis (Figure 1.1). Heterotaxy can be further divided into subgroups based on the type of 
symmetry (right isomerism vs left isomerism) or on spleen status (polysplenia vs asplenia) 
(Bellchambers and Ware 2018), all of which can cause a wide range of congenital malformations (Zhu 
et al. 2006; Sutherland and Ware 2009).  
Heterotaxy is associated with severe and complex cardiovascular disorders, leading to considerable 
morbidity and mortality, which can be amplified by issues with the pulmonary, gastrointestinal and 
genitourinary systems (Zhu et al. 2006; Catana and Apostu 2017). Approximately 3% of congenital 
heart diseases are attributable to Heterotaxy, which has an overall prevalence of 1/10,000 live births. 
This may, however, be subject to underestimation and underdiagnoses due to the embryonic lethality, 
variable expressivity and incomplete penetrance associated with the disorder (Lin et al. 2000; Belmont 
et al. 2004). Several genes have been associated with human cases of Heterotaxy including NODAL, 
CFC1, CRELD1, FOXH1, SESSNI, LEFTYA, GDF1, ACV2B and NKX2.5 (Sutherland and Ware 2009; 
Bellchambers and Ware 2018), however, the gene most commonly mutated in human patients is  
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Figure 1.1: Comparison of organ arrangement in Heterotaxy. The normal arrangement of visceral 
organs is termed situs solitus, where organs such as the heart, stomach and spleen are on the left, and 
the liver on the right. Heterotaxy (also known as situs ambiguous) occurs when the heart and visceral 
organs are oriented independently of one another. Situs inversus describes the complete mirror image 
of internal organs from normal arrangement. Figure adapted from Ruth Arkell. 
  
Left Right 
Situs solitus Heterotaxy Situs inversus 
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the X-linked ZIC3, with mutations being both familial (>75%) and sporadic (3%) (Gebbia et al. 1997; 
Sutherland and Ware 2009; Cowan et al. 2014). Mutation of each of these genes also causes aberrant 
L-R development in the mouse. Due to this, analysis of these mouse strains has identified the steps 
required for L-R axis formation during embryo development. 
1.2 Development of the Left-Right axis 
Establishment of the L-R axis occurs during early stages of embryogenesis at a time called gastrulation 
(6.0 days post coitum [dpc] in the mouse, day 14-17 in humans). A symmetry breaking event at a 
region of the mouse embryo called the node (or its equivalent structure in other organisms) results in 
the activation of a signalling cascade on one side of the embryo, leading to a distinct left and right 
(Figure 1.2). The node is a tear-drop structure located at the distal tip of the embryo, formed by a 
group of cells derived from the anterior primitive streak at approximately 7.0 dpc. The node is 
comprised of two distinct cell types. Roughly 200-300 cells, termed pit cells form the tear-drop shaped 
pit of the node, which are surrounded by 20-30 squamous cells termed crown cells. The pit cells have 
a single motile cilium that is located on the posterior side of each cell. The cilium tilt to the posterior 
side (at an angle of approximately 25-40°), protrude into the extracellular space and rotate in a 
clockwise direction (Okada et al. 2005; Nonaka et al. 2005). The surrounding crown cells also contain 
a single cilium, though it is not motile. Analysis of mouse models has demonstrated that both motility 
and cilia length are necessary for the correct development of L-R asymmetry. Embryos with pit cells 
that lack cilia, or produce cilia that are immotile, randomise L-R axis establishment and present with 
L-R patterning defects including cardiac abnormalities (Nonaka et al. 1998; Murcia et al. 2000; 
McGrath et al. 2003). Additionally, mutation of Rfx3, a gene that regulates cilia growth, causes 
significantly shorter cilia than wildtype embryos and results in L-R asymmetry abnormalities (Bonnafe 
et al. 2004).  
Asymmetric gene expression required for correct L-R establishment is created by a process known as 
nodal flow; the movement of extracellular fluid at the node, generated by cilia rotation, towards the 
left side of the embryo (Hirokawa et al. 2006) (Figure 1.2). Reversal of nodal flow (by artificially 
directing fluid to the right side) results in a complete reversal of L-R patterning in cultured mouse 
embryos (Nonaka et al. 2002). There are, however, two different models of how this signal is 
processed/interpreted and the mechanisms surrounding this process remain debated amongst 
developmental biologists.  
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Figure 1.2: L-R symmetry breaking in the murine embryo. The embryonic node is induced to form at 
mid gastrulation (7.0 dpc) and over 24 hours develops into a shallow, crescent shaped pit consisting 
of pit and crown cells (Lee and Anderson 2008). (2) A monocilium, extending into the extracellular 
space, forms on the apical surface of each pit and crown cell; these become posteriorly polarised over 
time. Signalling molecules (such as Nodal) are expressed in the crown cells. (3) The cilia of the pit cells 
rotate in a clockwise direction directing leftward flow of extracellular fluid within the node. It is posited 
that this leftward nodal-flow is sensed by immotile crown cell cilia, prompting a Ca2+ flux in the left 
(but not the right) crown cells which modifies gene expression (Norris 2012). By the end of this 24 
hour period (at 8.0 dpc) the first known asymmetries in gene expression are detected within node 
crown cells (Dand5, and soon thereafter Nodal, become symmetrically expressed in the node crown). 
WNT3 ligand is also asymmetrically expressed and canonical signalling then amplifies the initial Dand5 
asymmetry (Nakamura et al. 2012). (4) The asymmetric signal(s) are propagated to the left lateral 
plate mesoderm (LPM) and prevented from spreading to the right LPM by the recently formed midline 
barrier. (5) NODAL signalling in the left LPM controls its own expression, and that of other molecules 
that ultimately direct organ position and other asymmetries (Norris 2012). A: anterior, P: posterior, D: 
dorsal, V: ventral, R: right, L: left. Figure taken with permission from Ruth Arkell. 
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The first model of how the movement of extracellular fluid is translated into asymmetric gene 
expression is known as the morphogen model. This model suggests that a particular morphogen is 
secreted in the node cavity and transported to the left side via nodal flow (Nonaka et al. 1998; Okada 
et al. 2005). This results in a concentration gradient of that morphogen across the node, which is 
greater on the left side than the right. The high morphogen concentration is detected by cells on the 
left border of the node and results in the expression of genes such as Nodal in the left crown cells, 
followed by signal transduction triggering asymmetric gene expression in the left lateral plate 
mesoderm (LPM). The signalling molecule and its corresponding receptors, however, have yet to be 
identified. An extension of this hypothesis comes from a study by Tanaka et al. 2005, who observed 
the movement of particles, termed nodal vesicular parcels, in the node cavity. These membrane-
bound vesicles are transported to the left of the node and burst upon cilia contact to release their 
morphogen cargo. The authors propose the transported morphogens include Sonic Hedgehog and 
Retinoic acid, however, additional studies are needed to corroborate and extend these findings. 
The alternative model is known as the two cilia hypothesis. This model proposes that it is the physical 
stimulation of the flow which is detected by mechano-sensing cilia on the left side crown cells 
(McGrath et al. 2003). Bending of the sensory cilia by the flow activates an increase of Ca2+ signalling 
in these left-sided cells, which in turn initiates the asymmetric expression of genes such as Nodal on 
the left of the embryo (McGrath et al.2003; Hirokawa et al. 2006). This model is supported by analysis 
of mice with a mutation in Pkd2, a gene which encodes for a Ca2+ ion channel that is implicated in 
polycystic kidney disease. In the kidney, PKD2 interacts with another protein (PKD1) to form a mecaho-
transducing complex localised on the immotile cilia of kidney tubule cells. The proteins detect urine 
flow and generate a Ca2+ signal in response (Yoder et al. 2002; Nauli et al. 2003). Although Pkd1 is not 
expressed in the embryonic node, a related protein Pkd1-like1 (PKD1L1) is expressed alongside PKD2 
in the ciliated cells of the node and is required for response to nodal flow and L-R axis determination 
in the mouse, implicating Ca2+ signalling in L-R patterning (Pennekamp et al. 2002; Field et al. 2011). 
By analogy, it is proposed that that PKD2 and PKD1L1 form a complex in the left-sided crown cell cilia 
and upon deflection by nodal flow generate a Ca2+ signal. Despite McGrath et al. 2003 observing 
asymmetric Ca2+ signalling in the node of mouse embryos and abnormal Ca2+ signalling in mutant 
embryos, recent studies have challenged this idea and have suggested that Ca2+ signalling is not 
responsible for mechano-sensation of cilia in the node as Ca2+ responses were not produced at a 
physiological level of fluid flow when measured via a transgenic calcium indicator (Delling et al. 2016). 
Despite their differences, both the morphogen and two cilia models result in a similar outcome – 
detection of signal on the left side of the embryo and not the right, leading to asymmetric gene 
expression.  
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1.3 ZIC3 and human Heterotaxy 
To date, 42 mutations in ZIC3 have been associated with human Heterotaxy in published studies 
(Gebbia et al. 1997; Mégarbané et al. 2000; Ware et al. 2004; Chhin et al. 2007; Wessels et al. 2010; 
De Luca et al. 2010; Ma et al. 2012; D’Alessandro et al. 2013a, b; Cowan et al. 2014; Paulussen et al. 
2016; El Malti et al. 2016; Li et al. 2018). These include 18 missense mutations, 8 nonsense, 9 
frameshift, 6 in-frame deletions/duplications and a single intronic mutation (Figure 1.3). Just over half 
of the mutations (22/42) occur within the highly conserved zinc finger domain (ZFD) of the ZIC3 
protein. However, there are eight nonsense and frameshift mutations that occur prior to the ZFD that 
are predicted to cause protein truncation either before or within the ZFD, thus increasing the total 
number of mutations affecting the ZFD (either directly or indirectly) to 30/42 (71%). The ZIC ZFD has 
been assigned many functional properties including DNA binding, protein-protein interaction and 
nuclear localisation (Bedard et al. 2007; Lim et al. 2010; Pourebrahim et al. 2011), and therefore, 
mutations that occur within this domain are predicted to negatively affect or even ablate protein 
function. It is unknown, however, if all 42 identified ZIC3 human mutations are indeed pathogenic, nor 
is it known the exact mechanism by which pathogenic mutations lead to Heterotaxy. 
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Figure 1.3: ZIC3 alleles in human Heterotaxy.  The location of all 42 known human mutations in ZIC3 that are associated with Heterotaxy in humans is shown. 
These include 18 missense, 9 frameshift 8 nonsense, 6 in-frame expansions or deletions and 1 intron mutation. Of these mutations, 22 (52%) occur within the 
highly conserved zinc finger domain of the ZIC3 protein. Experimental analysis is needed to determine if all 42 mutations are pathogenic. C: Cysteine, H: 
Histidine, N’: N-terminus, C’: C-terminus.
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1.4 ZIC3 is associated with Heterotaxy in the mouse 
Zic3 null mice recapitulate human Heterotaxy phenotypes and therefore provide a good model of ZIC3 
protein function. In addition to Heterotaxy, Zic3 null mice display gastrulation defects, neural tube 
defects and axial patterning abnormalities (Purandare et al. 2002). Targeted construction of 
conditional mouse alleles has enabled the deletion of Zic3 in specific cells and facilitated the analysis 
of the temporal and spatial requirements of Zic3 during development. Genetic data from two 
independent research groups (summarised in Table 1.1) demonstrated ZIC3 is not required in the 
developing heart or node cells to prevent Heterotaxy (Table 1.1) (Jiang et al. 2013; Sutherland et al. 
2013). For example, despite the broad range of cardiac defects observed in Zic3 null models, removal 
of Zic3 from cardiac progenitors using Cre strains Mesp1-Cre, Nkx2.5-Cre, Mef2c-Cre, Wnt1-Cre, or 
βMyHC-Cre did not result in cardiac defects. Similarly, deletion of Zic3 in the lateral crown cells or the 
ciliated node pit cells did not result in Heterotaxy (Table 1.1, Nodal-dependant enhancer-Cre, [NDE-
Cre], Foxj1-Cre). Instead, Zic3 is required in the ectoderm or nascent mesoderm during gastrulation to 
prevent L-R axis defects. Deletion of Zic3 in cells expressing Brachyury (T-Cre) displayed increased 
lethality, heart looping defects and situs abnormalities. T-Cre is expressed in the migrating primitive 
streak before node development, which suggests Zic3 is required prior to node development to 
prevent L-R axis defects (Perantoni 2005; Sutherland et al. 2013). Laterality defects were also observed 
when Zic3 was deleted from cells in the pluripotent epiblast (Sox2-Cre) (Jiang et al. 2013). Ultimately 
this identifies a role for ZIC3 during early gastrulation before node formation to prevent Heterotaxy.  
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Table 1.1 Temporal and spatial requirement of ZIC3 in the prevention of L-R axis defects occurs prior to node formation. L-R: left-right 
Structure 
Allele symbol; 
Cre target 
Cells targeted 
Temporal expression of Cre 
target 
L-R axis 
defects 
Reference 
Ectoderm 
Zic3del/y; Sox2-
Cre+ 
Cells in the pluripotent ectoderm 
Prior to and during 
gastrulation  
Present (Jiang et al. 2013) 
Nascent 
mesendoderm 
Zic3del/y; T-Cre+ 
Cells migrating through the 
wings of mesoderm 
During gastrulation and 
mesoderm migration 
Present 
(Jiang et al. 2013; 
Sutherland et al. 2013) 
Node 
Zic3del/y; NDE-
Cre+ 
Lateral crown cells of the node During L-R symmetry breaking Absent (Sutherland et al. 2013) 
Zic3del/y; FoxJ1-
Cre+ 
Ciliated node pit cells During L-R symmetry breaking Absent (Sutherland et al. 2013) 
Lateral plate 
mesoderm 
Zic3del/y; Mesp1-
Cre+ 
Lateral plate mesoderm anterior 
to the node 
Early cardiac development Absent (Jiang et al. 2013) 
Heart 
Zic3del/y; Mef2c-
Cre+ 
Anterior heart field Cardiac development Absent (Sutherland et al. 2013) 
Zic3del/y; Nkx2.5-
Cre+ 
Cardiac cresent and 
cardiomyocytes 
Cardiac development Absent 
(Jiang et al. 2013; 
Sutherland et al. 2013) 
Zic3del/y; Wnt1-
Cre+ 
Cardiac neural crest cells Cardiac development Absent 
(Jiang et al. 2013; 
Sutherland et al. 2013) 
Zic3del/y; βMyHC-
Cre+ 
Embryonic and fetal 
cardiomyocytes 
Late cardiac development Absent (Sutherland et al. 2013) 
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1.5 The ZIC family of transcription factors 
The Zinc finger of the cerebellum (Zic) genes encode a family of multifunctional proteins that regulate 
gene expression (Ali et al. 2012; Houtmeyers et al. 2013). The Zic genes were first identified by their 
homology to the Drosophila gene odd-pared (opa; Aruga et al. 1994), while opa itself was isolated in 
a genetic screen for mutations that disrupt segmentation of the Drosophila embryo (Nüsslein-Volhard 
and Wieschaus 1980). Analysis of mutant flies identified opa as a pair-rule gene and subsequent 
cloning revealed opa also regulates the expression of genes required for the development of visceral 
mesoderm and midgut morphogenesis (Benedyk et al. 1994; Cimbora and Sakonju 1995). Sequence 
analysis showed that opa contains a zinc finger domain (ZFD) made up of five C2H2 zinc fingers. As 
these domains are commonly associated with DNA binding, opa was assumed to be a transcription 
factor. The first vertebrate Zic gene (Zic1) was identified by cDNA screening for genes differentially 
expressed in the cerebellum (Aruga et al. 1994). Subsequently, Zics2-4 were identified in the mouse 
on the basis of their homology to Zic1 (Aruga et al. 1996a, b). We now know that in mice, as in man, 
there are five ZIC genes (Furushima et al. 2000), each of which encodes a transcriptional regulator 
protein containing a ZFD.  
1.5.1 Genome organisation 
The genomic arrangement, as well as the gene and protein structure of the Zic molecules, has been 
conserved throughout evolution in both vertebrate and invertebrate species (Aruga et al. 2006). 
Genome sequencing of a large number of vertebrate organisms found that the Zic genes are arranged 
in tandem pairs. In the human genome, the five ZIC genes reside at three locations. ZIC1 and ZIC4 are 
arranged as a divergently transcribed tandem gene pair on chromosome 3, as are ZIC2 and ZIC5 on 
chromosome 13, while ZIC3 is an X-linked singleton (Figure 1.4) (Ali et al. 2012; Houtmeyers et al. 
2013). Furthermore, sequencing and phylogenetic analysis have revealed that the ZIC genes can be 
divided into two subgroups (Subgroup A containing ZIC1-3 and Subgroup B containing ZIC4-5), based 
on similarities in nucleotide sequence and protein structure (Aruga et al. 2006; Houtmeyers et al. 
2013).  
Aruga et al., 2006 provides a model of Zic gene evolution, where a single ancestral Zic gene (with a 
single intron) underwent a tandem duplication event followed by sequence modification. This 
generated two isoforms in which one acquired an additional intron and the other underwent sequence 
divergence with the loss of structural domains (including the ZOC domain) and the divergence of zinc 
finger 1 (Houtmeyers et al. 2013). This was followed by two genome duplication events that would  
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Figure 1.4: Genomic arrangement of human ZIC genes. The arrangement of ZIC genes on the human 
genome, as shown in the Ensembl genome browser. ZIC1 and ZIC4 are located on chromosome (Chr) 
3, ZIC2 and ZIC5 are located on chromosome 13, while ZIC3 is on the X-chromosome. Each bi-gene 
clusters contains a ZIC gene from Subgroup A (ZIC1, ZIC2, ZIC3) and Subgroup B (ZIC4, ZIC5). UTR: 
untranslated region; ZFNC: zinc finger N-terminal conserved region; ZOC: Zic-Opa conserved region; 
ZF: zinc finger. This figure was taken from Houtmeyers et al. 2013. 
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have produced eight Zic genes organised in four bi-gene clusters, with each containing a Zic gene from 
Subgroup A and Subgroup B. Due to gene loss or de-novo duplication events, the number of Zic genes 
vary in number between species, from the single opa gene found in Drosophila to seven zic genes in 
Zebrafish and five Zic genes present in Xenopus, mouse and man. 
1.5.2 Zic Pleiotropy 
Although the vertebrate Zic genes were named based on the tissue from which they were first isolated 
(murine cerebellum), animal and human genetics show the five genes often function outside of brain 
development and instead are necessary during early embryonic development (Table 1.2) (Aruga et al. 
1994; Houtmeyers et al. 2013; Diamand et al. 2018). Analysis of multiple murine Zic alleles yielded an 
extensive list of processes, tissues and organs that require the function of one or more murine Zic 
genes for normal development. Processes affected by the absence of Zic gene function include axis 
formation, as well as the patterning and morphogenesis of the central nervous, visual, musculo-
skeletal and vascular systems (Table 1.2) (Diamand et al. 2018). Analysis of these alleles not only 
illustrates the diverse function of the proteins, but highlights the fact that different Zic alleles give rise 
to the same phenotype. For example, mutation of Zic1, Zic2, Zic3 and Zic5 all produce skeletal 
abnormalities, while all ZICs are involved in forebrain development, particularly in cerebellum size and 
patterning.  
Moreover, the catalogue of Zic related phenotypes shown in Table 1.2 makes clear the remarkable 
extent of Zic gene pleiotropy, a term which refers to the production of two or more apparently 
unrelated effects by a single gene. For example, Zic1 and Zic4 mouse mutants are small at birth and 
have cerebellar abnormalities. Similarly, mutation of Zic5 affects diverse systems or processes such as 
neurulation, neural crest development, skeletal and eye development. Zic3 mutation, like Zic2, affects 
a broad range of tissues or processes, some of which are linked by their ontogeny (for example, the 
limb and tail defects may both reflect a role in skeletal development) and others which arise from a 
role in multiple tissues (such as craniofacial, cerebellar, neural tube and ventral closure defects). 
Overall, the extent of Zic gene pleiotropy implies multiple sites of expression and overlapping 
expression of Zic family members during embryonic development, and a multitude of molecular roles 
for the ZIC proteins during this time.  
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Table 1.2: Murine Zic loss-of-function phenotypes. 
 Zic phenotypes Genotypes References 
G
a
st
ru
la
ti
o
n
 
Primitive Streak 
Dysgenesis 
Zic3-/-, Zic3-/Y (Ware et al. 2006a) 
Failure of Anterior 
Notochord Production  
Zic2Ku/Ku (Warr et al. 2008) 
Left-right axis defect Zic2Ku/Ku 
Zic3Bn/Bn, Zic3Bn/Y, Zic3Bn/+, Zic3-/-, 
Zic3-/Y 
Zic3 Ka/Ka, Zic3Ka/Y 
(Carrel et al. 2000; Purandare et al. 
2002; Ahmed et al. 2013; Barratt et 
al. 2014)  
Node cilia defects Zic2Ku/Ku (Barratt et al. 2014) 
P
a
tt
er
n
in
g
 a
n
d
 M
o
rp
h
o
g
en
es
is
 
Exencephaly Zic2Ku/Ku, Zic2kd/kd, Zic2m1Nisw/ m1Nisw 
Zic3Bn/Bn, Zic3Bn/Y,  
Zic3-/-, Zic3-/Y, 
Zic5-/-(a), Zic5-/- (b) 
(Zhang and Niswander; Nagai et al. 
2000; Klootwijk et al. 2000; 
Purandare et al. 2002; Elms et al. 
2003; Inoue et al. 2004; Furushima et 
al. 2005)  
Spina Bifida (and 
curled tail) 
Zic2Ku/+, Zic2kd/kd, Zic2m1Nisw/ m1Nisw 
Zic3Bn/Bn, Zic3Bn/Y 
(Zhang and Niswander; Garber 1952; 
Nagai et al. 2000; Klootwijk et al. 
2000; Elms et al. 2003)  
Omphalocele Zic3Bn/Bn, Zic3Bn/Y (Klootwijk et al. 2000) 
Cleft lip Zic3Bn/Bn, Zic3Bn/Y (Klootwijk et al. 2000) 
Cranial Neural crest 
deficit 
Zic2Ku/Ku, Zic2kd/kd 
Zic5-/-(a), Zic5-/-(b) 
(Nagai et al. 2000; Elms et al. 2003; 
Inoue et al. 2004; Furushima et al. 
2005) 
Trunk Neural Crest 
Deficit 
Zic2Ku/Ku (Elms et al. 2003) 
Hindbrain patterning Zic2Ku/Ku (Elms et al. 2003) 
Sk
el
et
a
l D
ef
ec
ts
 
Craniofacial Zic5-/- (a), Zic5-/- (b) (Inoue et al. 2004; Furushima et al. 
2005) 
Sternum/ribs Zic5-/-(a), Zic1-/-  (Aruga et al. 1999; Inoue et al. 2004) 
Vertebral arches Zic1-/-,  
Zic2kd/kd, Zic2kd/+;Zic3Bn/Y 
Zic3Bn/X, Zic3Bn/Bn, Zic3Bn/Y, Zic3-/+,  
Zic3-/-, Zic3-/Y,  
Zic5-/-(a) 
(GrüNeberg 1963; Aruga et al. 1999; 
Nagai et al. 2000; Purandare et al. 
2002; Inoue et al. 2004, 2007)  
Tail (reduced number 
and or dysmorphic 
caudal vertebrae) 
Zic2kd/kd,  
Zic3Bn/X, Zic3Bn/Bn, Zic3Bn/Y, Zic3-/+,  
Zic3-/-, Zic3-/Y  
Zic3Ka/+ 
Zic5-/- (a) 
(GrüNeberg 1963; Purandare et al. 
2002; Inoue et al. 2004; Ahmed et al. 
2013) 
Limb Zic2kd/kd (Nagai et al. 2000) 
Classical HPE Zic2Ku/Ku, (Warr et al. 2008) 
Roof-plate 
abnormality/MIH HPE 
Zic2kd/kd,  
Zic5-/- (b) 
(Nagai et al. 2000; Furushima et al. 
2005) 
Dorsal spinal cord 
hypoplasia 
Zic1-/- (Aruga et al. 1998) 
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O
rg
a
n
o
g
en
es
is
 
Forebrain 
Dysgenesis of medial 
structures 
Zic1-/-, Zic1-/-;Zic3Bn/Y 
Zic3-/+, Zic3-/-, Zic3-/Y, Zic3Bn/Bn 
Zic5-/- (a) 
(Purandare et al. 2002; Inoue et al. 
2004; Furushima et al. 2005) 
Enlarged ventricles Zic5-/- (b) (Furushima et al. 2005) 
Microcephaly Zic2kd/kd, Zic5-/- (a) (Nagai et al. 2000; Furushima et al. 
2005) 
Cerebellum: Reduced 
Size 
Zic1-/-,  
Zic1-/+; Zic4-/+  
Zic1-/-;Zic4-/- 
Zic3Bn/Y, Zic3Bn/Bn 
(Aruga et al. 1998; Aruga 2004; 
Grinberg et al. 2004; Blank et al. 
2011) 
Cerebellum: Folia 
Patterning 
Zic1-/-,  
Zic1-/+;Zic2kd/+  
Zic1-/+;Zic4-/+  
Zic1-/-;Zic4-/-,  
Zic1-/+;Zic2Kd/+ 
Zic3Bn/Y, Zic3Bn/Bn 
(Aruga et al. 1998, 2002; Aruga 2004; 
Grinberg et al. 2004; Blank et al. 
2011),  
Non-forebrain 
Hydrocephalus Zic1-/+;Zic2kd/+  
Zic5-/- (a) 
(Aruga et al. 2002; Inoue et al. 2004) 
Eye: Micro and 
anopthalmia 
Zic2kd/kd,  
Zic3Bn/Bn, Zic3Bn/Y  
Zic5-/- (b) 
(Klootwijk et al. 2000; Herrera et al. 
2003; Furushima et al. 2005) 
Eye: Optic chiasm: 
morphology 
Zic2kd/kd (Herrera et al. 2003) 
Eye: aberrant 
ipsilateral projection 
of retinal ganglion 
cells 
Zic2kd/+, Zic2kd/kd (Herrera et al. 2003) 
Limb Zic2kd/kd  
Zic3Bn/Y, Zic3Bn/Bn,  
(Garber 1952) 
Small size at birth Zic1-/+;Zic4-/+,  
Zic1-/-; Zic4-/- 
Zic2kd/kd,  
Zic3Bn/Bn, Zic3Bn/Y  
Zic5-/-  
(Garber 1952; Nagai et al. 2000; 
Inoue et al. 2004; Grinberg et al. 
2004) 
Abnormal intestine 
morphology 
Zic2m1Nisw/m1Nisw (Zhang and Niswander) 
Abnormal enteric 
neural crest 
morphology 
Zic2m1Nisw/m1Nisw (Zhang and Niswander) 
Abnormal neurite 
morphology 
Zic2m1Nisw/m1Nisw (Zhang and Niswander) 
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P
o
st
 B
ir
th
 
Embryonic lethality Zic2Ku/Ku,  
Zic3Bn/Bn, Zic3Bn/Y, Zic3-/-, Zic3-/Y 
(Garber 1952; Purandare et al. 2002; 
Elms et al. 2003) 
Peri-natal lethality Zic2kd/kd, Zic2m1Nisw/m1Nisw 
Zic5-/ -(a) 
(Zhang and Niswander; Nagai et al. 
2000; Inoue et al. 2004) 
 
Juvenile lethality Zic1-/+;Zic2kd/+ (4 weeks),  
Zic1-/+;Zic4-/+ (4 weeks),  
Zic1-/-;Zic4-/-,  
Zic1-/-, Zic2kd/kd  
Zic5-/- (4 weeks) (a) 
(Nagai et al. 2000; Aruga et al. 2002; 
Inoue et al. 2004; Grinberg et al. 
2004; Blank et al. 2011) 
B
eh
a
vi
o
u
ra
l 
Pre-pulse inhibition Zic2+/kd (Ogura et al. 2001) 
Motor control Zic1-/+, Zic1-/-, 
Zic1-/+;Zic4-/+,  
Zic1-/-;Zic4-/- 
Zic3Bn/Y, Zic3Bn/Bn,  
(Ogura et al. 2001; Aruga 2004; 
Grinberg et al. 2004) 
Abnormal gait and 
posture 
Zic1-/+; 
Zic2kd/+  
Zic5-/- (a) 
(Aruga et al. 2002; Inoue et al. 2004) 
 (a) Zic5Tm1Jaru strain, (b) Zic5Tm1Siastrain 
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1.5.3 Expression during early embryo development  
The temporal-spatial distribution of murine Zic gene transcripts has been documented across a range 
of developmental stages and (as reviewed in Houtmeyers et al. 2013) the murine Zic genes can be 
divided into two groups based on their overlapping expression patterns during early embryo 
development. Zic2, Zic3 and Zic5 are the first of the gene family to be expressed, with transcription of 
each initiating prior to implantation. During gastrulation, Zic2, Zic3 and Zic5 are co-expressed in the 
ectoderm and some of the newly formed mesoderm that ingresses through the primitive streak, whilst 
Zic1 and Zic4 are not yet detected (Figure 1.5) (Furushima et al. 2000; Elms et al. 2004; Houtmeyers et 
al. 2013). By the early head-fold stage, all three expressed genes are restricted to the neurectoderm 
and later become limited to the most dorsal neurectoderm that will form the future neural crest cells 
and dorsal neurons, as well as pre-somitic and somatic populations of the lateral mesoderm. In 
contrast, Zic1 and Zic4 expression initiate during early organogenesis in the neurectoderm and somitic 
mesoderm. By 9.5 dpc, all five murine Zic genes are co-expressed in the dorsal spinal cord, the dorsal 
cranial neural tube and in the somites, with small differences in expression domains such as the 
absence of Zic4 expression in the roof-plate of the neural tube (Figure 1.5) (Nagai et al. 1997; 
Furushima et al. 2000; Elms et al. 2004). One day later, the expression of Zic2, Zic3 and Zic5 is initiated 
in newly developing eye and in the limb buds. At later stages of development, Zic gene expression has 
not been assayed in the entire embryo, but brain expression patterns have been reported. The 
progenitor cells of the thalamus, preoptic area, the septum, cortical hem and the retina all express the 
Zic genes in largely overlapping domains at mid-gestation. Zic expression in the central nervous system 
becomes more restricted by embryonic day 12.5 at which time all five Zic genes are expressed in the 
dorsal midline neural tissues (including the cortical hem, the septum, and the ventricular and sub-
ventricular zone) and ventral neural tube (Figure 1.5). Interestingly, as shown in Figure 1.5, these 
expression groups mirror the genomic arrangement of the genes. The Zic1/4 bi-gene pair form one 
expression group, whilst the single gene Zic3 and the Zic2/5 bi-gene pair form another. It is possible 
that the bi-gene pairs share regulatory regions as a direct result of their evolved tandem gene 
arrangement, resulting in similar gene expression patterns (Houtmeyers et al. 2013).  
 
36 
 
 
 
 
 
 
37 
 
Figure 1.5: Co-expression of the murine Zic genes during mouse gastrulation and organogenesis. The 
murine Zic gene expression subclasses reflect their genomic arrangement. Subclass B genes are 
expressed prior to and throughout gastrulation, during neurulation, and in organogenesis. Subclass A 
gene expression does not initiate until after neurulation and is absent from the optic cup, the forelimb 
bud and the pre-somitic mesoderm at early organogenesis. (A) Lateral view of 7.5 dpc mouse embryos 
(anterior is to the left), (B) dorsal view of 8.5 dpc mouse embryos (anterior is to the top) and (C) lateral 
view of 9.5 dpc mouse embryos (anterior is to the left) following whole mount in situ hybridization to 
Zic1-5 (courtesy of Kristen Barratt). (D) Coronal sections of 12.0 dpc mouse forebrains through the 
hippocampus and habenular nucleus following whole-mount in situ hybridization to Zic1-5 (courtesy 
of Jun Aruga). Figure taken from Diamand et al. 2018. 
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1.5.4 ZIC molecular functions 
1.5.4.1 ZIC proteins function as transcription factors 
As previously described, the ZIC genes are orthologs of the Drosophila transcription factor encoding 
pair-rule gene, odd-paired (opa). The defining feature of all ZIC proteins (including opa) is the highly 
conserved ZFD, which is able to bind DNA, meaning the ZIC genes are presumed to encode DNA 
binding transcription factors (Figure 1.6). Transcription factors play essential roles in gene regulation 
by controlling the activation and repression of target genes. To achieve this, they contain a DNA 
binding domain that recognises and binds to short but specific DNA sequences in the enhancer or 
promotor region of a target gene (Wingender et al. 2013). Eukaryotic transcription factors are 
classified into 10 different superclasses based on the DNA binding domains they possess, with the 
largest superclass being the zinc coordinating DNA binding domain which encompasses 52% of all 
transcription factors investigated, which include the ZIC proteins (Wingender et al. 2013, 2018). 
Transcription factors can also bind within nucleosomal DNA and trigger chromatin remodelling and 
nucleosome positioning (which can increase accessibility for other proteins), which also influences 
gene expression (Spitz and Furlong 2012). Moreover, transcription factors contain other regulatory 
domains, called transactivation domains, which interact with the basal transcription machinery, 
recruit co-factors via protein binding domains and form transcriptional complexes at enhancers to co-
operatively modulate the transcription of gene targets. Ultimately transcription factors have a 
bipartite structure requiring both a DNA binding domain and transactivation domain to regulate target 
gene expression. 
 Nuclear localisation 
Transcription factors recognise and bind to specific DNA binding sites, a process that occurs in the 
nucleus. Transcription factors therefore need a mechanism for nuclear entry. This process is usually 
facilitated by the presence of specific amino acid sequences within the protein known as nuclear 
localisation signals (NLSs), which are recognised by and interact with nuclear import receptors present 
on the nuclear membrane (Jans et al. 2000). Generally, NLSs are composed of multiple monopartite 
or bipartite clusters of positively charged basic amino acids such as arginine and lysine (Hicks and 
Raikhel 2003). Sequence analysis of the ZIC proteins, however, shows that none contain a canonical 
nuclear localisation signal. Instead, experimental analysis of human ZIC3 via two independent studies 
found the ZFD is necessary for nuclear import. For example, Bedard et al. 2007 reported that 90% of 
wildtype ZIC3 transfected in NIH3T3 cells was localised to the nucleus. When putative NLS mutations 
were made in the ZFD, nuclear localisation of the mutant proteins was reduced to 20-30%. Similarly,  
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Figure 1.6: Structural features of the human ZIC proteins. All five ZIC proteins contain a zinc finger 
domain comprised of five tandem C2H2 type zinc fingers. This domain is highly conserved however ZIC4 
and ZIC5 each contain a diverged first zinc finger. All proteins contain a conserved domain (14-21 
amino acids) directly upstream of the zinc finger domain termed the ZFNC. ZIC1-3 contain the highly 
conserved ZOC domain, a short (9-10 amino acids) region in the N-terminus. Functions of the ZOC and 
ZFNC are not yet clearly understood. Several low complexity regions (stretches of alanine, proline, 
histidine, serine and glycine) also exist with the type and number varying between all five proteins. A: 
alanine, H; histidine, P: proline, S/G: serine/glycine, ZOC: Zic-opa conserved, ZFNC; zinc finger N-
terminus conserved, C2H2: Cysteine-two, Histidine-two.  
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Hatayama et al. 2008 made several deletion constructs of ZIC3, lacking various zinc fingers of the ZFD, 
that when transfected into NIH3T3 cells, perturbed nuclear localisation. Together it is suggested the 
ZFD (fingers 2-5) is essential for nuclear localisation and presumably harbours an interspersed nuclear 
localisation signal (Bedard et al. 2007; Hatayama et al. 2008).  
 DNA binding domain 
The ZIC DNA binding domain is most closely related to the ZFD of the GLI, GLIS and NKL families and is 
highly conserved between ZIC family members both within an individual species and across species 
(Aruga 2004). C2H2 type zinc fingers contain two cysteine (C) and two histidine (H) residues that 
tetrahedrally co-ordinate a zinc (Zn2+) ion and are often involved in DNA binding (Iuchi 2001). The ZIC 
ZFD is, however, distinguished by an atypical first zinc finger. Often, one to five amino acid residues 
are located between the two cysteines of a C2H2 zinc finger. In the ZIC proteins, however, the first zinc 
finger can contain between 6 to 38 amino acids, varying between all species so far examined (Aruga 
et al. 2006; Layden et al. 2010). Additionally, structural analysis of the ZIC3 protein indicates that the 
first two zinc fingers of the ZFD may not be canonical (DNA binding) C2H2 type zinc fingers and instead 
form a single structural unit called the tandem CWCH2 motif. This motif is characterised by the 
presence of a tryptophan residue located between the two canonical cysteines of each zinc finger 
(Hatayama and Aruga 2010). Additionally, the CWCH2 motif is conserved across a wide range of 
metazoan species (Aruga et al. 2006), which is indicative of biological significance. Moreover, a 
missense mutation of the tryptophan in the first zinc finger of ZIC3 is associated with congenital heart 
malformation in humans. Both protein stability and nuclear localisation are affected by this mutation 
when overexpressed in NIH3T3 cells (Chhin et al. 2007). The function of the CWCH2 motif is not yet 
fully understood, however, it has been suggested that it may modulate DNA binding by zinc fingers 3-
5 or be involved in protein-protein interactions (Hatayama and Aruga 2010; Houtmeyers et al. 2013).  
Despite the presence of a ZFD, little is known about ZIC in vivo downstream targets. Studies using 
embryonic stem cells have provided some evidence for the DNA binding properties of ZIC3 and its 
involvement in the regulation of stem cell pluripotency. For example, using ChIP-on-chip experiments, 
Lim et al. 2010 found 379 Zic3-enriched promotor targets including those of Oct4, Sox2 and Nanog. 
Further analysis by Lim et al (2010) identified ZIC3 is capable of binding and activating the Nanog 
promoter using in vitro DNA binding assays, demonstrating its potential as a transcriptional activator. 
A protein binding microarray identified the same consensus sequence identified by Lim et al (2010), 
to be bound by the ZFD of ZIC1-3 (Badis et al. 2009). Furthermore, mutations located within the ZFD 
of many ZIC proteins can result in a loss of DNA binding and are associated with severe congenital 
defects (Ware et al. 2004; Brown et al. 2005). In many cases, however, the DNA binding ability of these 
alleles was tested with a purified protein corresponding only to the ZFD portion of the ZIC protein 
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(indeed, purification of a full-length ZIC protein has never been reported). While it remains possible 
that the full-length variant proteins may perform differently in the same DNA binding assay, overall 
there is good evidence that the ZIC proteins can bind DNA to exert transcription control and that the 
ZFD is required for this function 
 Transactivation  
Aside from the DNA binding domain, transcription factors also require a transactivation domain. This 
region of the protein is separate to the DNA binding domain and interacts with other proteins and 
transcriptional machinery necessary to regulate transcription of target genes. To date, the ZIC 
transactivation domain has not yet been identified. It is expected an important functional domain such 
as this would be conserved between the ZIC proteins, similar to the ZIC DNA binding domain 
conservation. Although a specific transactivation domain has not yet been identified within the ZIC 
proteins, there are many evolutionary conserved domains within the ZICs with unknown function 
(Figure 1.6), that may have a role in transactivation.  
The best characterised evolutionary conserved domain is called the ZIC opa conserved (ZOC) domain, 
which is a small (9-10 amino acids) region located in the N-terminus of the protein conserved in ZIC1-
3 (Figure 1.6). This domain is one of two shown to be involved in transcriptional activation (the other 
being the ZFD), and has also been shown to be involved in protein-protein interactions, such as binding 
the myogenic repressor protein, I-mfa (Mizugishi et al. 2004). Additionally, a small (14-21 amino acids) 
conserved region, located directly prior to the ZFD called the zinc finger N-flanking conserved (ZFNC) 
domain is found in all five ZIC proteins and is subject to the post-translational modification 
SUMOylation in human ZIC3 (Aruga et al. 2006; Chen et al. 2013). As reviewed in Houtmeyers et al. 
2013 phylogenetic comparison of the ZIC protein sequences has led to the classification of ZICs into 
two distinct structural subclasses based on the presence of the ZOC domain and the variation within 
the first zinc finger. The structural subclass A contains the more highly conserved ZIC1, 2 and 3 proteins 
and subclass B contains the less conserved ZIC4 and ZIC5 proteins (Figure 1.6). Notably, the subclass 
division is reflected in the genome arrangement and evolution of the Zic genes, since each gene pair 
(i.e. Zic1/Zic4 and Zic2/Zic5) contains one subclass A and one subclass B protein (Figure 1.5, 1.6).  
Recently, two previously unannotated domains were identified in the Arkell laboratory based on 
sequence conservation (Arkell lab, unpublished). These domains are only present in subclass A (ZICs1-
3) proteins and were subsequently named SANC (Subclass A N terminally conserved) and SACC 
(Subclass A C terminally conserved). The SANC domain is made of 10 amino acids (amino acid position 
159-168 within ZIC3), while the SACC domain is made of 14 amino acids (amino acid position 418-431 
within ZIC3). The function of these domains, however, is not yet known. 
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In addition to these evolutionary conserved domains, each murine ZIC protein contains several low 
complexity regions (including poly-alanine, -histidine, -proline, and -serine/glycine tracts), with the 
number and type of sequence varying between the five ZIC proteins (Figure 1.6). Low complexity 
regions can undergo expansion and contraction mutations that alter protein function, and poly-
alanine tract expansions in ZIC2 and ZIC3 are associated with human disease pathogenesis. Expansion 
of the alanine tract in ZIC2 is implicated in Holoprosencephaly, while expansion mutations of this 
domain in ZIC3 are associated with Heterotaxy (Brown et al. 2001; Frank et al. 2015). Cell-based 
overexpression assays have shown that expansion of the ZIC2 alanine tract from 15As to 25As results 
in a near-complete loss of transactivation ability, dependent on the promoter that is used (Brown et 
al. 2005), suggesting a role for the alanine tract in the modulation of ZIC transactivation. It is unclear, 
however, if poly-alanine tract expansions affect the function of other ZIC family members. Previous 
analysis of ZIC3 found no significant change in transactivation ability upon modification of the alanine 
tract (Cowan et al. 2014), a result which may be attributed to the differences in promoters and 
experimental conditions (including cell lines, reporters and time at which luciferase activity was 
measured) in the two studies (Brown et al. 2005; Cowan et al. 2014). 
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1.5.4.2 ZIC proteins function as co-factors  
Although C2H2 type zinc fingers were originally identified as DNA binding domains, it is now clear that 
these domains are also involved in protein-protein interactions (Brayer and Segal 2008). The ZICs were 
amongst the first proteins to show that C2H2 ZFDs could bind proteins in addition to DNA (Koyabu et 
al. 2001b) demonstrating the bi-functional properties of ZFDs. In addition to its role as a classical DNA 
binding transcriptional activator, ZIC proteins have also been implicated as a protein binding co-factor 
in the Shh, Nodal and Wnt signalling pathways during embryonic development. In all cases, the ZIC 
proteins have been shown to physically interact with the key transcriptional mediators of each 
signalling pathway (i.e. GLI mediators of HH signals, SMAD mediators of Nodal signals and TCF/LEF 
mediators of canonical Wnt signals).  
 ZIC in the Shh pathway 
ZIC3 can directly bind the ZFD of the Shh-mediator protein GLI3 in glutathione-S-transferase (GST) 
pull-down assays using overexpressed protein in mammalian cell lines (Koyabu et al. 2001b). The ZIC 
proteins can bind GLI DNA binding sites with lower affinity than GLI proteins themselves, however, 
they do not stimulate transcription at these GLI binding sites (Mizugishi et al. 2001). However, ZIC3 
synergises with GLI3 to stimulate transcription at GLI DNA binding sites at higher levels than GLI 
protein would alone in cell-based transactivation assays (Mizugishi et al. 2001; Koyabu et al. 2001b; 
Quinn et al. 2012). Additionally, whole mount gene expression analysis in wildtype murine embryos 
has shown that Zic3 expression overlaps with that of Gli3 in the somites, forebrain, midbrain, 
hindbrain and limb buds at 10.5-11.5 dpc. Moreover, the polydactyly phenotype exhibited by Gli3+/- 
heterozygotes is rescued when crossed with a Zic3 null allele (Zic3-/-) (Quinn et al. 2012). Although this 
implies a functional relationship between ZIC3 and Gli3 and suggests a role for ZIC3 in limb 
development and regulation of Shh signalling, conditional null alleles for Zic3 generated by a variety 
of Cre strains and ZIC3 loss-of-function models demonstrate a requirement for ZIC3 in the nascent 
mesoderm early on during gastrulation to prevent L-R axis defects (Ahmed et al. 2013; Sutherland et 
al. 2013). This loss-of-function phenotype occurs prior to the time of Shh directed limb patterning and 
before Hh ligands are expressed in the embryo. Ultimately, this suggests that the primary function of 
ZIC3 in Heterotaxy occurs upstream of Shh signalling at gastrulation.  
 ZIC in the Nodal pathway 
Recent studies have shown that ZIC2 can physically bind to SMAD2 and SMAD3 proteins which are 
transcriptional mediators of Nodal signalling (Shen 2007; Houtmeyers et al. 2016). This interaction 
was demonstrated by co-immunoprecipitation following overexpression of proteins in HEK293T cells 
and the interaction was localised to the N-terminal domain of ZIC2. ZIC2 was also found to complex 
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with endogenously expressed phosphorylated SMAD2 protein (Houtmeyers et al. 2016). Furthermore, 
transactivation assays in HEK293T cells showed that ZIC2 can antagonise SMAD-dependent 
transactivation in the absence of any known ZIC binding sites, suggesting ZIC2 does not itself bind 
DNA, but acts in complex with other proteins to exert transcriptional control. Complementing this cell 
work, in vivo studies have shown ZIC2 intersects the Nodal pathway during murine gastrulation 
(Houtmeyers et al. 2016). For example, halving the dose of Nodal activity on the mutant Zic2Ku/Ku 
background precipitates anterior truncation in ~80% of Zic2Ku/Ku embryos, a known consequence of 
loss of Nodal signalling (whereas Nodal+/- embryos exhibit no phenotype) (Houtmeyers et al. 2016). 
This apparent Nodal haploinsufficiency in the absence of ZIC2 function implies that ZIC2 potentiates 
the Nodal signal during murine gastrulation. 
 ZIC in the Wnt pathway 
Two independent studies have demonstrated that ZIC proteins can inhibit β-catenin mediated Wnt 
signalling by interacting with the TCF family of transcriptional repressors. For example, overexpression 
of wildtype β-catenin in Xenopus embryos results in the formation of a secondary axis (indicative of 
an elevated Wnt signalling phenotype). This phenotype can be rescued if Zic2 or Zic3 RNA is also 
overexpressed (via injection into the embryos; Pourebrahim et al. 2011; Fujimi et al. 2012), 
demonstrating Zic2 and Zic3 can inhibit the β-catenin induced secondary axis in Xenopus embryos. 
Currently, there is no in vivo evidence of this interaction in the mouse. Fujimi et al. 2012 also 
demonstrated that all five Xenopus Zics (Zic1-5) can inhibit Wnt signalling in a gastrula based TOPflash 
assay at varying degrees. Similarly, ZIC2 has also been shown to inhibit β-catenin mediated Wnt 
signalling in an overexpression cell-based TOPflash assay (Pourebrahim et al. 2011).  
Importantly, it has been demonstrated ZIC2 physically binds to TCF7L2 (previously TCF4) but does not 
itself bind to DNA to inhibit Wnt-dependent TCF/β-catenin mediated transcription (Pourebrahim et al. 
2011). The precise domain within the ZIC proteins that interacts with the TCF proteins is unknown, 
although the authors localised this activity to the ZIC2 ZFD via a set of domain mapping experiments 
in transformed mammalian cell lines (HEK293T and COS7 cells) using overexpression of large ZIC2 
deletion mutants. ZIC2 protein truncated before the ZFD was unable to interact with TCF7L2, thus the 
authors suggest that the ZFD is required for this interaction. However, the study did not perform 
subcellular localisation studies on the proteins and consequently failed to demonstrate whether the 
truncated forms of ZIC2 used localise to the nucleus (the site of ZIC/TCF interaction). Furthermore, 
due to the fact the ZIC proteins contain an interspersed nuclear localisation signal within the ZFD, the 
lack of ZIC2-TCF7L2 interaction observed by Pourebrahim et al. 2011 in mutants lacking a ZFD could 
simply reflect a lack of nuclear ZIC protein. Further domain mapping was performed with truncated 
forms of TCF7L2 protein co-immunoprecipitated with full-length ZIC2 to determine where ZIC2 binds 
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TCF7L2. It was found that TCF7L2 variants lacking the HMG domain and C-terminus were unable to co-
immunoprecipitate ZIC2. An in vitro protein binding assay also confirmed this variant could not bind 
ZIC2 and the authors determined the HMG domain of TCF7L2 is necessary for the ZIC2-TCF7L2 
interaction (Pourebrahim et al. 2011).  
The Arkell laboratory has also demonstrated that all five human ZIC proteins (ZIC1-5) inhibit Wnt 
signalling in a cell-based TOPflash assay (Figure 1.7A, unpublished data). In this experiment, the 
addition of wildtype β-catenin in this system is representative of a low Wnt environment. In contrast, 
β-catenin-ΔN89 is used in the TOPflash assay to represent a high Wnt environment. β-catenin-ΔN89 
contains an N-terminal deletion of the first 89 amino acids. The protein consequently lacks the N-
terminal phosphorylation sites, which are required for the normal degradation of the protein. 
Therefore, this form of β-catenin is able to evade the degradation complex and be constitutively 
expressed in the cell nucleus. All five human ZIC proteins are able to inhibit Wnt signalling in a low 
Wnt environment (in the presence of wildtype β-catenin), however, this inhibition is lost in a high Wnt 
environment (in the presence of β-catenin-ΔN89) (Figure 1.7).  
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Figure 1.7: ZIC proteins can inhibit Wnt signalling in a low Wnt environment. HEK293T cells were 
transfected with a TOPflash reporter (TOP-β-gl-luc2), either (A) V5-tagged β-catenin-wt (to stimulate 
a low Wnt environment [called β-cat-wt]) or (B) β-catenin-N89 (to stimulate a high Wnt environment 
[called β-cat-N89]) and a V5-tagged human ZIC expression plasmid (hZIC1-5) shown. Luminescence 
was measured 24 hours post-transfection in each of three internal replicate samples. Values shown 
depict the mean relative luciferase values pooled from three independent repeats. Error bars 
represent SEM. a, b, c, d, e, f: p<0.05 two-way ANOVA. Experiment performed by H. Bellchambers.   
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1.6 The Wnt signalling pathway 
Wnt signalling is a key pathway involved in many critical developmental processes such as cell 
differentiation, proliferation and migration. Wnt activity must be tightly controlled during both 
embryo development and adult homeostasis, as evidenced by severe developmental defects 
associated with the pathway and by the many forms of cancer that are caused by dysregulated Wnt 
signalling (Haegel et al. 1995; Morkel et al. 2003; Zhan et al. 2017). The ligands that simulate Wnt 
signalling can be divided into two distinct classes: classical Wnts (Wnt1, -3a, -8, and -8b) generally 
activate the canonical Wnt pathway, whilst non-classical Wnts (Wnt4, -5a, and -11) typically activate 
the non-canonical pathways, which include the planar cell polarity (PCP) pathway and the 
Wnt/Calcium signalling pathway (Rao and Kühl 2010). Both the canonical and non-canonical pathways 
involve a Wnt ligand binding to a cell surface receptor, called Frizzled, which results in a cascade of 
events that stimulates several intracellular processes.  
Non-canonical Wnt signalling is independent of the β-catenin protein. The PCP pathway is named as 
such because it is involved in establishing cell polarity and regulates cell movement during events that 
include gastrulation and neural tube closure (Komiya and Habas 2008). Wnt/Calcium signalling 
activates calcium-dependent pathways to mediate cell adhesion and controls genes responsible for 
cell migration (Croce and McClay 2008; Gó Mez-Orte et al. 2013). In contrast, the canonical Wnt 
pathway is dependent on the co-activator protein β-catenin to drive gene expression (Figure 1.8). In 
the absence of WNT ligand stimulation, β-catenin levels are depleted by its degradation in the 
cytoplasm by a destruction complex composed of adenomatous polyposis coli (APC), glycogen 
synthase kinase 3 (GSK3), and kinases casein kinase 1 (CK1), which prevent β-catenin entering the 
nucleus (Behrens et al. 1998; Liu et al. 2002). In this state, the T-cell Factor/Lymphoid Enhancer-
binding Factor (TCF/LEF) transcription factors interact with co-repressor proteins, such as the 
Groucho/transducin like Enhancer of split (Gro/TLE) family, to inhibit the transcription of Wnt target 
genes (Brannon et al. 1999; Brantjes 2001). In a Wnt activated state, a WNT ligand binds to Frizzled 
and β-catenin is released from the destruction complex and accumulates in the cytoplasm. β-catenin 
can then translocate into the nucleus where it displaces the Groucho/TLE co-repressor complexes and 
physically interacts with the TCF/LEF transcription factors to activate expression of Wnt target genes 
(He et al. 1998; Tetsu and McCormick 1999; Rao and Kühl 2010).  
It is well recognised that in Drosophila and Xenopus models, TCF proteins interact with the Gro/TLE 
co-repressors (Cavallo et al. 1998; Roose et al. 1998; Brantjes 2001). Using overexpressed protein in 
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Figure 1.8: Diagram of the canonical Wnt signalling pathway. (A) In the absence of a Wnt ligand, 
cytoplasmic levels of β-catenin are restrained. β-catenin is phosphorylated (P) by the degradation 
complex (Axin, GSK3, APC, CK1) and ubiquitinated (U) by the SCF complex which targets β-catenin for 
ubiquitin dependent degradation via the ubiquitin ligase β-TrCP (Cadigan and Peifer 2009). In the 
nucleus, Wnt gene targets are repressed by TCF proteins, TLE co-repressors and repressing 
transcription factors (R-TF). (B) Upon binding of a Wnt ligand to a receptor complex (Fz/Lrp5/6) on the 
cell membrane, a host of intracellular signalling cascades are triggered, releasing β-catenin from the 
degradation complex resulting in an accumulation of cytoplasmic β-catenin. This prompts nuclear 
import of β-catenin, where it associates with TCF proteins to drive transcription of Wnt target genes. 
(Figure adapted from Arkell et al. 2013).  
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cell-based TOPflash assays, it has been demonstrated that all mammalian Groucho members can 
inhibit reporter activation when co-expressed with TCF proteins. This transcriptional repression is 
dependent on the interaction between histone deacetylases and the Gro/TLE proteins (Brantjes 
2001). In vivo evidence of this interaction is not as well documented and there is no current mouse 
Gro/TLE allele that disrupts this TCF mediated repression to produce an elevated Wnt phenotype 
during embryo development. Consequently, it is unclear whether the Gro/TLE proteins act as TCF co-
repressors during murine gastrulation. More recently, murine studies have demonstrated the HESX1 
transcription factor interacts with TLE proteins (Carvalho et al. 2010) and results in elevated Wnt 
phenotypes including anterior truncation when mutated. Furthermore, the Hex1 phenotype is 
exacerbated when Tcf7l1 is also mutated, suggesting a genetic interaction between the two proteins 
to inhibit Wnt signalling. 
A key regulator in the canonical Wnt pathway is the β-catenin protein, encoded by the Ctnnb1 gene. 
β-catenin is the crucial mediator in gene transactivation, interacting with the TCF/LEF proteins to drive 
expression of Wnt target genes. As the β-catenin protein does not contain a DNA binding domain, it 
instead interacts with other DNA bound proteins to regulate the expression of Wnt specific genes. The 
protein contains a centrally located and conserved domain consisting of 12 armadillo repeats, which 
are involved in binding a variety of protein partners, flanked by N-terminal and C-terminal domains 
that interact with several co-activators and are involved in chromatin remodelling (Xu and Kimelman 
2007; Mosimann et al. 2009).  
1.7 Canonical Wnt signalling must be tightly regulated at mouse gastrulation 
Canonical Wnt signalling is one of the key pathways activated during early embryogenesis and is 
necessary during gastrulation in establishing the anterior-posterior axis (Huelsken et al. 2000; Hikasa 
and Sokol 2013). This pathway must be tightly controlled as dysregulation of Wnt signalling during 
embryonic development has been shown to cause a myriad of severe morphological defects. Wnt 
signalling is also important for the development of the primitive streak as loss-of-function mutations 
of Wnt activators block primitive streak formation (Huelsken et al. 2000; Kelly 2004). Gain-of-function 
alleles of Wnt activators and loss-of-function alleles of Wnt repressors lead to similar phenotypes due 
to the over-activation of Wnt signalling. The two most distinct phenotypes associated with elevated 
canonical Wnt signalling are anterior truncation and posterior axis duplication in mouse and other 
vertebrates (Zeng et al. 1997; Fossat et al. 2011). For example, ectopic activation of Wnt signalling by 
injection of β-catenin mRNA into Xenopus embryos or loss of Wnt repressors such as Axin leads to a 
duplicated axis phenotype (Funayama et al. 1995; Zeng et al. 1997). Murine studies have also shown 
that Dkk1 null embryos, lacking the DKK1 Wnt repressor, causes loss of head structures and partial or 
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complete truncation of the forebrain and midbrain (Mukhopadhyay et al. 2001; Fossat et al. 2011). 
Similarly, Tcf7l1-/- mouse embryos demonstrate an elevated Wnt phenotype during gastrulation and 
present with many morphological defects including duplicated axis structures such as the node and 
notochord and all Tcf7l1-/- embryos have anterior truncations (Merrill et al. 2004). Collectively, these 
studies demonstrate the essential role for the correct regulation of the Wnt pathway during 
embryonic development.  
Additionally, these mutant phenotypes indicate that the anterior of the embryo requires low levels of 
Wnt signalling during gastrulation and that elevation of Wnt signalling causes the posteriorisation of 
the anterior neuroectoderm and produces additional body axes. It is therefore crucial that Wnt levels 
are tightly regulated during development to prevent these phenotypes. More specifically, it is 
suggested that in all animal models investigated so far, activators of Wnt signalling and negative 
regulators are distributed at opposite ends of the embryo, resulting in Wnt signal distributed as a 
gradient along the anterior-posterior axis, with greater activity at the posterior side (Lu et al. 2011; 
Arkell et al. 2013).  
1.8 The TCF/LEF family of transcription factors  
Both humans and mice have four TCF genes: TCF7, TCF7L1, TCF7L2 (formally known as TCF1, TCF3 and 
TCF4, respectively) and LEF1. All TCF/LEF proteins contain a HMG box which recognises a specific DNA 
binding motif (known as a Wnt responsive element), and a highly conserved β-catenin binding domain 
in the N-terminus of the protein required for the transcriptional activation of target genes (Arce et al. 
2006; Hrckulak et al. 2016). TCF7L1 and TCF7L2 have an additional C-terminal Binding Protein (CtBP) 
binding domain in their C-terminus, a short amino acid sequence that is absent in TCF7 and LEF 
proteins, which mediates the interaction with CtBP proteins. CtBPs are well known as transcriptional 
co-repressors and can inhibit transcription in a histone deacetylase-dependent or -independent 
manner (Chinnadurai 2002). Although CtBP has been shown to interact with TCF proteins (Brannon et 
al. 1999), it is not clear whether this interaction has any true functional significance in vivo as the 
current evidence is contradictory. The interaction between CtBP and TCF proteins has been shown to 
mediate repression of transcription in cell-based TOPflash assays as well as the repression of Wnt 
target genes in Xenopus embryos (Brannon et al. 1999; Valenta et al. 2003). Conversely, there are 
reports that demonstrate that CtBP-dependent repression acts independently of TCF proteins in cell 
assays, and instead functions by binding to APC and sequesters cytoplasmic β-catenin, resulting in less 
freely available β-catenin for transcription activation (Hamada and Bienz 2004). Ctbp2 loss-of-function 
in mouse embryos is embryonic lethal and results in axial truncations, delayed neural development 
and reduced Brachyury (T) expression, consistent with decreased Wnt activity.  
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The TCF/LEF protein family have been shown to have overlapping expression patterns during embryo 
development which become more specialised in adult tissues. The exception is TCF7L1, which is the 
only family member that has been detected at the onset of gastrulation in mouse embryos (Merrill et 
al. 2004; Hrckulak et al. 2016). Despite the functional redundancy between the TCF/LEF protein family, 
it has become apparent that each protein possesses unique functions. For example, to date, loss-of-
function of Tcf7l1 in mice results in a gastrulation phenotype that is not seen in Tcf7, Tcf7l2 or Lef1 
mutants (Table 1.3). As stated above, the null allele of Tcf7l1 (Tcf7l1-/-) results in duplicated axis and 
abnormal node development, a phenotype commonly associated with elevated Wnt signalling at 
gastrulation (Pöpperl et al. 1997; Zeng et al. 1997). Other defects include enlarged hearts, foregut 
defects and large blood vessels (Merrill et al. 2004). Additionally, loss of Tcf7l1 in mice is embryonic 
lethal as Tcf7l1-/- embryos do not survive past embryonic day 10.5. Overall, the primary role of TCF7L1 
during gastrulation is to repress Wnt signalling (Merrill et al. 2004).  
In vivo studies have shown that TCF7L1 acts independently of β-catenin interaction during gastrulation 
(Wu et al. 2012). Mouse embryos containing a Tcf3ΔN knock-in mutation that prevents the interaction 
between TCF7L1 and β-catenin proteins progress through gastrulation without defects and do not 
display the elevated Wnt phenotype associated with Tcf7l1-/- embryos. Evidently, the role of TCF7L1 
during gastrulation does not directly involve binding to β-catenin and this model instead suggests the 
primary role of TCF7L1, at gastrulation, is that of a repressor rather than an activator of Wnt signalling.  
1.9 Zic3 loss-of-function phenocopies elevated Wnt alleles 
Zic3 null embryos are classified into four categories based on the severity of their phenotype and 
ability to initiate gastrulation (Ware 2006). The most severe phenotype is designated Type I in which 
embryos fail to gastrulate and resemble the null phenotype of Nodal (Conlon et al. 1994; Ware et al. 
2006b). In contrast, Type II mutant embryos initiate gastrulation but display a variable phenotype. 
These embryos have abnormal mesoderm and primitive streak formation. Type II mutants also have 
a duplicated axis phenotype. Type III embryos proceed through gastrulation without defects, however, 
show evidence of caudal truncation and abnormal somite development. Type IV embryos show no 
defects at the ages examined by the authors.  
In addition to L-R axis defects, murine embryos null for Zic3 (described by Sutherland et al. 2013) have 
abnormal node morphology, a phenotype seen in elevated Wnt mutants (Merrill et al. 2004). 
Moreover, recent studies have shown that a Zic3 loss-of-function mutation caused by a premature 
stop codon also shows signs of anterior truncation, axis defects and node abnormalities (Alzahrani 
2017; Arkell lab, unpublished), which are similarly hallmarks of an elevated Wnt phenotype. These 
mutant mouse models show that dysregulation of Zic3 causes elevated Wnt signalling and ultimately  
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Table 1.3: TCF/LEF family loss-of-function phenotypes  
Gene Allele Phenotype Reference 
Tcf7 Tcf7tmCle, null 
Blocked thymocyte development. Mice are viable 
and fertile 
(Verbeek et al. 
1995) 
Tcf7l1 Tcf7l1tm1.1Bjme, null 
Duplicated mesoderm structures (node and 
notochord), embryonic lethal (Tcf7l1-/- embryos do 
not survive past embryonic day 10.5) 
(Merrill et al. 
2004) 
Tcf7l2 Tcf7l2tm1Cle, null 
Neonatal lethality, decreased number of villi and 
reduced amount of epithelial cells in the small 
intestine. Heterozygous mice are viable and fertile 
(Korinek et al. 
1998) 
Lef1 Lef1tm1Rug, null 
Postnatal lethality, impaired development of hair, 
teeth and mammary glands 
(Van Genderen et 
al. 1994) 
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identify a role for ZIC3 in the repression of Wnt signalling during gastrulation. Due to the similarities 
between Zic3 loss-of-function mutants and Tcf7l1 null embryos (as well as other Wnt inhibitor 
mutants), it is hypothesised that ZIC3 acts with TCF7L1 as a co-repressor of Wnt signalling during 
early embryonic development. It still remains to be shown, however, whether ZIC3 directly 
functions with TCF7L1 and whether altered Wnt signalling is responsible for human Heterotaxy 
phenotypes.  
1.10 Scope of the thesis 
Mutation of ZIC3 is implicated in human Heterotaxy patients and loss-of-function alleles of Zic3 
phenocopy elevated Wnt alleles. This introduces a central hypothesis that questions whether ZIC3 
interacts with TCF7L1 during gastrulation to repress canonical Wnt activity and prevent Heterotaxy. 
This thesis aims to investigate whether: 
1. ZIC3 can physically interact with TCF7L1 in vitro  
2. ZIC3 Heterotaxy associated variant proteins have altered Wnt pathway function 
3. the co-factor and transcription factor functions of ZIC3 be separated 
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Chapter 2: Materials and Methods 
2.1 Plasmids 
The following reporter and expression constructs were available within the Arkell laboratory. 
Constructs were generated by myself, unless otherwise stated.  
2.1.1 General Reporter and Expression Constructs 
 p(ZM2)6-β-gl-luc2 reporter plasmid (constructed by Jerry Ahmed; Arkell laboratory). Six 
tandem copies of a ZIC DNA binding motif (CCC AGC GGG G) inserted upstream of the human 
β-globin minimal promoter and the coding sequence (CDS) for the Photinus pyralis luciferase 
gene. The plasmid provides a read-out of ZIC transactivation ability (see Appendix A for 
plasmid map). 
 pTOP-β-gl-luc2 reporter plasmid (constructed by Helen Bellchambers; Arkell laboratory). 
Three tandem copies of a TCF DNA binding motif (AAG ATC AAA GGG) inserted upstream of 
the human β-globin minimal promoter and the CDS for the P. pyralis luciferase gene. The 
plasmid provides a read-out of TCF dependent Wnt transactivation ability (see Appendix A for 
plasmid map). 
 pENTR™3C (pENTR-3C) vector (commercial vector, Invitrogen™; Cat. No. 11817-012). Used to 
create ‘Entry’ clones for Gateway® Recombination Cloning Technology (Life Technologies). 
Contains a multiple cloning site (MCS) that surrounds the negative selection gene ccdB. The 
MCS is flanked by attL sites required for Gateway® LR recombination cloning. A kanamycin 
resistance gene is included for selection in Escherichia coli (E. coli) (see Appendix A for plasmid 
map). 
 V5-Dest (pcDNA3.1-nV5-DEST) Gateway Destination plasmid (commercial vector; Invitrogen; 
Cat. No. 12290-012). Used for Gateway recombination cloning. Contains a human 
cytomegalovirus (CMV) promoter for expression in mammalian cells upstream of the CDS for 
the V5 epitope tag. Recombination based cloning sites (attR) are included to enable in-frame 
fusion of an inserted CDS with the V5 tag followed by the bovine growth hormone 
polyadenylation (bGH polyA) stop sequence. The V5 epitope tag will be fused to the N-
terminus of the inserted CDS (see Appendix A for plasmid map). 
 V1-ORF, ORF-V1 Gateway Destination plasmids (a gift from Darren Saunders, Garvan 
Institute of Medical Research, Australia). Destination vector used for Gateway Cloning. 
Contains the CMV promoter upstream of part of the Venus CDS, coding for the N-terminal 158 
amino acids of the Venus fluorescent molecule (termed V1) tag followed by two attR sites 
surrounding a ccdB gene for LR recombination based cloning (see Section 2.2.5). Venus is a 
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modified version of the Yellow Fluorescent Protein (YFP) (which itself is a variant of the Green 
Fluorescent Protein (GFP) derived from the jellyfish Aequorea Victoria). The V1 tag itself is not 
fluorescent and will only produce a fluorescent signal when interacting with V2 (the C-terminal 
section of the Venus protein).V1 tag will be attached to the N-terminus (V1-ORF) or C-
terminus (ORF-V1) of the expressed protein (see Appendix A for plasmid map). 
 V2-ORF Destination vector (a gift from Darren Saunders, Garvan Institute of Medical 
Research, Australia) used for Gateway Cloning. Contains the CMV promoter upstream of part 
of the Venus CDS, coding for the C-terminal 81 amino acids of the Venus fluorescent molecule 
(termed V2) tag followed by two attR sites surrounding a ccdB gene for LR recombination 
based cloning (see Section 2.2.5; Appendix A for plasmid map).  
 pFLAG-CMV-TCF7L2: Originally pFLAG-CMV-TCF4 (Idogawa et al., 2005). Mammalian 
expression construct containing human TCF7L2 cDNA. A gift from Sabine Tejpar (Department 
of Oncology, Katholieke University Leuven, Belgium).  
 Myc-Tcf7l1 (pBM58-Tcf7l1): pcDNA3 vector containing full length murine Tcf7l1 cDNA tagged 
with a Myc epitope. A gift from Bradley Merrill (Department of Biochemistry and Molecular 
Genetics, University of Illinois at Chicago; see Appendix A for plasmid map). 
 pENTR3C-hZIC3-wt: Gateway entry vector (constructed by Jerry Ahmed; Arkell laboratory). An 
Entry clone containing the human ZIC2 CDS flanked by att recombination sites to catalyse 
transfer of the hZIC2 CDS to any Gateway Destination vector. 
 pUC57-hTCF7L1 (commercial vector, Genscript): Contains the entire human TCF7L1 CDS 
within the pUC57 vector backbone with att recombination sites on either side of the TCF7L1 
CDS.  
 pUC57-mZic3 (commercial vector, Genscript): Contains the entire mouse Zic3 CDS within the 
pUC57 vector backbone with attR recombination sites on either side of the Zic3 CDS. 
 pENTR3C-mTcf7l1: The 1943 bp murine Tcf7l1 CDS was amplified from Myc-Tcf7l1 (pBM58-
Tcf7l1) plasmid DNA with oligonucleotides containing XhoI and BamHI restriction sites 
(Ark_1578 and Ark_1579, Table 2.8). Following a gel extraction clean-up, the Tcf7l1 fragment 
and the Gateway Entry vector pENTR3C were digested with XhoI and BamHI (section 2.3.2), 
releasing the ccdB fragment from pENTR-3C. The Tcf7l1 fragment was ligated into the digested 
pENTR30 via traditional T4 ligation methods (section 2.3.4). The final vector is an entry clone 
containing the mouse Tcf7l1 CDS flanked by attR recombination sites to catalyse transfer of 
the Tcf7l1 CDS to any Gateway destination vector (see Appendix A for plasmid map). 
 V2-Tcf7l1 Expression plasmid: Contains a CMV promoter for expression in mammalian cells 
upstream of the C-terminal section of the CDS for Venus fluorescent protein in-frame with 
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wildtype Tcf7l1 CDS for expression of a V2-Tcf7l1 fusion protein. (See Appendix A for plasmid 
maps). 
 pβ-catenin-V5-HIsA (V5-β-catenin) Expression plasmid: A gift from Yoshitaki Sekido (Usami 
et al. 2003). Contains a CMV promoter for expression in mammalian cells upstream of the 
human β-catenin CDS in-frame with the CDS for the V5 epitope tag and 6 tandem Histidine 
residues followed by the bGH polyA stop sequence, for expression of V5-tagged wildtype β-
catenin protein. (See Appendix A for plasmid map). 
 pΔN89-β-catenin Expression plasmid: A gift from Sabine Tejpar; Department of Oncology, 
Katholieke University Leuven, Belgium); originally described in (Munemitsu et al. 1996). 
Contains a CMV promoter for expression in mammalian cells upstream of the Myc epitope tag 
CDS in-frame with a mutated human β-catenin CDS (N terminal 89 residues deleted) for 
expression of Myc-tagged ΔN89 β-catenin protein. The deleted residues contain 
phosphorylation sites necessary for β-catenin ubiquitination and degradation, and thus the 
ΔN89 β-catenin protein is stabilised and has elevated transactivation ability relative to 
wildtype β-catenin. (See Appendix A for plasmid map). 
 pV1-hZIC3-wt Expression plasmid (constructed by Helen Bellchambers): Contains a CMV 
promoter for expression in mammalian cells upstream of the N-terminal section of the CDS 
for Venus fluorescent protein in-frame with wildtype hZIC3 CDS for expression of a V1-ZIC3 
fusion protein. (See Appendix A for plasmid maps).  
 pnV5-hZIC3-wt Expression plasmid (constructed by Jerry Ahmed): Contains a CMV promoter 
for expression in mammalian cells upstream the V5 epitope tag CDS in-frame with the hZIC3 
wildtype CDS followed by the bGH polyA stop sequence, for expression of V5-tagged wildtype 
ZIC3 protein (see Appendix A for plasmid map). 
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2.1.2 ZIC3 variant constructs 
All ZIC3 variant plasmids were produced via site directed mutagenesis of the pENTR3C-ZIC3-wt 
plasmid (section 2.2.2). The following constructs were generated: 
 Premature termination codon (PTC) containing mutants: pENTR-ZIC3-C268X, pENTR-ZIC3-
Q292X, pENTR-ZIC3-E325LfsX84, pENTR-ZIC3-K408X, pENTR-ZIC3-E155X, pENTR-ZIC3-
Y199delfsX19, pENTR-ZIC3-Q249X, pENTR-ZIC3-S252X and pENTR-ZIC3-E291GfsX53 all 
contain a nonsense mutation, except pENTR-ZIC3-E325LfsX84, pENTR-ZIC3-Y199delfsX19 and 
pENTR-ZIC3-E291GfsX53, which contain a frame-shift mutation. Construct names show the 
specific amino acid (C268, Q292, K408, E155, Q292, and S252) that is mutated to a stop codon 
(X), with numbers indicating amino acid number of the translated protein product. ZIC3 
variants pENTR-ZIC3-C268X, pENTR-ZIC3-Q292X, pENTR-ZIC3-E325LfsX84, and pENTR-ZIC3-
K408X were made by Jerry Ahmed 
 Human missense mutations: pENTR-ZIC3-C253S, pENTR-ZIC3-W255G, pENTR-ZIC3-H286R, 
pENTR-ZIC3-G17C, pENTR-ZIC3-S109C, pENTR-ZIC3-P217A, pENTR-ZIC3-H318N and pENTR-
ZIC3-A447G. Each mutant contained a missense mutation altering a single amino acid within 
ZIC3 Variants C253S, W255G and H286R affect a conserved residue in ZF1 
 Targeted Zinc finger mutations: pENTR-ZIC3-C268S, pENTR-ZIC3-C302S, pENTR-ZIC3-C335S, 
pENTR-ZIC3-C365S, and pENTR-ZIC3-C393S. Each construct contained a missense mutation 
that converted the second cysteine (C) of ZF1 (C268), ZF2 (C302), ZF3 (C335), ZF4 (C365) or 
ZF5 (C393) to serine (S). Mutations were installed using site-directed mutagenesis (section 
2.2.2). pENTR-ZIC3-C365S was constructed by Jerry Ahmed  
 Low complexity region deletion mutants: pENTR-ZIC3-Aladel, pENTR-ZIC3-Hisdel. Constructs 
were missing either the Alanine repeat or the Histidine repeat of ZIC3 
 Conserved domain deletion mutants: pENTR-ZIC3-ZOCdel, pENTR-ZIC3-ZFNCdel, pENTR-
ZIC3-N’del, pENTR-ZIC3-SANCdel, pENTR-ZIC3-SACCdel. Mutants were missing either the ZOC 
domain (ZIC3-ZOCdel), the ZFNC domain (ZIC3-ZFNCdel), the whole N-terminus region 
preceding the ZFD (ZIC3-Ndel), the SANC domain (ZIC3-SANCdel) or the SACC domain (ZIC3-
SACC del). 
All ZIC3 ‘Entry’ clones (pENTR-ZIC3-) were transferred to the V5-DEST expression vector via a 
Gateway® LR Clonase reaction (Life Technologies; section 2.2.5) to generate V5-ZIC3-C268X, V5-ZIC3-
Q292X, V5-ZIC3-E325LfsX84, V5-ZIC3-K408X, V5-ZIC3-E155X, V5-ZIC3-Y199delfsX19, V5-ZIC3-Q249X, 
V5-ZIC3-S252X, V5-ZIC3-E291GfsX53, V5-ZIC3-C253S, V5-ZIC3-W255G, V5-ZIC3-H286R, V5-ZIC3-
G17C, V5-ZIC3-S109C, V5-ZIC3-P217A, V5-ZIC3-H318N, V5-ZIC3-A447G, V5-ZIC3-C268S, V5-ZIC3-
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C302S, V5-ZIC3-C335S, V5-ZIC3-C365S, V5-ZIC3-C393S, V5-ZIC3-Aladel, V5-ZIC3-Hisdel, V5-ZIC3-
SANCdel, V5-ZIC3-SACCdel, V5-ZIC3-ZOCdel, V5-ZIC3-ZFNC and V5-ZIC3-N’del. 
 
Similarly, all Entry’ clones (pENTR-) were transferred to the V1-DEST expression vector via a Gateway® 
LR Clonase reaction (Life Technologies; section 2.2.5) to generate: V1-ZIC3-C268X, V1-ZIC3-Q292X, 
V1-ZIC3-E325LfsX84, V1-ZIC3-K408X, V1-ZIC3-E155X, V1-ZIC3-Y199delfsX19, V1-ZIC3-Q249X, V1-
ZIC3-S252X, V1-ZIC3-E291GfsX53, V1-ZIC3-C253S, V1-ZIC3-W255G, V1-ZIC3-H286R, V1-ZIC3-G17C, 
V1-ZIC3-S109C, V1-ZIC3-P217A, V1-ZIC3-H318N, V1-ZIC3-A447G, V1-ZIC3-C268S, V1-ZIC3-C302S, V1-
ZIC3-C335S, V1-ZIC3-C365S, V1-ZIC3-C393S, V1-ZIC3-Aladel, V1-ZIC3-Hisdel, V1-ZIC3-SANCdel, V1-
ZIC3-SACCdel, V1-ZIC3-ZOCdel, V1-ZIC3-ZFNC and V1-ZIC3-N’del. 
2.1.3 Yeast two-Hybrid vectors  
 pDEST-32: Gateway Destination vector containing the GAL4 DNA binding domain (commercial 
vector; provided with ProQuest Two-Hybrid System, Invitrogen). This vector is used to clone 
a gene of interest in-frame with the GAL4 DNA binding Domain to be used in Yeast Two-Hybrid 
assays. The vector contains the ADH1 promotor and TRP1 CDS for selection on plates lacking 
tryptophan. 
 pDEST-22: Gateway Destination vector containing the GAL4 Activation domain (commercial 
vector; provided with ProQuest Two-Hybrid System, Invitrogen). This vector is used to clone 
a gene of interest in-frame with the GAL4 Activation domain to be used in Yeast Two-Hybrid 
assays. The vector contains the ADH1 promotor and LEU2 CDS for selection on plates lacking 
leucine.  
 p32-ZIC3: ProQuest Two-Hybrid expression construct containing human ZIC3 CDS fused with 
the GAL4 DNA Binding Domain. Construct was generated via a Gateway LR recombination 
reaction using plasmids pENTR-ZIC3-wt and pDEST-32. 
 p32-Tcf7l1: ProQuest Two-Hybrid expression construct containing Tcf7l1 CDS fused with the 
GAL4 DNA Binding Domain. Construct was generated via a Gateway LR recombination reaction 
using plasmids pENTR-Tcf7l1-wt and pDEST-32. 
 p22-ZIC3-wt: ProQuest Two-Hybrid expression construct containing human ZIC3 CDS fused 
with the GAL4 Activation Domain. Construct was generated via a Gateway LR recombination 
reaction using plasmids pENTR-ZIC3-wt and pDEST-22. 
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 p22-Tcf7l1: ProQuest Two-Hybrid expression construct containing Tcf7l1 CDS fused with the 
GAL4 Activation Domain. Construct was generated via a Gateway LR recombination reaction 
using plasmids pENTR-Tcf7l1-wt and pDEST-22. 
 pEXP32-Krev1: ProQuest Two-Hybrid expression construct (commercial vector; provided with 
ProQuest Two-Hybrid System, Invitrogen) containing full length wildtype rat Krev1 CDS fused 
with the GAL4 DNA Binding Domain. Used as a control vector (Bait plasmid) in conjunction 
with pEXP22-RALGDS to demonstrate a positive protein interaction.  
 pEXP22-RalGDS-wt: ProQuest Two-Hybrid expression construct (commercial vector; provided 
with ProQuest Two-Hybrid System, Invitrogen) containing the wildtype Ras association 
domain of the RalGDS protein. Used as a control vector (Prey plasmid) in conjunction with 
pEXP32-Krev1 to demonstrate a strong positive protein interaction.  
 pEXP22-RalGDS-m1: ProQuest Two-Hybrid expression construct (commercial vector; 
provided with ProQuest Two-Hybrid System, Invitrogen) containing a mutant form of the Ras 
association domain of the RalGDS protein. Used as a control vector (Prey plasmid) in 
conjunction with pEXP32-Krev1 to demonstrate a weak positive protein interaction.  
 pEXP22-RalGDS-m2: ProQuest Two-Hybrid expression construct (commercial vector; 
provided with ProQuest Two-Hybrid System, Invitrogen) containing a mutant form of the Ras 
association domain of the RalGDS protein. Used as a control vector (Prey plasmid) in 
conjunction with pEXP32-Krev1 to demonstrate a negative protein interaction.   
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2.2 Molecular Cloning 
2.2.1 Buffer and Solutions  
 Luria Broth (LB) media: 25 g/L Difco™ LB broth, Miller; Bacto.  
 LB Agar: 40 g/L Difco™ LB agar, Miller; Bacto. 
 Lysis Solution: 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl (Sigma-Aldrich) pH 8.5, 1 
mM EDTA (ethylenediaminetetraacetic acid; Ajax Chemicals), 5% Tween-20 (Sigma-Aldrich) 
and 0.4 mg/mL of Proteinase K (Roche). 
 Loading Dye 10x: 20% glycerol (Merck), 19.2% 0.5 M Na2EDTA (Sigma-Aldrich) and 0.001% 
bromophenol blue (Sigma-Aldrich). 
2.2.2 Site directed mutagenesis 
Mutations in the ZIC3 CDS (C253S, W255G, H286R, E155X, C268S, C302S, C335S, C365S, C393S C268X, 
Q292X, E325LfsX84 and K408X) were created using the QuikChange Lightning Site-Directed 
Mutagenesis kit (Agilent Technologies; Cat. No. 210518) by following manufacturer’s instructions. 
Mutagenesis PCRs (polymerase chain reaction) were performed in a total volume of 50 μL using 100 
ng of pENTR-ZIC3-wt and 0.25 μM of each primer (Table 2.1, 2.2). Cycling parameters are shown in 
Table 2.3. Upon PCR completion, samples were treated with 2 μL of DpnI enzyme (NEB; Table 2.4) by 
incubation at 37°C for 2 h. The reaction was precipitated (yeast precipitation, section 2.3.5.2) and 
electro-transformed into DH5α electrocompetent cells, or transformed using L10-Gold® (Agilent) 
ultracompetent bacteria cells (supplied with kit) via heat-shock according to manufacturer’s 
instructions. 
All other mutations within the ZIC3 CDS were created using site-directed mutagenesis with a proof-
reading Taq polymerase. For deletion mutations, primers were constructed to amplify the entire 
plasmid sequence (Table 2.1, 2.2), except the region to be deleted (Pérez-Pinera et al. 2006). The 
forward primer binds at the C-terminal side of the target region, while the reverse primer binds at the 
N-terminal side (Figure 2.1). The primers bind the template via their 3’-ends, while their 5’-ends 
contain complimentary overhangs. Ultimately the 5’-end of each primer contains a region of homology 
to each other (at least 15-16 bp) that allows annealing into a double-stranded DNA fragment. 
Mutagenesis PCRs were performed with the PfuUltra II Hotstart PCR Master Mix (Agilent 
Technologies; Cat. No. 600850) in a total volume of 50 μL using 10 ng of pENTR-ZIC3-wt, 0.2 μM of 
each primer and the cycling conditions shown in Table 2.5. The reaction was then precipitated (section 
2.3.5.2) followed by digestion with DpnI (NEB; Cat. No. R0176) for 2 h. DNA was then precipitated and 
electro-transformed into E. coli (section 2.2.3). The resulting bacterial colonies were screened for the 
correct plasmid via colony PCR (section 2.2.4) and/or DNA sequencing (section 2.3.6).  
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Table 2.1: Primers for site directed mutagenesis of pENT-ZIC3-wt to create human ZIC3 Heterotaxy 
associated variants.  F: forward, R: reverse 
Mutation Primer # Sequence (5’-3’) 
ZIC3-C268X 
Ark1399_F CGG CCC AAG AAG AGC TGA GAC CGG ACC TTC AGC 
Ark1400_R GCT GAA GGT CCG GTC TCA GCT CTT CTT GGG CCG 
ZIC3-Q292X 
Ark1401_F GTG GGG GGC CCG GAG TAG AAC AAC CAC GTC TGC 
Ark1402_R GCA GAC GTG GTT GTT CTA CTC CGG GCC CCC CAC 
ZIC3-E325LfsX84 
Ark1403_F CCG AGT GCA CAC GGG CTT GAG AAG CCC TTC CCA 
Ark1404_R TGG GAA GGG CTT CTC AAG CCC GTG TGC ACT CGG 
ZIC3-K408X 
Ark1405_F CTG CGC AAA CAC ATG TAG GTT CAT GAA TCT CAA 
Ark1406_R TTG AGA TTC ATG AAC CTA CAT GTG TTT GCG CAG 
ZIC3-Y199delfsX19 
Ark1806_F GCTGACCCAGCCCGCGCACGGACCC 
Ark1807_R CGGGCTGGGTCAGCACGGCCGAAC 
ZIC3-Q249X 
Ark1810_F GCCAATCAAGTAGGAGCTGTCGT 
Ark1811_R ACGACAGCTCCTACTTGATTGGC 
ZIC3-S252X 
Ark1812_F CAGGAGCTGTAGTGCAAGTGGATC 
Ark1813_R GATCCACTTGCACTACAGCTCCTG 
ZIC3-E291GfsX53 
Ark1808_F TGGAGCATGTGGGGGGGCCCGGAGCA 
Ark1809_R TGCTCCGGGCCCCCCCACATGCTCCA 
ZIC3-E155X 
Ark1655_F GGC ATC CCC TAG CCC CCT AGC TAC TTG 
Ark1656_R CAA GTA GCT AGG GGG CTA GGG GAT GCC 
ZIC3-C253S 
Ark1649_F CAG GAG CTG TCG TCC AAG TGG ATC GAC 
Ark1650_R GTC GAT CCA CTT GGA CGA CAG CTC CTG 
ZIC3-W255G 
Ark1651_F CG TGC AAG GGG ATC GAC GAG GCT C 
Ark1652_R G AGC CTC GTC GAT CCC CTT GCA CG 
ZIC3-H286R Ark1653_F GTC ACC ATG GAG CGT GTG GGG GGC 
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Ark1654_R GCC CCC CAC ACG CTC CAT GGT GAC 
ZIC3-G17C 
Ark1794_F CTGGGAGTGTGCAGCTTCGG 
Ark1795_R CCGAAGCTGCACACTCCCAG 
ZIC3-S109C 
Ark1796_F CGCTGCCTGTGCCGCCTTC 
Ark1797_R GAAGGCGGCACAGGCAGCG 
ZIC3-P217A 
Ark1798_F CGCTCAGTTTGCTAACTACAGCC 
Ark1799_R GGCTGTAGTTAGCAAACTGAGCG 
ZIC3-H318N 
Ark1689_F TAC AAA CTG GTC AAC AAC ATC CGA GTG C 
Ark1690_R GCA CTC GGA TGT TGT TGA CCA GTT TGT A 
ZIC3-A447G 
Ark1804_F CCCCTTCTGGAGTTCAAACTAGC 
Ark1805_R GCTAGTTTGAACTCCAGAAGGGG 
 
Table 2.2: Primers for site directed mutagenesis of pENT-ZIC3-wt to create ZIC3 structural variants. 
Mutation Primer Sequence (5’-3’) 
ZIC3-SANC-del 
Ark1753_F CCC CCT AGT GGC GCT GGG CAC CCG TC 
Ark1752_R CCC AGC GCC ACT AGG GGG CTC GGG GAT GC 
ZIC3-SACC-del 
Ark1739_F TCA GAC TCC GCT ATA GCT TCA GCA AAC AGT AAA GAT ACC 
Ark1738_R AGC TAT AGC GGA GTC TGA CCC TTG AGA TTC ATG AAC 
ZIC3-ZOC-del 
Ark1644_F CCT TCA ACT CAA GCT CCG GGC TCA GTG A 
Ark1643_R CGG AGC TTG AGT TGA AGG CGG CAG AG 
ZIC3-ZFNC-del 
Ark1648_F AC GGT CCT CTG TCG TGC AAG TGG ATC G 
Ark1647_R A CGA CAG AGG ACC GTG GTG GGC CG  
ZIC3-N’-del 
Ark1675_F CGA ATT CAT GTG CAA GTG GAT CGA CGA G 
Ark1676_R CTT GCA CAT GAA TTC GGT ACC GGA TCC AG 
ZIC3-Ala-del 
Ark1692_F CCC ACT TCA AGC TGA GCC CTG CC 
Ark1691_R TCA GCT TGA AGT GGG TTG AGT CCC CGA A 
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ZIC3-His-del 
Ark1694_F GGG CAC CAG CCA GGT CCC CAG C 
Ark1693_R CCT GGC TGG TGC CCA GGG CGT TGG CGT A 
ZIC3-C268S 
Ark1608_F CCCAAGAAGAGCTCCGACCGGACCTTCAGC 
Ark1609_R GCTGAAGGTCCGGTCGGAGCTCTTCTTGGG 
ZIC3-C302S 
Ark1610_F GCTACTGGGAGGAGTCCCCCCGGGAG 
Ark1611_R CTCCCGGGGGGACTCCTCCCAGTAGC 
ZIC3-C335S 
Ark1612_F CCTTCCCGGGCTCCGGGAAGATCTTTGCC 
Ark1613_R GGCAAAGATCTTCCCGGAGCCCGGGAAGG 
ZIC3-393S 
Ark1614_F CCCTATATCTGCAAAGTGTCCGACAAGTCCTACACG 
Ark1615_R CGTGTAGGACTTGTCGGACACTTTGCAGATATAGGG 
 
  
64 
 
Table 2.3: Thermal cycling parameters using the QuikChange Lightning Site-Directed Mutagenesis 
kit. 
Program Temperature Time Cycles 
Initial denaturation 95°C 2 min 1 
Denature 95°C 20 sec 
18 Anneal 60°C 10 sec 
Extend 68°C 115 sec 
Polish 68°C 5 min 1 
 
 
Table 2.4: Reaction conditions for restriction enzyme digests.  All restriction enzymes sourced from 
New England Biolabs (NEB). m: methylated 
Enzyme Recognition Sequence 
(5’ to 3’) 
/ = denotes cut site 
Incubation 
Temperature (°C) 
Incubation 
Time (h) 
NEB Buffer 
EcoRI G/AATTC 37 2 NEB1,2 or CutSmart 
BamHI G/GATCC 37 2 CutSmart 
XhoI C/TCGAG 37 2 CutSmart 
DpnI GAm/TC 37 2 NEB2 or CutSmart 
 
 
Table 2.5: Thermal cycling parameters for site directed mutagenesis using PfuUltra II Hotstart 
polymerase. 
Program Temperature Time Cycles 
Initial denaturation 95°C 2 min 1 
Denature 95°C 20 sec 
30 Anneal 60°C 20 sec 
Extend 72°C 57 sec 
Polish 72°C 3 min 1 
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Figure 2.1: Creation of deletion mutants by overlap extension PCR. 1: Primers (pF: forward primer; 
pR: reverse primer) are designed to have their 5’-ends directed towards each other and 3’-ends 
oriented such that the DNA polymerase extends the entire plasmid, except the region to be deleted. 
The PCR is performed with a proofreading DNA polymerase. 2: PCR products are precipitated (to 
isolate DNA from the reaction mixture) and 3: treated with DpnI to digest the methylated template 
plasmid (Lacks and Greenberg 1975). 4: Following another round of DNA precipitation, bacteria are 
electro-transformed with the newly synthesised mutant plasmid. Screening of colonies can be done 
via colony PCR and/or DNA sequencing.   
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2.2.3 Bacterial transformation and culture 
Bacterial transformation 
For electroporation, ~20 ng of plasmid DNA, or 1 μL of a precipitated ligation reaction or LR reaction, 
were added to ice-cold E. coli cells (stored at -80°C). The cells and DNA were transferred to a chilled 
0.2 cm electrocuvette (BioRad) and electroporated in an E.coli Gene Pulser (BioRad) set to deliver an 
electric field of 12.5 kVcm-1 (2.5 Kv, 25 F and 200 ) to allow entry of the plasmid DNA. Immediately 
after pulsing, 500 μL of LB media (Bacto; Cat. No. 244620) was added to the electrocuvette to revive 
the bacteria and the solution was transferred to a 1.5 mL Eppendorf tube and incubated for 1 h on a 
rotating platform at 37°C. The bacterial solution was then plated on to LB Agar (Bacto; Cat. No. 
244520) containing 0.1 mg/mL of the appropriate antibiotic (ampicillin: Sigma-Aldrich; Cat. No. A9518-
5G, or kanamycin: Sigma-Aldrich; Cat. No. 60615-5G) and incubated for 16 h at 37°C. 
2.2.4 Colony PCR 
To enable direct analysis of the resulting bacterial colonies without isolation of plasmid DNA, colony 
PCRs were performed. Single colonies were hand-picked from the agar plate using a sterile pipette tip 
and the tip placed into 20 µL of AnalaR H2O for 5 min to allow resuspension of the colony. 
Subsequently, 5 µL of the bacterial/H2O solution was used in a standard 20 µL PCR using the primers 
listed in Table 2.6. The remaining bacterial suspension was stored at 4°C until analysis was complete. 
Colonies positive for the required DNA were used to inoculate 5 mL of LB broth containing 100 μg/mL 
of either ampicillin or kanamycin in a vented 15 mL tube. The tubes were incubated in a shaking 37°C 
incubator for 16 h. 
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Table 2.6: Primers used for screening of bacterial colonies containing the desired plasmids. 
Plasmid Primer # Sequence (5’-3’) TA (°C) 
pENTR3C-
ZIC3-Aladel 
Ark1152_F ATCCGGTACCGAATTCACCCTCTCTCACTTCGG 
60 
Ark1009_R ATGCAGGCTGCTCGCCGAGC 
pENTR3C-
ZIC3-Hisdel 
Ark1225_F CTATCTTCAGGCCAGAGC 
57 
Ark1009_R ATGCAGGCTGCTCGCCGAGC 
pENTR3C-
ZIC3-SANC 
Ark1225_F CTATCTTCAGGCCAGAGC 
50 
Ark1019_R TGACCAGTTTGTACTTCGCC 
pENTR3C-
ZIC3-SACC 
Ark1173_F TGGTCAACCACATCCGAGTGC 
55 
Ark1256_R GACTGATAGTGACCTGTTCGTTG 
pENTR3C-
ZIC3-ZOC 
Ark1225_F CTATCTTCAGGCCAGAGC 
50 
Ark1019_R TGACCAGTTTGTACTTCGCC 
pENTR3C-
ZIC3-ZFNC 
Ark1225_F CTATCTTCAGGCCAGAGC 
50 
Ark1019_R TGACCAGTTTGTACTTCGCC 
 
  
68 
 
2.2.5 Gateway Left-Right Recombination reaction 
DNA sequences were transferred from Entry vectors (pENTR) into Destination expression vectors (V5-
DEST, V1-ORF, V2-ORF) using a Gateway LR recombination (Invitrogen™) reaction (Figure 2.2). 
Gateway cloning utilises the Lambda phage attachment (att) site-specific recombination system to 
transfer DNA sequences between two vectors with high efficiency. This system is based on that used 
by bacteriophage lambda during integration/excision of phage DNA into a bacterial chromosome 
(Craig and Nash 1984). In bacteria, integration of DNA occurs through specific attP sites on the phage 
chromosome and attB sites on the bacterial chromosome and is mediated by intergrase (Int) and 
intergrase host factor (IHF) proteins, which bind to the specific att sites to cleave and join target DNA. 
After recombination, the integrated phage DNA is now flanked by hybrid attL and attR sites in the 
bacterial chromosome (attP x attB  attL + attR). The desired plasmid is selected by a combination 
of antibiotic resistance and the negative selection of the original Destination vector based on the 
presence of the lethal ccdB gene. 
Each LR reaction (performed according to modified manufacturer’s instructions) contained equal 
amounts (150 ng) of ‘Entry’ and ‘Destination’ vectors, in a total volume of 9 L of Tris-EDTA (10 mM 
Tris-Cl, pH 8.0 1 mM EDTA) and half the recommended amount of LR Clonase II Mix (1 L). The reaction 
products were precipitated in the presence of 5 µL of yeast RNA (1 µg/µL; Sigma-Aldrich; see section 
2.3.5.2) before being electro-transformed into DH5α bacteria (section 2.2.3) and grown on ampicillin 
agar plates to select for the desired plasmid.  
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Figure 2.2: The Gateway Left-Right (LR) Recombination Reaction. Gateway cloning utilises the 
Lambda phage site-specific recombination system to transfer DNA sequences between two vectors 
with high efficiency. An ‘Entry’ Clone contains the gene of interest (ZIC3), flanked by attL1 and attL2 
sites and the kanamycin resistance CDS (KnR). The ‘Destination’ vector contains the CDS for the cell 
lethal ccdB gene flanked by attR1 and attR2 sites, and the ampicillin resistance CDS (AmpR). The ‘Entry’ 
clone and Destination Vector undergo a site-specific recombination reaction mediated by the LR 
Clonase Enzyme Mix to form the desired Expression Clone containing the gene of interest and an 
unviable by-product. The reaction is transformed into DH5α bacteria (in which the ccdB gene product 
is lethal) and grown on ampicillin+ media to select bacteria containing the desired expression clone. 
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Small scale and large scale plasmid isolation (Mini and Midi prep) 
Depending on the amount of DNA required, plasmid DNA was isolated using two methods. To isolate 
small quantities of plasmid DNA (<5 g), single colonies were handpicked from LB-agar plates using a 
sterile tip and placed in a 14 mL bacterial culture tube containing 3-5 mL LB broth with an appropriate 
antibiotic (0.1 g/mL) and incubated overnight (16 h; 37˚C with shaking at 160 rpm). The plasmid DNA 
was then isolated using the High Pure Plasmid Isolation Kit (Scientifix; Cat. No. 740588.25) following 
the manufacturer’s instructions. The resulting plasmid DNA was suspended in 100 L of AnalaR H2O. 
For larger quantities of DNA (>5 g), a bacterial starter culture was made by inoculating 3 mL of LB 
broth containing the appropriate antibiotic (0.1 g/mL) with a single bacterial colony. The starter 
culture was incubated for 5-8 h (37°C with shaking at 160 rpm) and 100 L of this culture was then 
added to a further 100 mL of LB Broth and incubated overnight (16 h; 37˚C with shaking at 160 rpm). 
The bacterial cells were pelleted by centrifugation at 3,200 x g for 20 min at 4˚C and DNA was isolated 
using the NucleoBond Xtra Midi Plasmid DNA purification kit (Scientifix; 740410.5) following the 
manufacturer’s instructions. The resulting plasmid DNA was suspended in an appropriate amount of 
AnalaR H2O. The concentration and purity of the plasmid DNA was determined using a 
spectrophotometer (NanoDrop 1000 v8.1) and the DNA stored at -20˚C until required.  
2.3 General Molecular Biology 
2.3.1 Polymerase Chain Reaction (PCR) 
PCR was carried out using a Mastercycler® Vapo.protect™ or Mastercycler® Epgradient S™ 
(Eppendorf). PCR primers were designed for sequencing, colony PCR and general PCR amplification 
(Table 2.6 and Table 2.8). To promote specificity, primers were designed such that they had a G/C 
clamp at the 3’ end where three of the five 3’ most bases were G or C. The melting temperature (Tm) 
of the primers was designed to be within 45–65°C and primer pairs were designed to have a Tm within 
5°C of each other. PCR products were amplified with 10-20 ng of plasmid DNA with each of the two of 
the primers at a final concentration 0.5 µM. Reactions were made in a total volume of 20 µL using a 
commercial PCR buffer at 1X (ImmoMix [Bioline], ReddyMix [Bioline] or ReddyMixKCl [Thermo 
Scientific]; Table 2.7). Thermal cycling was performed using a standard PCR program in which, after an 
initial denaturation step (94°C, 5 min), the DNA is briefly denatured at 95°C (30 s per cycle), the primers 
annealed to the template DNA at a temperature empirically determined for each primer pair (30 s per 
cycle) and then the amplicon extended at 72°C (30 s per cycle). Before a final extension at 72°C for 7 
min. Success of the PCR was analysed by gel electrophoresis. 
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Table 2.7: PCR mastermixes used for amplifying plasmid and genomic DNA. 
Buffer Components Supplier 
2X ImmoMix™ IMMOLASE™ DNA 
Polymerase, Stabiliser, 2 mM 
dNTPs, 
32 mM (NH4)2SO4, 134 mM 
Tris-HCl [pH 8.3], 0.02% 
Tween 20, 3 mM MgCl2 
Bioline 
2X PCR ReddyMix™ 
Master Mix with KCl 
ThermoPrime Taq 
polymerase, 75 mM Tris-HCl 
(pH 
8.8), 50 mM KCl, 20 mM 
(NH4)2SO4, 1.5 mM MgCl2, 
0.01% (v/v) Tween 20, 0.2 
mM dNTPs, Inert dye 
Thermo Scientific 
2X PCR ReddyMix™ 
Master Mix without 
KCl 
ThermoPrime Taq 
polymerase, 75 mM Tris-HCl 
(pH 
8.8), 20 mM (NH4)2SO4, 1.5 
mM MgCl2, 0.01% (v/v) 
Tween 20, 0.2 mM dNTPs, 
Inert dye 
Thermo Scientific 
PfuUltra II Hotstart PCR 
Master MIX 
PfuUltra II Fusion HS DNA 
polymerase, reaction buffer, 
magnesium and dNTPs* 
Agilent Technologies 
*component concentrations not disclosed by the manufacturer  
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2.3.2 Restriction Enzyme Digestion 
Plasmid DNA was digested with restriction enzymes for either diagnostic or cloning purposes. The 
amount of restriction enzyme per reaction was calculated according to the general principle that one 
unit of a restriction enzyme can digest to completion 1 µg of plasmid DNA in 1 h. A minimum 5 fold 
excess of restriction enzyme to DNA (5 U/µg of plasmid DNA) was used in each restriction enzyme 
digest. Additional reaction components (such as restriction enzyme buffer and BSA) were added as 
recommended by the manufacturer of the restriction enzyme (Table 2.4) and all reactions were 
conducted in a volume that ensured the restriction enzyme component did not exceed 10% of the 
total reaction volume. The reactions were incubated at the recommended temperature for 2-3 h and 
heat inactivated as appropriate for the enzyme used.  
2.3.3 Agarose Gel Electrophoresis 
To analyse DNA fragments, samples were separated by horizontal gel electrophoresis. Agarose gels 
were created using Ultrapure Agarose (Life Technologies) and 1X TBE buffer (0.1 M Tris-HCl, 0.09 M 
boric acid and 0.001 M EDTA; Amresco). Agarose gels contained RedSafe™ DNA gel stain (1:20,000 
dilution; Intron Biotechnology) to allow DNA to be visualised. DNA that ranged between 10,000 bp 
and 500 bp was run on a 1% gel, whilst DNA between 500 bp and 100 bp was run on a 2% gel. Samples 
were prepared for electrophoresis by the addition of 10X loading dye and 500 ng of the 1 Kb+ DNA 
ladder (Life Technologies), which was loaded onto all gels to enable sizing of the electrophoresed DNA. 
Agarose gels were electrophoresed at 6-8 V/cm-1 until the DNA was sufficiently resolved (generally 20-
40 min). The Gel Doc XR system and the accompanying Quantity One software (Bio-Rad) were used to 
visualise DNA products on the gel using an ultraviolet (UV) light source, and to photograph the gel. 
2.3.4 DNA Ligation 
DNA fragments were inserted into a prepared vector using T4 DNA ligase (NEB). To increase the 
probability of the production of the desired ligation product, two reactions with different vector to 
insert molar ratios (1:2 and 1:5) were generated for each insert/vector combination, calculated with 
the following formula: 
𝐼𝑛𝑠𝑒𝑟𝑡 𝑙𝑒𝑛𝑔𝑡ℎ (𝑏𝑝)
𝑉𝑒𝑐𝑡𝑜𝑟 𝑙𝑒𝑛𝑔𝑡ℎ
× 50 𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 = 𝑥 𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑜𝑟 1: 1 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 
The insert and vector DNA were mixed in the presence of 200 U of T4 DNA ligase and 1 x T4 Ligase 
Buffer (NEB) in a total volume of 20 µL AnalaR H2O. Ligation reactions were incubated at room 
temperature for 1 h or at 16oC overnight (16 h) to increase the number of transformants. The ligated 
DNA was purified by precipitation in the presence of 5 µL of yeast RNA (1 µg/µL; Sigma-Aldrich; Section 
2.3.5). E. coli bacteria (DH5-α) were electro-transformed with the purified ligated DNA (1 µL) before 
growth on LB-agar plates.  
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2.3.5 Purification of DNA 
2.3.5.1 Gel extraction and PCR clean up 
DNA fragments were purified from agarose gels using the NucleoSpin® Gel and PCR Clean-up Kit 
(Scientifix). Upon PCR fragment or digested plasmid DNA separation via agarose electrophoresis the 
gel was placed under UV light to visualise the position of the DNA bands, and the appropriate band 
cut from the gel (using a clean scalpel blade) and placed into a clean 1.5 mL micro-centrifuge tube. 
The weight of the gel slice was determined and Buffer NTI was added (200 μL of buffer per 100 mg of 
agarose gel). The DNA was purified out of the agarose according to manufacturer’s instructions. DNA 
was eluted in 25 µL AnalaR H2O and the concentration and purity of the DNA was determined using a 
spectrophotometer (NanoDrop 1000 v8.1) and stored at -20°C until required. 
2.3.5.2 Ethanol precipitation  
Plasmid DNA and/or inserts prepared for ligation (via PCR and/or restriction enzyme digest) were 
purified via ethanol precipitation. To the reaction tube, 0.25X of the reaction volume of 10 M 
Ammonium Acetate (NH4OAc) was added, followed by 10X the NH4OAc volume of 100% ethanol at -
20°C. Tubes were briefly vortexed and centrifuged at 16,000 x g for 20 min to pellet the DNA. 
Supernatant was removed and 180 μL of 70% ethanol at -20°C was added followed by centrifugation 
at 16,000 x g for 2 min. Supernatant was removed and tubes left to air-dry before 20 μL of Analar H2O 
was added to resuspend the precipitated DNA. To purify ligated plasmids from ligation reactions, 
ethanol precipitation was used with the following changes: in a 20 μL ligation reaction, 5 μL of yeast 
tRNA (1 μg/μL), 12.5 μL of 7.5 M NH4OAc and 70 μL of 100% ethanol were added at -20°C. All other 
steps were followed except DNA was dissolved in 5-7 μL of Analar H2O. 
2.3.6 DNA sequencing 
Sanger sequencing of DNA fragments or plasmids was performed at the Biomolecular Research Facility 
(BRF) at the Australian National University (ANU). Each reaction (20 µL total volume) contained the 
DNA of interest (250 ng plasmid DNA or 20 ng of PCR product) and 3 pmol of the appropriate 
sequencing primer (Table 2.8), 1 µL Big Dye (BRF; ANU) in Sequencing Buffer (BRF; ANU) to give final 
reaction conditions of 70 mM Tris-HCL (pH 9.0 at 25oC), 1.75 mM MgCl2 and 1 µL of Big-Dye 
Terminating mixture (BDT). The reactions were subjected to cycle sequencing using program outlined 
in Table 2.9 in a Mastercycler PCR machine (Eppendorf). 
The reactions were precipitated by the addition of 125 mM EDTA (pH 8.0) to a final concentration of 
10 mM, followed by the addition of 3 M NaOAc (pH 5.2) to a final concentration of 0.12 M and 2.5 
times the final reaction volume of 100% ethanol. The reactions were incubated for 20 min at room  
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Table 2.8: Sequencing primers. 
Name (Number) Sequence (5’->3’) and Purpose 
Ark_T7 Seq_F (929) TAATACGACTCACTATAGGG 
Sequence across 5' vector/insert junction in pcDNA3.1 nV5 clones, V1-ZIC3 
clones, V2-TCF7L1 clone and β-catenin-V5-HisA clone 
 
Ark_bGH Seq_R 
(930) 
TAGAAGGCACAGTCGAGG 
Sequence across 3' vector/insert junction in pcDNA3.1 nV5 clones, V1-ZIC2 
clones, V2-TCF7L2 clone and β-catenin-V5-HisA clone  
Ark_1152_F ATCCGGTACCGAATTCACCCTCTCTCACTTCGG 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1225_F CTATCTTCAGGCCAGAGC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1172_R CACCATCATCACCACACCAGC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1153_R GTGCGGCCGCGAATTCCCGCTCTAGAACTAGTGG 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1173_F TGGTCAACCACATCCGAGTGC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1008_F TCCAGCTGGCATCCCCGAGC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1009_R ATGCAGGCTGCTCGCCGAGC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1010_F GTGCACACGGGCGAGAAGCC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1011_R TGACCAGTTTGTACTTCGCC 
Internal to hZIC3 CDS, use for sequencing hZIC3 wt and variant clones 
Ark_1015_F GAA AGC CGC TTC TTG TAA TC 
Internal to β-catenin CDS, use for sequencing β-catenin wt and variants 
Ark_1016_R  TGG CCT CAA GGG CTA GTT TCT 
Internal to β-catenin CDS, use for sequencing β-catenin wt and variants 
Ark_1580_F TTACCCACTGTCTCCAG 
Internal to Tcf7l1 CDS, use for sequencing mouse Tcf7l1 
Ark_1412_R GTGCAATGTAACATCAG 
Sequence across 3' vector/insert junction in pENT3C plasmids. Used for 
sequencing mouse pENTR-Tcf7l1 
Ark_1578_F AGGGATCCATGCCCCAGCTC 
To PCR amplify Tcf7l1 fragment. Contains XhoI and BamHI restriction sites 
Ark_1579_R CCCTCGAGGCCTGAAGATCAGCTACTGG 
To PCR amplify Tcf7l1 fragment. Contains XhoI and BamHI restriction sites 
Ark_1411_F AACTAAGCAGAAGGCCA 
Sequence across 3' vector/insert junction in pENT3C plasmids. Used for 
sequencing mouse pENTR-Tcf7l1 
Ark_1581_R GACAGTGGGTAATACGG 
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Internal to Tcf7l1 CDS, use for sequencing mouse Tcf7l1 
Ark_1583_R TCTTGCTCTTAGAGGCC 
Internal to Tcf7l1 CDS, use for sequencing mouse Tcf7l1 
Ark_1582_F AGAGCAAGAAGCCATGC 
Internal to Tcf7l1 CDS, use for sequencing mouse Tcf7l1 
 
 
Table 2.9: Thermal cycling parameters for DNA sequencing 
Program Step Temperature (oC) Time Cycles 
Initial Denature 94  10 min 1 
Denature 96 10 sec 
x 30 Anneal 50 5 sec 
Extend 60 4 min 
Stop 4 Indefinite hold 1 
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temperature and centrifuged at 3,200 x g for 30 min, 4°C. To remove the supernatant, the reaction 
plate was inverted onto paper towel and centrifuged upside down until 201 x g to remove any 
remaining supernatant. Samples were briefly air-dried in the dark then wrapped in foil to protect the 
light sensitive dye. Samples were submitted for sequencing immediately or stored at -20°C until they 
could be submitted. Samples were analysed on an ABI 3730 sequencer (Applied Biosystems) within 
the BRF or an ABI 3130 Genetic Analyser in the Research School of Biology (RSB) Sequencing Facility 
within ANU. The resulting electronic sequence files were analysed using Geneious software version 
5.5.9 (Biomatters). 
2.4 Culture of mammalian cell lines 
2.4.1 Cell culture 
Human Embryonic Kidney 293T (HEK293T) cells, a highly transfectable line that are commonly used in 
ZIC in vitro assays, were used to study the effect of ZIC3 mutations. The cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich; Cat no D6429) supplemented with 10% 
(v/v) fetal bovine serum (Life Technologies or Interpath Services), 2 mM L-glutamine and 0.1 mM non-
essential amino acid solution (Life Technologies; referred to as supplemented DMEM from herein). 
The cells were grown on sterile tissue culture plasticware (Corning) in a humidified chamber at 37°C 
with 5% CO2. All procedures were performed in a laminar flow hood with sterile techniques. 
2.4.2 Passaging Cells 
Adherent cells grown in culture plasticware (T75 cm2 or T25 cm2) were generally passaged once they 
reached 70-80% confluency. The culture media was removed and cells washed with Phosphate 
Buffered Saline (PBS; Amresco) using ~0.05 mL/cm2 culture surface. Cells were detached from the 
surface of the flask by incubation in a minimal volume of trypsin (0.5 g/L) in PBS for a maximum of 5 
min in a humidified incubator (37˚C with 5% CO2). After incubation, supplemented DMEM was added 
to inactivate the trypsin and the solution repeatedly pipetted to create a homogeneous cell solution. 
An appropriate amount of the cell suspension, as determined by end use experiments, was transferred 
to new tissue culture plasticware containing supplemented DMEM. Additional supplemented media 
was added to the new tissue culture plasticware to reach the minimum volume requirements for each 
dish/flask.  
2.4.3 Transfection of mammalian cell lines 
Cells to be transfected were plated into 6-well or 12-well sterile tissue culture dishes (Corning; Table 
2.10). If the cells were to be used for immunofluorescence or for a proximity ligation assay, two circular 
glass coverslips (13 mm, No. 1 thickness; ProSciTech) were added to each well of a 6-well dish before  
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Table 2.10: Transfection amounts based on culture plate sizes.  Separate dilutions were made for 
Lipofectamine™ 2000 and plasmid DNA e.g. in a 12-well plate, 4 μL of Lipofectamine™ 2000 was 
diluted in 100 μL of unsupplemented DMEM, whilst 1.6 μg of plasmid DNA was diluted in another 100 
μL unsupplemented DMEM. 
Multi-well 
plate 
Well diameter 
(Bottom mm) 
Cell number 
(100% 
confluency) 
Lipofectamine™ 
2000 (µL/well) 
Total 
plasmid 
DNA (µg) 
Working 
volume 
6-well plate 34.8 9.5 x 105 10  4.0 2-3 mL 
12-well plate 22.1 3.8 x 105 4  1.6 
0.75-1.5 
mL 
96-well plate 6.4 3.2 x 104 - - 100-200 µL 
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the cells were plated. Cells were transfected when 60-80% confluent. All cells were transiently 
transfected with plasmid DNA using a lipid-based transfection agent (LipofectamineTM 2000; Life 
Technologies). The Lipofectamine™ 2000 reagent was diluted 1:25 in unsupplemented DMEM and 
incubated at room temperature (~25°C) for 5 min. The appropriate plasmid DNA was diluted in a 
separate volume of unsupplemented DMEM equivalent to that used to dilute the Lipofectamine™ 
2000. At the end of the 5 min incubation, the Lipofectamine™ 2000 solution was added to the DNA 
dilution and incubated at room temperature for 20 min to enable DNA-liposome complex formation. 
During this time, the media on the cells was replaced with fresh supplemented DMEM. The DNA-
Lipofectamine™ 2000 mixture was added drop-wise to the well containing cells. The plate was then 
gently rocked to mix the solutions and returned to the 37°C humidified incubator. 
2.4.4 Luciferase reporter assays 
The experimental design of the luciferase reporter assays is shown in Figure 2.3. In all cases, HEK293T 
cells grown to 70% confluency in tissue culture grade 12-well plates were transfected with the 
appropriate combination of reporter and expression constructs. For the ZIC transactivation assays, 
cells were transfected with 0.8 µg of reporter plasmid p(ZM2)6-β-gl-luc2 and 0.8 µg of one expression 
vector (V5-hZIC3-wt or one of the V5-hZIC3-variant expression constructs) or a plasmid from which no 
protein would be generated (V5-DEST) as a negative control. For the TCF/β-catenin transactivation 
assays (TOPflash), cells were transfected with 0.5 µg of a reporter plasmid pTOP-β-gl-luc2, a β-catenin 
expression plasmid (pβ-Catenin-V5-HIsA or pCANΔN89-β-catenin) and a ZIC expression construct (V5-
ZIC3-wt or one of the V5-ZIC3-variant expression constructs) or a plasmid from which no protein would 
be generated (V5-DEST; 0.5 µg) as a negative control. Total DNA concentration did not exceed 1.6 µg.  
For all luciferase assays, each well of transfected cells was passaged 6-8 h after transfection and split 
into three wells of a solid white tissue culture grade 96-well plate (Costar®, Corning; Cat. No. CLS3917) 
to generate three internal repeats for each experiment. The position of each internal replicate sample 
was randomised for each experiment to avoid plate reader bias from the luminometer. The remaining 
cells were plated in one well of a 6-well plate for SDS-PAGE and western blot. The luciferase activity 
of each sample in the 96-well plate was determined 24 h post-transfection by incubation with a 
luciferase substrate (Promega ONE-Glo luciferase reagent, Promega, Cat. No. E6110). The culture 
media was replaced with 100 µL of a 1:1 (v/v) mix of the ONE-Glo luciferase reagent and DMEM, and 
cells incubated for 15 min at ambient conditions. The intensity of luminescence produced was 
measured by the GloMax®-96 Microplate Luminometer (Promega), or the TECAN Infinite M1000 Pro 
plate reader. Upon result analysis, the luciferase activity was normalised to V5-DEST to determine 
relative luciferase activity. The mean relative luciferase activity and standard deviation were  
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Figure 2.3: Experimental design of luciferase assays.  HEK293T cells grown on a 12-well plate were 
transfected with a reporter construct that contains DNA binding motifs and a mammalian promoter 
upstream of the P. pyralis luciferase cDNA (left blue shaded semi-circle). They are also co-transfected 
with an expression vector (various colours). In some cases, the expression vector does not contain a 
cDNA (V5-Dest; white). This serves as a negative control to reveal the background level of luciferase 
and/or ensures equivalent amounts of DNA are included in each transfection. Approximately 5.5 h 
post-transfection, each transfection is split as shown. First, 4% of the transfected cells are transferred 
to each of three wells in a 96-well plate (to generate three internal replicates for the luciferase assay) 
and the remaining 88% of cells are transferred to one well of a 6-well plate (to be collected for lysis, 
SDS-PAGE and western blot analysis of the overexpressed protein). The cells for luciferase assay are 
distributed on the 96-well plate in an order generated by a randomised list of sample numbers to 
ensure that the plate position of each sample varies between external replicate experiments. Culture 
media without cells is added to adjacent wells surrounding the ones in use (orange). Luciferase 
substrate is added to each sample in the 96-well plate 18.5 h after the split (24 h post-transfection) 
and the plate read in a luminometer. After luciferase activity has been recorded, cells from the 6-well 
plate are lysed, the nuclear fraction recovered and subjected to SDS-PAGE and western blot analysis.  
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calculated from three internal repeats (using Microsoft Excel). Where pooled data is shown, data 
represents at least three independent repeats, with luminescence values from one representative 
experiment shown. The data was subjected to a two-way ANOVA using Genstat and a Fisher’s least 
significant difference (LSD) test performed (α = 0.05) as described in section 2.7. 
2.4.5 Bimolecular Fluorescence Complementation 
The experimental design of the Bimolecular Fluorescence Complementation (BiFC) assays were similar 
to the luciferase assays. HEK293T cells were grown to 70% confluency in tissue culture grade 12-well 
plates and transfected with 800 ng each of V1- and V2-tagged expression constructs. V1 and V2 are 
N-terminal and C-terminal fragments, respectively, of the F46L form of YFP, that exhibits an increased 
rate of maturation at 37oC relative to both YFP and GFP (Nagai et al. 2002). For the competition 
experiments the cells were co-transfected with 1 μg of pV2-Tcf7l1, 1 μg of pV1-hZIC3-wt and 
increasing amounts (0.5 – 2.0 µg) of pnV5-hZIC3-C268X (along with pnV5-DEST to equalise the amount 
of transfected DNA).  
Each well of transfected cells was split 24 h post-transfection into three wells of a solid white tissue-
culture grade 96-well plate (Costar®) to generate the three internal repeats. The position of each 
internal replicate sample was randomised for each experiment to avoid plate reader bias from the 
luminometer. The remaining cells were plated in one well of a 6-well plate for SDS-PAGE and western 
blot. 24 h after splitting (i.e. 48 h post-transfection), media was removed from each sample in the 96-
well plate and replaced with 100 μL PBS. The fluorescent intensity from each well was then detected 
using a TECAN Infinite m1000 Pro plate reader. Venus fluorescence was measured using Excitation 
wavelength 515 nm and Emission wavelength 528 nm. 16 measurements were taken from each well 
to give an average fluorescent intensity. A minimum of three independent biological experiments 
were carried out. Fluorescent intensity data was subjected to a two-way ANOVA using Genstat and a 
Fisher’s LSD test performed (α = 0.05) as described in section 2.7. 
2.4.6 Proximity Ligation Assay 
Proximity ligation assays (PLA) were conducted according to the manufacturer’s instructions using the 
Duolink® In Situ Red Starter Kit Mouse/Rabbit (DUO92101-1KT) which included Anti-Rabbit PLUS and 
Anti-Mouse MINUS PLA probes. HEK293T cells grown on coverslips in a 6-well plate were transfected 
with 1 μg of appropriate expression plasmids. 24 h post-transfection, cells were fixed, prepared for 
immunofluorescent staining and primary antibodies hybridised as per section 2.5.6. Coverslips were 
mounted cell side down onto glass slides (76 x 26 mm, No. 1 thickness, ProSciTech G300FB) with 
Duolink® In Situ Mounting Medium with DAPI (Sigma-Aldrich, DUO82040). Nail polish was used to seal 
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the edges of the coverslip to prevent the cells from drying out. Images were acquired using a Zeiss 
Axio Observer (1.210) fluorescent microscope.  
2.5 Analysis of cultured cells 
2.5.1 Nuclear and Cytoplasmic Protein Lysates 
HEK293T cells to be processed for western blotting were processed with the NE-PER fractionation kit 
(ThermoScientific) according to the manufacturer’s instructions, but with reagent volumes altered. 
Media was removed from the cultured HEK293T cells in a 6-well plate and a cell suspension made in 
800 μL fresh unsupplemented DMEM. Cell were pelleted by centrifugation at 20,800 x g and the media 
removed and replaced with 100 μL of Cytoplasmic Extraction Reagent (CERI) with 1X cOmplete Mini 
EDTA-free Protease Inhibitor Cocktail (Roche) added. Cells were vortexed briefly and incubated for 10 
min (4oC). The CERII buffer was then added (5.5 μL per well in a 6-well plate, ice-cold) and the mixture 
vortexed and incubated on ice for an additional 1 min, and then vortexed prior to centrifugation for 
15 min at 20,800 x g at 4oC. The supernatant (containing cytoplasmic proteins) was transferred to a 
pre-chilled micro-centrifuge tube. The pellet was then resuspended in ice-cold Nuclear Extraction 
Reagent (NER) (50 μL per well of a 6-well plate) with added 1X protease inhibitor to release nuclear 
proteins and incubated on ice. The cells were vortexed for 15 s every 10 min for a total of 40 min. The 
nuclear fraction was separated by centrifugation at 20,800 x g (25 min, 4oC). The supernatant 
containing the nuclear proteins was transferred to a pre-chilled micro-centrifuge tube. Lysates were 
then either stored at -80oC until required or immediately processed for Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). 
2.5.2 SDS-PAGE  
Protein from cytoplasmic and nuclear cell lysates was separated by molecular weight (MW) on an 
acrylamide gel. Polyacrylamide gels were prepared in a Mini PROTEAN® casting apparatus (BioRad). 
An 8-10% polyacrylamide ‘Running’ gel (Table 2.11) was made and overlaid with hydrated butanol 
(Sigma-Aldrich) and left at room temperature to polymerise for 1 h. Following polymerisation, the 
butanol was removed and the running gel overlaid with a 3.75% polyacrylamide ‘Stacking’ gel (Table 
2.12) and a comb inserted to create wells for loading samples. The gel was left at room temperature 
for a further 1 h to polymerise. Once polymerisation was complete, the gels were placed into a BIORAD 
Mini PROTEAN® Tetra Cell apparatus filled with 1X SDS-PAGE Running Buffer (192 mM glycine, 24.9 
mM tris base and 3.47 mM SDS). To prepare lysates for SDS-PAGE, a 1:20 dilution of Dithiothreitol 
(DTT, Sigma-Aldrich; 20X stock solution) and 1:4 dilution of Sample buffer (NUPAGE® LDS Sample 
Buffer, a proprietary solution supplied as 4X, Invitrogen) was added and the lysate heated for 5 min  
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Table 2.11: Composition of 8-10% polyacrylamide ‘running’ gel used to separate proteins according 
to molecular weight.  Volumes shown produce two gels of 1.5 mm thickness. 
Composition 
Volume (mL) 
8% 10% 
40% Acryl:Bisacryl (37.5:1; Sigma-Aldrich) 5.0 6.25 
1.5M Tris (pH = 6.8; Merck) 6.25 6.25 
10% SDS (Roche) 0.25 0.25 
Deionised H2O 13.25 12 
10% Ammonium persulphate (Sigma-Aldrich) 0.25 0.25 
Tetramethylethylenediamine (TEMED; Sigma-Aldrich) 0.025 0.025 
 
 
Table 2.12: Composition of 3.75% polyacrylamide ‘stacking’ gel used for sample loading.  Volumes 
shown produce two gels of 1.5 mm thickness. 
Composition Volume (mL) 
40% Acryl:Bisacryl (37.5:1; Sigma-Aldrich) 0.47 
0.5M Tris (pH = 6.8; Merck) 1.25 
10% SDS (Roche) 0.05 
Deionised H2O 3.18 
10% Ammonium persulphate (Sigma-Aldrich) 0.10 
TEMED (Sigma-Aldrich) 0.01 
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at 90°C to denature the proteins. The lysates were cooled and 20-30 µL of each sample was loaded 
into the pre-made gels. A pre-stained molecular weight ladder (PageRulerTM Prestained Protein ladder; 
ThermoScientific) was loaded in the first and last well of the gel to enable sizing of the detected 
proteins. Samples were electrophoresed at 100 V for 80-120 min to separate the proteins, using the 
separation of the protein ladder as a guide for run time.  
2.5.3 Wet transfer 
After separation by SDS-PAGE, proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Millipore ImmobilinTM–P) via wet transfer. The membrane was first activated via soaking 
in 100% (v/v) methanol for 2 min prior to being assembled for wet transfer. Cold (4°C) 1X Towbins 
Transfer buffer (192 mM glycine, 24.8 mM Tris, 20% methanol, pH = 7.4) was poured into a transfer 
tray and thin transfer sponges soaked to eliminate any bubbles. The SDS-PAGE gel was prepared for 
wet transfer by removing it from the BIORAD Mini PROTEAN® Tetra Cell (BioRad) system and 
discarding the ‘stacking’ portion of the gel. The prepared SDS-PAGE gel was positioned over the PVDF 
membrane and sandwiched together between blotting paper (3 mm Chromatography paper, 
Whatman®) and the thin transfer sponges before being assembled in the wet transfer apparatus 
(BIORAD Trans-Blot SD-Semi-dry Transfer Cell apparatus; BioRad). The transfer apparatus was placed 
within an ice cavity to keep cool and the transfer was run at 15 V overnight (16 h). 
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2.5.4 Detection of proteins via western blot 
Upon completion of the wet transfer, the PVDF membrane was rinsed with 1X PBS once and then 
blocked in skim milk blocking buffer (1X PBS with 5% (w/v) skim milk and 0.2% (v/v) Tween-20) for 1 
h (room temperature with shaking). After blocking, the membrane was incubated with primary 
antibodies diluted in 3 mL blocking buffer (see Table 2.13 for dilutions) for 2 h (room temperature 
with rotation). The membrane was then washed with blocking buffer (six washes, 5-10 min each at 
room temperature with shaking) and then incubated with the appropriate Horseradish Peroxidase 
(HRP)-conjugated secondary antibodies diluted in 3 mL blocking buffer (See Table 2.14 for dilutions) 
for 1.5-2 h (room temperature with rotation). The membrane was then washed in 1X PBS with 0.2% 
Tween-20 (Sigma-Aldrich; six washes, 5-10 min each at room temperature with shaking). Lastly the 
membrane was rinsed with 1X PBS prior to developing. For western blot to detect the Venus protein 
(by hybridization with an anti-GFP antibody), the blocking buffer for both primary and secondary post-
hybridization washes was 1x TBS (1L: 50 mM Tris-Cl, pH 7.6; 150 mM NaCl) with 0.2% Tween20 (Sigma-
Aldrich). 
Upon completion of antibody hybridisation, the membrane was treated with SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Scientific; ~37 µL per cm2 of membrane) and incubated for 5 
min in the dark. The SuperSignal West Pico Chemiluminescent Substrate contains a substrate upon 
which the HRP tag of the secondary antibody can act to produce a chemiluminescent signal. Following 
incubation, excess detection reagent was drained and the membrane wrapped in cling wrap. Under 
safe light conditions, the membrane was exposed to X-ray film (CL-Xposure™ Film; Thermo Scientific 
or Amersham Hyperfilm MP; GE Healthcare Ltd.) for various times (10 s to 16 h). The film was 
developed using a Multigrade Paper Developer solution (Ilford) and fixed using a Rapid Fixer solution 
(Ilford). The film was then rinsed with H2O and air-dried. Once dry, the X-ray film was aligned with the 
membrane and the marker bands from the protein ladder traced onto the film to enable measurement 
of detected protein bands. Alternatively, following incubation with the Chemiluminescent Substrate, 
the membrane was immediately exposed to a charge-coupled camera via the ImageQuant™ LAS4000 
biomolecular imager (GE Healthcare Life Sciences) for 10 s - 10 min (dependent on the experiment 
and antibody used) and a digital image produced.  
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Table 2.13: Primary Antibodies used for western blotting. 
Antibody Dilution 
Mouse anti-TCF7L1 (Abcam; cat.no. ab86175) 1/1,000 
Goat anti-β-catenin (Santa Cruz; sc-1496) 1/500 
Mouse anti-V5 (Life Technologies; cat. no. R960-25)  1/3,000 
Mouse anti- β-tubulin (Abcam; cat. no. ab7792) 1/1,000 
Mouse anti-TATA Binding Protein (TBP; Abcam; cat. no. ab818) 1/2,000 
Rabbit anti-V5 (Abcam; cat. no. ab9116) 1/7,500 
Rabbit anti-GFP (Cell signaling technology; no.2555) 1/1,500 
 
 
Table 2.14: HRP-Conjugated Secondary Antibodies used for western blotting. 
Antibody Dilution 
HRP-Rabbit anti-Goat IgG Conjugate (Life Technologies; cat. no. 81-
1620) 
1/5,000 
HRP-Donkey anti-Rabbit IgG Conjugate (Jackson Immunoresearch; cat. 
no. 711-035-152) 
1/5,000 
HRP-Rabbit anti-Mouse IgG Conjugate (Life Technologies; cat. no. 61-
6520) 
1/5,000 
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2.5.5 Antibody removal and re-hybridisation 
When two different proteins on the same membrane with a similar molecular weight need to be 
detected, it is necessary to sequentially detect the proteins. In this case the first round of primary and 
secondary antibodies was removed as follows: the membrane was re-hydrated in 
1X PBS for 15 min (room temperature with shaking). The PBS was removed and 15 mL of western blot 
Stripping Buffer (ThermoScientific) applied to the blot and incubated with shaking for 5-10 min. The 
stripping solution was removed prior to washing the blot three times with 1X PBS for a total of 30 min. 
To check antibody removal, the blot was treated with SuperSignal® West Pico Chemiluminescent 
Substrate (Thermo Scientific). If no signal was detected the membrane was hybridised with the next 
round of antibodies. 
2.5.6 Immunofluorescence Staining and Microscopy  
HEK293T cells to be transfected for immunofluorescence staining and microscopy were grown on 
sterilised circular glass coverslips (13 mm, No. 1 thickness; ProSciTech) in 35 mm culture dishes (Iwaki 
or Nunc) until 70-80% confluent. The transfected cells were grown for 24 h before the coverslips were 
removed and the cells fixed in 4% paraformaldehyde (PFA; Electron Microscopy Sciences) in 1X PBS 
(30 min, room temperature). The PFA was removed and the cells washed in 1X PBS (3 x 5 min, room 
temperature) before being permeabilised by addition of 0.25% Triton X-100 (Sigma-Aldrich) in 1X PBS 
(5 min, room temperature). The cells were again washed in 1X PBS (3 x 5 min, room temperature) 
before incubation in blocking solution (5% w/v Diploma brand skim milk powder in 1X PBS) (1 h, room 
temperature). After blocking, the cells were exposed to a combination of primary antibodies diluted 
in 30 µL (per coverslip of cells) of blocking solution (see Table 2.15 for dilutions; 1 h, room temperature 
in a humidified chamber). The cells were washed with 300 µL of the blocking solution (6 x 5 min, room 
temperature). Fluorophore conjugated secondary antibodies (used to detect the primary antibodies) 
were diluted in blocking buffer and 30 µL of diluted secondary antibody (see Table 2.16 for dilutions) 
was then applied to the cells (1 h, room temperature, in a darkened humidified chamber). The cells 
were then washed in 1X PBS (6 x 5 min, room temperature) and mounted cell side down onto glass 
slides (76 x 26 mm, No. 1 thickness, ProSciTech Cat. No. G300FB) with anti-fade mounting agent (2.4 
mM n-propyl gallate (Sigma-Aldrich). Nail polish was used to seal the edges of the coverslip to prevent 
the cells from drying out. For DAPI (4', 6-diamidino-2-phenylindole) staining (to define the cell nuclei) 
cells were incubated with 30 μL of DAPI (0.005 mg/mL in 1X PBS; Life Technologies) for 5 min at room 
temperature. Cells were then washed three times with 1X PBS followed by mounting the coverslips 
onto glass slides. Prepared slides were viewed and recorded using a DeltaVision Elite fluorescence 
microscope fitted with a 60X oil immersion objective (Olympus; PlanApo N 60X/1.42 Oil), or a Zeiss 
Axio Observer (1.210) fluorescent microscope under 40X objective.  
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Table 2.15: Primary antibodies used for immunofluorescence staining. 
Primary Antibody Dilution 
Mouse anti-V5 (Life Technologies; cat. no. R960-25) 1/200 
 Rabbit anti-V5 (Abcam; cat. no. ab9116) 1/500 
 Mouse anti-TCF7L1 (Abcam; cat.no. ab86175) 1/200 
Mouse anti-TCF7L2 (Abcam; cat.no. 32873) 1/200 
Mouse anti-FLAG (Sigma, cat no. F1804)  1/200 
 Rabbit anti-Lamin B1 (Abcam; cat. no. ab16048) 1/1,000 
 
 
Table 2.16: Fluorophore-conjugated secondary antibodies used for immunofluorescence staining. 
Secondary Antibody Dilution 
Alexa594-conjugated anti-mouse (Life Technologies, cat. no. A21203) 1/500 
Alexa488-conjugated anti-rabbit (Life Technologies, cat. no. A21206) 1/500 
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2.5.7 Microscopy - Quantification of Relative Localisation Pattern 
Image files were renamed by a member of the Arkell laboratory prior to quantification and later de-
coded to minimise operator bias. Subcellular distribution of transfected ZIC proteins in 30-100 
transfected cells was scored blind per experiment. For each cell, the nuclear and cytoplasmic 
boundaries were traced using the Intuos® 2 graphics tablet (Wacom) and the average fluorescence 
intensity from each compartment [nuclear (NF) and cytoplasmic (CF)] measured using ImageJ (NIH) 
software. The cytoplasmic boundary was determined by V5-ZIC3 protein that had not entered the 
nucleus. In cases where cytoplasmic V5-ZIC3 was scarce and did not give a clear cytoplasmic boundary, 
the brightness of the image was altered to increase the intensity of the cytoplasmic protein. This trace 
was used for the original V5-ZIC3 channel and the nucleus was excluded to enable measurement of 
the cytoplasmic fluorescence density. Background intensity (measured in three different parts of each 
image) was subtracted from NF and CF to obtain corrected fluorescence intensities. These corrected NF 
and CF values were added to determine total fluorescence intensity (TF) from each cell, before 
calculating the % nuclear (NF/ TF) and % cytoplasmic (CF/ TF) fluorescence. Percentages from all scored 
cells were averaged to determine the localization pattern of the protein in the experiment. Three 
independent experiments were conducted and the % localization in each cellular compartment 
averaged across the three experiments.  
2.6 Yeast Two-Hybrid assay 
Yeast two-hybrid experiments were conducted using the ProQuestTM Two-Hybrid System (Invitrogen, 
Cat no PQ1000101) following the manufacturer’s instructions (Invitrogen 2005). MaV203 yeast were 
streaked onto a YPAD (10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose, 20 g/L Bacto Agar, 40 mg/L 
adenine sulfate) agar plate and incubated at 30°C for ~48 h until single colonies were formed. 
Transformation of MaV203 competent cells were plated on SC-Leu-Trp plates (6.75 g/L yeast nitrogen 
base, 20 g/L glucose, 0.55 g/L synthetic complete mixture [Dropout complete], 0.02 g/L adenine 0.02 
g/L histidine, 0.05 g/L lysine and 0.02 g/L uracil , 22 g/L Bacto Agar [pH 5.5]) for 48-60 h until single 
colonies were formed before patching two independent colonies onto a single SC-Leu-Trp plate. 
Replica cleaning was performed as required using sterile filter paper and a standard replica plating 
tool under sterile conditions. Colonies were replica plated onto SC-Leu-Trp-Ura (SC-Leu-Trp plates 
without addition of Histidine) SC-Leu-Trp+5FOA (SC-Leu-Trp plates with addition of 5FOA at 0.2% final 
concentration, [Formedium]), SC-Leu-Trp+3AT (SC-Leu-Trp plates with addition of 3AT at 100 mM, 50 
mM, 25 mM and 10 mM; Sigma-Aldrich, A8056). Extent of colony growth was compared to positive 
and negative controls that were supplied within the kit.  
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2.7 Statistical analysis 
For luciferase and BiFC assays, the luminescence or fluorescence value from each data point was used 
to generate a data set for statistical analysis. Nine data points were generated for each treatment 
(three internal replicates from each of three external repeats). Luciferase and BiFC data were all 
subjected to a two-way ANOVA using Genstat software and a Fisher’s least significant difference (LSD) 
test performed (α = 0.05) to determine which treatments differ significantly from the others. If the 
difference between two means is larger than the computed LSD, then the treatments are considered 
significantly different. The test assigns a unique letter to the treatments that are significantly different 
to all other treatments (e.g. a, b, c, d etc.). If two treatments are not significantly different then they 
are assigned the same letter.  
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Chapter 3: Can ZIC3 physically interact with TCF7L1 in vitro? 
3.1 Introduction 
3.1.1 Zic3 loss-of-function phenocopies elevated Wnt alleles 
Deletion of the murine Zic3 gene results in Heterotaxy, as do multiple other alleles with Zic3 loss-of-
function mutations, including the Zic3 katun mouse strain (Garber 1952; Gebbia et al. 1997; Klootwijk 
et al. 2000; Ahmed et al. 2013). The katun allele was first isolated in an ENU screen (Bogani et al. 2004) 
and showed phenotypic similarities to the Bn allele (which deletes the entire Zic3 gene). Genetic 
analysis revealed the katun mutation is a result of a guanine (G) to thymine (T) substitution at position 
1,283, resulting in the change of Glutamic acid into a termination codon at amino acid 249 (E249X). 
The mutation introduces a premature stop codon (PTC) two amino acids upstream of the ZFD of ZIC3 
and results in the translation of a protein that lacks the ZFD and C-terminus of the protein. Molecular 
analysis by the Arkell laboratory has demonstrated that the katun allele produces a functionally null 
protein. For example, the katun transcript is not subject to nonsense mediated decay (NMD) and, 
despite lacking nuclear import signals from the ZFD, the truncated protein is able to enter the nucleus 
via passive diffusion (Bedard et al. 2007; Ahmed et al. 2013). In cell-based reporter assays, the 
truncated protein was unable to initiate transcription at the ApoE promoter. Similarly, the protein 
could not inhibit canonical Wnt signalling via β-catenin mediated transcription when overexpressed 
in a HEK293T TOPflash assay (Ahmed et al. 2013).  
The katun phenotype is incompletely penetrant and highly variable. In vivo analysis of the katun allele 
by the Arkell laboratory has shown that heterozygous females (Zic3Ka/X) are viable and exhibit minor 
defects with decreased penetrance. For example, a subset of heterozygous mice exhibit tail kinks 
(Figure 3.1), a phenotype commonly reported with elevated canonical Wnt signalling (MacDonald 
2004; Bogani et al. 2004; Ahmed et al. 2013; Norum et al. 2015). As Zic3 is located on the X-
chromosome, male carriers of the katun mutation are hemizygous and display a more severe 
phenotype that resembles the phenotype of homozygous females (Zic3Ka/Ka). Hemizygous embryos 
exhibit partial dominant lethality, with mice also exhibiting tail kinks. These embryos also have 
morphological defects characteristic of Type I and Type II Zic3tm1Bca null embryos (Purandare 2002), 
including reduced or abnormal expression of mesoderm and endoderm markers Cer1 and Lim1 during 
gastrulation (Ahmed et al. 2013). A subset of Zic3Ka/Y embryos recovered at 9.5 dpc display heart 
looping defects, including sinistral looping, ventral looping, or hearts with no looping (49%), indicative 
of abnormal L-R axis formation. Additionally, katun embryos exhibit abnormal nodes; the fundamental 
structure involved in L-R axis determination, and a likely source of these defects (Figure3.1). Of greater  
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Figure 3.1: ZIC3 loss of function phenocopies elevated Wnt alleles. (A) Dorsal view of a Zic3Ka/Y 
embryo (following WMISH to Brachyury; Arkell laboratory, unpublished) and Tcf7l1-/- embryo (Merrill 
et al. 2004) exhibiting a third head fold (asterisk). B) Lateral view of a Zic3Ka/Y embryo (following WMISH 
to Brachyury and Follistatin; Arkell laboratory, unpublished) and ventral view of a Tcf7l1-/- embryo 
(following WMISH to Foxa2; Merrill et al. 2004) showing abnormal head development (asterisk) and 
axis duplications. The region within the rectangle of Zic3Ka/Y is expanded in showing the axis duplication 
as indicated by the black arrow. C) Lateral view of a wildtype, Zic3Ka/Y or Ctnnb1Bfc/+ embryo following 
WMISH to Fgf8 and Brachyury showing reduced expression of Fgf8 in the forebrain (asterisk) and a 
protrusion anteriorly to the head structure (black arrowhead; Arkell laboratory, unpublished). D) 
Zic3Ka/X and Wnt gain-of-function mutant Lrp-/+ mice exhibit tail kinks. E) Zic3Ka/Y (Ahmed et al. 2013), 
Ctnnb1Bfc/Bfc (K. Diamand; Arkell lab unpublished) and Tcf7l1-/- (Merrill et al. 2004) embryos display 
ectopic expression of Foxa2. EEX: embryonic/extra-embryonic boarder. F) SEM images of the surface 
of the node in Zic3Ka/Y (Arkell laboratory, unpublished), Zic3-/- (Sutherland et al. 2013), Zic3flox/flox; T-Cre 
(Sutherland et al. 2013), Tcf7l1-/- (Merrill et al. 2004), Ctnnb1Bfc/Bfc (Arkell laboratory, unpublished) and 
Lhx1 Δecto-null (Costello et al. 2015). The node in the wildtype embryo is a distinct tear-drop shaped 
depression with a clear edge. However, in Zic3 loss-of-function or Wnt gain-of-function alleles, the 
node has an abnormal shape and a disorganised border (dotted line). 
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significance, Zic3Ka/Y embryos exhibit anterior (forebrain) truncations, axis duplications and duplicated 
head folds (Figure 3.1). These severe phenotypes are consistently associated with elevated canonical 
Wnt signalling, including murine embryos null for the Wnt repressor Tcf7l1 (Figure 3.1; Zeng et al. 
1997; Merrill et al. 2004; Fossat et al. 2011; Alzahrani 2017). Zic3Ka/Y embryos also display ectopic 
expression of primitive streak marker Foxa2, consistent with alleles Tcf7l1-/- and Ctnnb1Bfc/Bfc, which 
result in a Wnt gain-of-function effect (Figure 3.1). Moreover, Tcf7l1-/- embryos, and other embryos 
that exhibit elevated canonical Wnt signalling, also have defective nodes, suggesting elevated Wnt 
signalling, defective node formation, and L-R axis establishments are correlated (Figure 3.1) (Merrill 
et al. 2004; Costello et al. 2015; Arkell unpublished). Overall, current in vitro and in vivo evidence 
strongly supports the hypothesis that ZIC3 acts to repress canonical Wnt signalling during murine 
gastrulation, preventing congenital malformations. Whether the ZIC3 and TCF7L1 proteins physically 
act together to achieve this outcome remains to be directly verified in vivo, but there is circumstantial 
evidence to support this.  
3.1.2 Zic3 and Tcf7l1 have overlapping expression patterns during gastrulation  
Analysis of various animal models has identified the need for restricted expression of Wnt signalling 
in the developing embryo. During normal gastrulation, Wnt signalling is distributed as a gradient along 
the anterior-posterior axis, with signal suppressed in the embryo’s anterior. This model suggests that 
the expression of Wnt antagonists would be greater at the anterior of the embryo, while distribution 
of Wnt activators and secreted ligands is greater at the posterior of the embryo (Figure 3.2). Mutations 
that result in the gain-of-function of activators or the loss-of-function of negative regulators of the 
Wnt signalling pathway can result similar phenotypes as they have a similar effect on the distribution 
of Wnt signal: Wnt signalling becomes elevated toward the anterior of the embryo.  
A prerequisite for ZIC3 to co-repress Wnt signalling in conjunction with TCF7L1 is that the two 
transcription factors must both be expressed in the same cells. The expression of Zic3 (during the time 
this interaction is proposed to occur i.e. gastrulation) in murine embryo development has been well 
documented by whole mount in situ hybridisation (WMISH) (Elms et al. 2004). Briefly, expression of 
Zic3 is initiated prior to gastrulation at 5.0 dpc and is detected throughout the extra-embryonic 
ectoderm and within some epiblast cells. Zic3 is not detected in distal epiblast cells or the endoderm 
at these stages. This pattern of expression is maintained until the onset of gastrulation, when Zic3 
ectoderm expression begins to recede from the anterior half of the embryo. Instead, Zic3 is expressed 
in the ectoderm of the embryo lined by the emerging primitive streak mesoderm (6.0 – 6.75 dpc). This 
mesoderm migrates anteriorly as wings to encircle the embryonic portion of the egg cylinder, or 
proximally as extra-embryonic mesoderm. The embryonic mesoderm wings and the ectoderm that 
forms the posterior amniotic fold at the posterior end of the embryo contains Zic3 transcripts but the 
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Figure 3.2: Wnt signalling is distributed as a gradient during gastrulation. Wnt signalling is distributed 
as a gradient along the anterior-posterior axis during murine gastrulation. Wnt antagonists (shaded in 
blue) are concentrated at the posterior side, whilst Wnt antagonists are concentrated at the anterior 
of the embryo. Pr: proximal, D: distal, A: anterior, P: posterior. Figure adapted from Barratt 2018. 
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extra-embryonic mesoderm does not (Figure 3.3). Mid- and late-streak stage embryos express Zic3 in 
the anterior definitive endoderm at the junction between the embryonic and extra-embryonic 
regions. Zic3 expression is not observed in the cells of the developing ventral node at the anterior 
primitive streak, or in the axial mesendoderm, which emerges from the node, but it is observed in 
ectoderm in this region. This pattern of Zic3 expression remains relatively constant throughout the 
rest of gastrulation. By the early headfold stage of development Zic3 expression in the extra-
embryonic ectoderm has ceased and expression in the embryonic ectoderm is restricted to the 
neuroectoderm. 
Currently, whole mount analysis on mouse embryos detailing the expression pattern of Tcf7l1 during 
gastrulation has not been published. Instead, protein expression using sectioned mouse embryos has 
been previously documented (Merrill et al. 2004). More recently, the Arkell laboratory has performed 
whole mount analysis of Tcf7l1 during gastrulation (unpublished data, Figure 3.3), which extends the 
immunohistochemistry analysis performed by Merrill et al. 2004. Briefly, during the onset of 
gastrulation, Tcf7l1 is expressed in the ectoderm of the embryo. As gastrulation proceeds and the 
mesoderm is formed, Tcf7l1 transcripts are restricted to the anterior and extra-embryonic region, but 
are not found in the endoderm, nor are transcripts detected in the node when it forms anterior to the 
primitive streak. During the early allantoic bud stage, Tcf7l1 expression begins to recede gradually 
from the allantoic bud and embryonic ectoderm beginning from the posterior-most region. The 
expression in both the ectoderm and mesoderm continues until head formation begins, establishing 
the domain of the brain progenitor. Notably, Tcf7l1 is detected as a gradient along the anterior-
posterior axis of the embryo, with expression concentrated at the anterior side and it also overlaps 
with Zic3 expression domains (Figure 3.3). For example, during MS-LS stages, Zic3 and Tcf7l1 are 
expressed throughout the ectoderm and migrating wings of mesoderm. Additionally, at the EHF stage, 
both genes are expressed in the developing head folds.  
3.1.3 Difficulties in studying ZIC protein function  
There are several issues faced when studying ZIC protein function. These include but are not limited 
to lack of good commercially available antibodies for ZIC protein detection, lack of in vitro expressed 
ZIC purified protein, lack of bona fide target DNA sequences and protein partners and low expression 
of ZIC proteins in cell lines (Hruz et al. 2008 Appendix B). The combination of these factors makes it 
difficult to characterise ZIC protein function in vivo or in vitro. To overcome these issues, 
overexpression studies using epitope tagged ZIC proteins and highly sensitive and robust cell based 
assays were conducted in this thesis.  
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Figure 3.3: Expression of Zic3 and Tcf7l1 during mouse gastrulation. Lateral view of whole mount 
wildtype murine embryos staged from Mid-streak (MS) to early headfold (EHF) stage hybridised to 
either Tcf7l1 or Zic3. Anterior is to the left in all images. Embryo stages are indicated on the panel. 
Expression of Zic3 at MS-LS is detected in the ectoderm and mesoderm throughout gastrulation, but 
reduced in the endoderm. By LB stage, Zic3 expression shifts towards the anterior ectoderm, and later 
becomes localised to the head-folds. Expression of Tcf7l1 at MS-LS is restricted to the ectoderm and 
the mesoderm throughout gastrulation and later becomes localised to the head-folds. MS: mid streak, 
LS: late-streak, EB: early bud, LB: late bud, EHF: early head fold. In situ performed by K. Barratt and K. 
Walsh, Arkell laboratory.   
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3.1.4 Chapter aims 
The TCF7L1 transcription factor acts as a Wnt repressor during early embryonic development and 
produces an elevated Wnt phenotype when mutated in mice (Merrill et al. 2004). Moreover, Zic3 loss-
of-function mouse models phenocopy the elevated Wnt phenotype seen in Tcf7l1-/-embryos, 
suggesting the ZIC3 protein also functions as a repressor of the pathway. As described in Chapter 1, 
both published (Pourebrahim et al. 2011; Fujimi et al. 2012) and unpublished data (Arkell laboratory) 
provides evidence that all ZIC proteins, including ZIC3, inhibit β-catenin mediated transcription in 
Xenopus embryos and cell based assays. Moreover, published data has demonstrated that ZIC2 
protein can directly interact with TCF7L2 via its ZFD in a co-immunoprecipitation assay when 
overexpressed in cell lines (Pourebrahim et al. 2011).  
A question arises as to whether ZIC3 and TCF7L1 share the same functional role during gastrulation: 
to co-operatively repress β-catenin dependent transcription. A model for ZIC3-TCF7L1 Wnt repression 
is proposed in which ZIC3 functions as a co-repressor of Wnt dependent transcription alongside 
TCF7L1 in the absence of Wnt stimulation. For this model to hold true, however, these proteins must 
physically and functionally interact. Currently, evidence demonstrating that these proteins function 
together is lacking. For example, though loss-of-function studies of both proteins produce common 
phenotypes, it remains to be shown whether ZIC3 and TCF7L1 are capable of direct protein interaction. 
Therefore, this chapter will aim to determine whether ZIC3 and TCF7L1 are capable of physical 
interaction through multiple molecular assays.  
98 
 
3.2 Results 
The overlapping expression pattern of Zic3 and Tcf7l1 during murine gastrulation indicates that these 
proteins may physically interact. Proof that the proteins can directly interact with each other would 
further support the hypothesis in which they function together to repress Wnt signalling during 
gastrulation. A variety of methods are routinely used in molecular biology to demonstrate protein-
protein interactions via overexpression of candidate interacting molecules. The use of multiple 
techniques, also known as orthogonal repeats, provide stronger evidence of the interaction compared 
to performing the same technique numerous times.  
3.2.1 Method 1: Co-immunoprecipitation 
A widely used method to investigate protein-protein interactions is co-immunoprecipitation, a 
technique that uses specific antibodies to ‘pull down’ and isolate proteins and their binding partners. 
Briefly, an antibody specific to one protein is incubated with a cell lysate that contains this target 
protein and its binding partner. This allows an antibody-protein complex to be formed and captured 
(often through the use of agarose or magnetic beads), while non-bound proteins are washed away. 
The target protein and binding partner are eluted and analysed via SDS-PAGE electrophoresis and 
western blot analysis to confirm the presence of both proteins. Successful immunoprecipitations, 
however, are highly dependent on the method and reagents used. There are several different lysis 
and wash buffers available that can be applied to immunoprecipitation protocols as protein complexes 
can be sensitive to the type of buffers used. As such, protocol optimisation is often required for each 
experiment. That is, there is not a ‘one method suits all’ approach for precipitating protein complexes.  
Previous studies have demonstrated that ZIC2 can bind TCF7L2 in co-immunoprecipitation 
experiments using overexpressed proteins in HEK293T cells (Pourebrahim et al. 2011). Due to the 
homology between ZIC2 to ZIC3 and TCF7L2 to TCF7L1, a co-immunoprecipitation experiment was 
conducted using the protocol outlined by Pourebrahim et al. 2011 and also established protocols in 
the Arkell laboratory to see if ZIC3 directly binds TCF7L1. HEK293T cells were transfected with V5-ZIC3 
and Myc-Tcf7l1 expression plasmids. Additionally, V5-ZIC2 and Flag-TCF7L2 expression plasmids were 
included as a positive control. An anti-V5 antibody was used to pull down V5-ZIC3/Myc-TCF7L1 or V5-
ZIC2/Flag-TCF7L2 protein complexes from the cell lysate, and either anti-Flag, anti-Myc, anti-TCF7L1 
or anti-TCF7L2 antibodies were used to detect the Myc-TCF7L1 or Flag-TCF7L2 proteins via western 
blotting (as well as anti-V5 to detect V5-ZIC proteins). Despite multiple attempts, co-
immunoprecipitation experiments with ZIC3 and TCF7L1 were inconclusive. Western blot analysis 
could not detect either TCF7L1 or TCF7L2 (i.e. the protein binding partner) following co-
immunoprecipitation and could only detect V5-ZIC proteins (the original pulled down protein) (Data 
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not shown). As the positive control (ZIC2 and TCF7L2) failed to detect TCF7L2 in the pull down, it was 
concluded there was an issue with the experimental technique, therefore the co-immunoprecipitation 
used could not confirm (or refute) an interaction between ZIC3 and TCF7L1. Due to the vast array of 
troubleshooting possibilities, other protein binding techniques were prioritised. Expression plasmids 
were sent to our collaborators (R. Houtmeyers, S. Tejpar; KU Leuven, Belgium), who have well 
established co-immunoprecipitation protocols within their laboratory. During thesis write-up, a 
successful Co-IP demonstrating a direct ZIC3 and TCF7L1 interaction was conducted by Rob 
Houtmeyers (KU Leuven, Belgium). Images, however, were not made available before thesis 
submission. 
3.2.2 Method 2: Yeast two-hybrid  
The yeast two-hybrid method was developed by Fields and Song in 1989 and is a simple and cost 
effective technique for identifying novel protein interactions as well as assessing known strong and 
weak protein interactions (Fields and Song 1989; Brückner et al. 2009). The system is based on the 
activation of reporter genes by the GAL4 transcription factor. In the yeast two-hybrid assay, the GAL4 
protein is split into two halves; the DNA binding domain and the activation domain. Stimulation of the 
reporter genes in the assay only occurs when the GAL4 protein is reconstituted into a functional 
transcription factor, which can drive gene expression (Mehla et al. 2015).  
The two proteins to be examined for interaction are termed the ‘bait’ and ‘prey’ proteins respectively. 
The ‘bait’ protein is expressed as a ‘hybrid’ as it is fused with the DNA binding domain of GAL4 and 
can recognise and bind to specific GAL4 DNA binding sites, which are located within a specific reporter 
construct integrated in the yeast genome. The ‘prey’ is similarly a fusion of the activation domain of 
the GAL4 protein and the second protein of interest. Reporter gene expression will be activated if a 
functional GAL4 protein is generated. This is only achieved if the bait and prey proteins interact to 
bring both the DNA binding domain and the activation domain of the GAL4 transcription factor 
together (Figure 3.4). In the absence of bait and prey interaction, expression of the reporter gene will 
not be induced as neither the bait or the prey are capable of transactivation in isolation (Figure 3.4). 
  
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Schematic of the yeast two-hybrid system. The yeast two-hybrid system utilises the DNA 
binding and activation domains of the GAL4 transcription factor. The DNA binding domain recognises 
and binds specific DNA sequences of a reporter gene and the activation domain is involved in 
interacting with transcriptional machinery including RNA polymerase. The ‘bait’ protein (Protein A) is 
fused to the DNA binding domain of GAL4, while the ‘prey’ protein (Protein B) is fused to the GAL4 
activation domain. (A) If the bait and prey proteins interact, a functional GAL4 transcription factor is 
reconstituted and can drive expression of reporter genes. (B) If the bait and prey proteins do not 
interact, the reporter gene is not activated. DBD: DNA binding domain, AD: activation domain.  
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The yeast strain used here (MaV203, S. cerevisiae) acts as a host strain for the bait and prey plasmids 
and contains copies of reporter genes HIS3, URA3 and lacZ downstream from GAL4-binding sites that 
have been integrated independently at different loci of the yeast genome. These genes are placed 
under the control of the GAL4 transcription factor and are essential for yeast growth. For example, 
the HIS3 and URA3 reporters are included for the biosynthesis of Histidine and Uracil respectively, and 
the yeast are grown on media lacking these essential acids, therefore, only yeast cells that contain 
interacting bait and prey proteins will drive expression of HIS3 or URA3 from the reporter and allow 
the formation of colonies on selective agar plates. A second means to assess the expression of HIS3 is 
the addition of the inhibitor 3-aminotriazole (3AT) to selective medium: 3AT is a competitive inhibitor 
of HIS3, and when added to selective medium in increasing concentrations, enables direct assessment 
of HIS3 expression levels. For example, yeast growth on selective plates containing higher 
concentration of 3AT would indicate greater HIS3 expression and consequently suggests a stronger 
protein-protein interaction, whilst a weak interaction is shown if yeast only grow on low 
concentrations of 3AT. Similarly, induction of URA3 can also be measured by the addition of the 
selective compound 5-Fluoroorotic Acid (5FOA). Interacting proteins that express URA3 results in the 
conversion of 5FOA into a toxic compound, 5-fluorouracil, resulting in cell death. Therefore 5FOA 
selects against positive interactions by killing yeast expressing URA3. As such, cell growth on a medium 
containing 5FOA would suggest absent (or weak) protein interaction.  
To determine whether ZIC3 and TCF7L1 proteins interact, both wildtype ZIC3 and Tcf7l1 cDNA were 
transferred into yeast two-hybrid compatible vectors as part of the Life Technologies ProQuestTM Two-
Hybrid System. Vector conversion uses Gateway LR recombination cloning technology to insert both 
ZIC3 and Tcf7l1 CDS into the required ‘bait’ and ‘prey’ vectors (pDEST-32 and pDEST-22). The cDNA for 
each protein of interest was cloned into both ‘bait’ and ‘prey’ vector backbones to ensure false 
negatives resulting from the fusion protein physically blocking the binding sites for each protein of 
interest was avoided. Four new plasmids were thereby generated to enable all conformations of bait 
and prey proteins: p32-ZIC3-wt, p32-Tcf7l1, p22-ZIC3-wt and p22-Tcf7l1 (Table 3.1). 
 
Table 3.1: Combination of bait and prey plasmids used in Yeast Two-Hybrid assays. The bait plasmid 
includes GAL4 DNA binding domain and the prey plasmid includes GAL4 activation domain. 
Plasmid Combination ‘Bait’ plasmid  ‘Prey’ plasmid  
1 p32-ZIC3-wt p22-Tcf7l1 
2 p32-Tcf7l1 p22-ZIC3-wt 
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3.2.2.1 ZIC3 and TCF7L1 show mild interaction in the Yeast two-hybrid assay 
To investigate the interaction between ZIC3 and TCF7L1 proteins, a yeast two-hybrid experiment was 
performed using the ProQuestTM Two-Hybrid system. Three different controls supplied in the kit were 
included in the assay based on the interaction between Krev1 (a member of the Ras family of GTP 
binding proteins) and RalGDS (the Ral guanine nucleotide dissociator stimulator protein) proteins 
(Herrmann et al. 1996; Serebriiskii et al. 1999): wildtype Krev1 and RalGDS generate a strong 
interaction control, whereas two mutant forms of RalGDS generate a weak and absent protein 
interaction, respectively. Two different conformations of ZIC3 and TCF7L1 were included to enable 
each to act as the ‘prey’ and ‘bait’ plasmids (Table 3.1). All plasmids were transformed into the 
MaV203 yeast strain and subsequently patch and replica plated onto selection plates (Figure 3.5).  
The results produced from the yeast two-hybrid assay were inconclusive. ZIC3:TCF7L1 transformants, 
from both combination 1 and combination 2, showed minimal (but not absent) growth on SC-Leu-Trp-
Ura and SC-Leu-Trp-His+3AT selection plates (Figure 3.5). Slight growth was seen on these plates 
compared to the ‘absent’ interaction control, which only presented with a faint haze of cells, 
presumed to be artefacts from replica plating. This is indicative that Histidine and Uracil reporter 
activation may be slightly induced from interacting ZIC3/TCF7L1 bait and prey proteins. More notably, 
cell death was present on SC-Leu-Trp+5FOA plates (ZIC3-TCF7L1 Conformation 1) at a level 
comparable to the weak interaction control, suggesting ZIC3 and TCF7L1 have a weak protein 
interaction (Figure 3.5).  
It should be noted, however, that the controls provided in the ProQuestTM Two-Hybrid kit do not 
clearly differentiate a strong and weak protein interaction in any experimental repeat conducted. In 
most cases, the strong and weak interaction controls looked very similar, making it difficult to interpret 
a true weak protein interaction from a strong one (a criticism of the kit used, not the technique itself). 
Nonetheless, results from the yeast two-hybrid assay did not convincingly indicate whether ZIC3 and 
TCF7L1 are protein partners or not. Therefore, other methods to identify protein-protein interactions 
were investigated to clarify this result. 
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Figure 3.5: Yeast two-hybrid suggests a weak interaction between ZIC3 and TCF7L1 proteins. A yeast 
two-hybrid assay was conducted using the ProQuestTM Two-Hybrid System (Invitrogen). Colonies were 
grown on the selection media shown to determine the level of protein interaction. A strong, weak and 
absent interaction controls were included as supplied with the kit. (A) Expected results for 
investigating protein interaction using the ProQuest Two-Hybrid system. Image sourced from 
Invitrogen ProQuest User manual. (B) Two combinations of ZIC3 and TCF7L1 plasmids were 
transformed. (1) p32-ZIC3-wt, p22-Tcf7l1 (ZIC3 as bait, Tcf7l1 as prey); (2) p32-Tcf7l1, p22-ZIC3-wt 
(Tcf7l1 as bait, ZIC3 as prey). Transformed yeast colonies were patched onto a master plate, replica 
plated onto selection plates and incubated for 24 hours at 30°C. Plates were replica cleaned as 
necessary and incubated for a further 48 hours. Two independent colonies are shown for each 
treatment. Black arrows indicate slight colony growth. 
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3.2.3 Method 3: Proximity ligation assay  
A Proximity Ligation Assay (PLA) is a highly specific and sensitive method designed to identify proteins, 
protein-protein interactions and post-translational modifications using standard immunofluorescence 
techniques (Weibrecht et al. 2014). PLA uses antibodies to target the protein(s) of interest, which 
theoretically allows the technique to be used on both tissues and cells (Leuchowius et al. 2011). For 
example, to detect protein-protein interactions, primary antibodies are first hybridised to the two 
proteins of interest (Figure 3.6). Secondary antibodies that are conjugated to complementary 
oligonucleotide probes bind to the primary antibodies attached to the proteins. If the two proteins of 
interest are in close proximity to each other (within 40 nm), the two oligonucleotides can hybridise 
and form a circular DNA molecule, which is then amplified by a mechanism known as rolling circle 
amplification. The amplification step produces several repeating sequences which are recognised by 
complementary detection oligos coupled to fluorochromes. The resulting fluorescent signal can be 
detected using a standard fluorescent microscope (Figure 3.6). If the PLA probes are too far apart, 
indicative of the two proteins not in binding distance, no fluorescence will be detected (Fredriksson 
et al. 2002; Söderberg et al. 2006; Weibrecht et al. 2014).  
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Figure 3.6: Schematic of how fluorescence is produced in a Proximity Ligation Assay. In situ Proximity 
Ligation assay (PLA) can be used to detect protein-protein interactions with high specificity and 
sensitivity. (A) Two primary antibodies recognise and bind to the proteins of interest. (B) Secondary 
antibodies conjugated to short oligonucleotide sequences (PLA probes) hybridise to the primary 
antibodies. (C) If the PLA probes are in close proximity, the probes will ligate and produce a circular 
DNA template, which is amplified via rolling circle amplification. (D) This creates repetitions of the 
same sequence to be recognised by complementary detection oligonucleotides coupled to 
fluorochromes which can be visualised through fluorescent microscopy.  
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3.2.3.1 Proximity ligation assay detects an interaction between ZIC3 and TCF7L1 
The DuoLink® PLA (Sigma) was used to demonstrate the interaction between ZIC3 and TCF7L1 as this 
system can be used to detect stable, weak or transient protein-protein interactions (Fredriksson et al. 
2002). HEK293T cells were co-transfected with a combination of either V5-ZIC3, V5-ZIC2, Myc-Tcf7l1, 
FLAG-TCF7L2 or V5-β-catenin and a PLA was performed according to manufactures instructions 
(Chapter 2.4.6). As expected , wildtype ZIC2 protein was able to interact and produce fluorescent 
signal when transfected with FLAG-TCF7L2, confirming this interaction that has been previously 
documented through co-immunoprecipitation by Pourebrahim et al. 2011 using overexpressed 
proteins. A secondary positive control V5-β-catenin-wt transfected with Myc-Tcf7l1 similarly produced 
detectable fluorescent signal when overexpressed in HEK293T cells. Fluorescent signal was also 
detected following combined overexpression of V5-ZIC3 and Myc-Tcf7l1 expression plasmids, 
suggesting a positive interaction between these two proteins (Figure 3.7). This assay indicates ZIC3 
and TCF7L1 are in close enough proximity to each other to infer the two proteins interact.  
Although this system can be used to confirm or investigate protein-protein interactions, limitations 
are encountered when assessing the strength of such interactions. The output of PLA shown here 
produces binary data in that an interaction is either present or absent. Although not pursued, it could 
be possible to use imaging software to trace around cells and quantify the fluorescence intensity for 
each cell positive for a PLA interaction. This has the potential to be used for downstream analysis to 
identify mutations that disrupt or hinder the ZIC3-TCF7L1 interaction. However, due to the cost of 
probes, detection reagents and antibodies for individual transfections, alternative methods were 
explored.  
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Figure 3.7: ZIC3 and TCF7L1 produce detectable fluorescence in a Proximity Ligation Assay. HEK293T 
cells were grown on coverslips and co-transfected with the expression plasmids shown. 24 hours post-
transfection, cells were fixed and prepared for immunofluorescence. Primary antibodies α-V5, α-
TCF7L1 or α-TCF7L2 were hybridised to appropriate cells before addition of PLA probes. Images of cells 
were captured with a fluorescent microscope. Three independent experiments were performed; one 
representative image from each PLA is shown.  
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3.2.4 Method 4: Bimolecular fluorescence complementation  
Bimolecular fluorescence complementation (BiFC) is a relatively new technique for identifying protein-
protein interactions. The assay relies on the Venus fluorescent protein producing a fluorescent signal 
when two proteins are in close proximity (Kodama and Hu 2012; Miller et al. 2015). Venus is a modified 
version of the Yellow Fluorescent Protein (which itself is a modified version of the Green Fluorescent 
Protein derived from the jellyfish Aequorea Victoria) (Nagai et al. 2002). The Venus protein is split into 
an N’ and C’ half, and each half is attached to the two test proteins of interest. The N’ and C’ halves of 
Venus are themselves non-fluorescent and will only produce a fluorescent signal when the fragments 
come together, reassemble and fold into their correct structure (Figure 3.8). When these test proteins 
interact or are in close enough proximity, the two fragments of Venus reassemble and produce a 
detectable fluorescent signal. BiFC has many advantages over other techniques as it allows direct 
visualisation of protein-protein interactions in living cells. Unlike other techniques, there is no need 
for fixation or cell lysis to detect protein interactions (Miller et al. 2015). Furthermore, BiFC is a 
quantitative technique that allows direct comparisons when analysing mutations (e.g. when 
identifying hypomorphic mutations). 
Though some BiFC compatible expression vectors already existed in the Arkell laboratory (expression 
plasmid pV1-hZIC3-wt), several expression vectors were also generated for this technique: mTcf7l1 
cDNA was cloned into the pV2-ORF vector backbone, and mouse Zic3 cDNA and human TCF7L1 cDNA 
were transferred to the V1-ORF and V2-ORF vector backbones, respectively, to investigate whether 
there is a difference in protein-protein interaction between mouse and human ZIC3 and TCF7L1 
proteins. The pV1-ZIC3 constructs produce a fusion protein with the N-terminal fragment of the Venus 
fluorescent protein attached to the ZIC3 protein (V1 tag), whilst the pV2-TCF7L1 constructs produce a 
fusion protein of TCF7L1 with the C-terminal fragment (V2) of the Venus fluorescent protein. If pV1-
ZIC3-wt protein interacts with pV2-TCF7L1, it will cause the V1 and V2 fragments of Venus to reform 
and give a detectable fluorescent signal (Figure 3.8). 
3.2.4.1 Bimolecular fluorescence complementation assay suggests ZIC3 and TCF7L1 interact 
To test the relative ability of wildtype ZIC3 to interact with TCF7L1 protein, HEK293T cells were 
transfected with V1-hZIC3-wt or V1-mZic3-wt along with either V2-hTCF7L1 or V2-mTcf7l1. 
Fluorescence intensity was measured using a fluorescent plate reader 48 hours post-transfection. Cells 
were then lysed and assessed by SDS-PAGE electrophoresis and western blot to confirm protein 
expression (Figure 3.9). When human ZIC3 was transfected with either mouse or human TCF7L1, a 2.8 
fold increase in fluorescence compared to background levels was observed (Figure 3.9). Similarly, a  
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Figure 3.8: Schematic of the production of fluorescence in the BiFC assay. pV1-hZIC3-wt produces a 
fusion protein with the V1 fragment of the Venus protein attached. pV2-Tcf7l1 produces the TCF7L1 
fusion protein with the V2 fragment of Venus attached. Only when the V1-hZIC3 protein is in close 
enough proximity to the V2-TCF7L1 protein will the Venus protein reform to give a fluorescent signal 
that can be visualised and/or quantified.  
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Figure 3.9: ZIC3 interacts with human and mouse TCF7L1 with the same strength. HEK239T cells were 
co-transfected with V1-hZIC3-wt or V1-mZIC3-wt along with either V2-hTCF7L1 or V2-mTcf7l1 
expression plasmids. The mean fluorescence intensity emitted from each of three internal replicate 
samples was detected 48 hours post-transfection. Three independent experiments were performed. 
(A) Mean fluorescence intensity of three internal replicates from one representative experiment. Error 
bars represent the SD between the three internal replicates. A western blot was performed to confirm 
expression of transfected proteins. Primary antibodies α-TCF7L1 was used to detect TCF7L1 protein, 
α-GFP was used to detect ZIC3 protein and α-TBP was used as a loading control. (B) Pooled data from 
three independent repeats. Values depict the mean relative luciferase values. Error bars depict SEM. 
Different letters denote statistical differences of p<0.05 calculated via a two-way ANOVA with 
Fischer’s unprotected post hoc test, where a is statistically significant to b etc.  
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2.8 fold increase was detected when mZIC3 was transfected with mTCF7L1, but only a 2.4 increase 
when transfected with hTCF7L1. These fold changes suggest that ZIC3 and TCF7L1 proteins are in close 
enough proximity to interact and suggests a direct protein-protein interaction. Moreover, no 
significant difference was found between hZIC3:hTCF7L1 transformants when compared to the 
interaction between hZIC3 and mTCF7L1 (Figure 3.9). Protein alignment of human and mouse TCF7L1 
protein sequences illustrates they share 95.2% similarity (Figure 3.10). As such, these proteins were 
used interchangeably in downstream BiFC analysis.  
A common control for BiFC or other proximity assays that confirm a specific interaction between your 
two proteins is occurring is to include a protein that contains a loss-of-function mutation or lacks the 
domain responsible for the protein-protein interaction. Such a mutation is yet to be identified for ZIC3 
or TCF7L1 proteins, therefore this control was unable to be included. An alternative control commonly 
used in BiFC studies is a competition assay. In this assay, increasing amounts of a non-Venus tagged 
protein is added into the assay to act in competition with the Venus tagged protein. As increasing 
amounts of this non-Venus tagged protein is added, the total fluorescence is expected to decrease. 
The work presented in Chapter 4 identifies a human ZIC3 variant, ZIC3-C268X, a mutant protein that 
interacts with TCF7L1 with greater affinity in the BiFC assay compared to wildtype ZIC3 (Chapter 4, 
Figure 4.5). As such, this V5 tagged ZIC3 variant was used as the competitor in these experiments to 
demonstrate the specificity of the assay. HEK293T cells were co-transfected with V1-ZIC3-wt, V2-
Tcf7l1 and increasing amounts of the non-fluorescent plasmid V5-ZIC3-C268X. Adding increasing 
concentrations of V5-ZIC3-C268X decreased overall fluorescence, demonstrating the fluorescence 
observed is due to the specific interaction between the ZIC3 and TCF7L1 proteins rather than random 
association of the V1 and V2 protein tags. (Figure 3.11).  
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Figure 3.10: Human TCF7L1 and mouse TCF7L1 share 95.2% protein sequence. Amino acid alignments 
between human TCF7L1 and mouse TCF7L1 using the online protein alignment tool SIM illustrates 
they share 95.2% of their protein sequence. Identical amino acids are indicated by an asterisk (*) 
below the aligned sequences.  
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Figure 3.11: Competition assay demonstrates V1-ZIC3 and V2-Tcf7l1 interact. HEK293T cells were co-
transfected with V1-hZIC3-wt, V2-mTcf7l1 constructs along with increasing amounts of pnV5-ZIC3-
C268X. The mean fluorescence intensity emitted from each of three internal replicate samples was 
detected 48 hours post-transfection. Three independent experiments were performed. (A) Mean 
fluorescence intensity of three internal replicates from one representative experiment. Error bars 
represent the SD between the three internal replicates. The corresponding western blot is shown 
below. α-TCF7L1 antibody was used to detect V2-Tcf7l1 protein, α-GFP antibody used to detect V1-
hZIC3-wt protein, α-V5 antibody was used to detect V5-hZIC3 protein and α-TBP was used as a loading 
control. wt: wildtype. (B) Pooled data from three independent repeats. Values depict the mean 
relative luciferase values. Error bars depict SEM Different letters denote statistical differences of 
p<0.05 calculated via a two-way ANOVA with Fischer’s unprotected post hoc test, where a is 
statistically significant to b etc. 
 
  
114 
 
3.3 Discussion  
The findings of this study build upon a novel hypothesis for ZIC3 function in the Wnt pathway during 
gastrulation. Zic3 loss-of-function mouse models demonstrate elevated Wnt phenotypes including 
forebrain truncations and axis duplications, suggesting ZIC3 functions as a repressor of the signalling 
pathway during embryogenesis. Given that ZIC2 can physically interact with a related protein TCF7L2 
in cell assays and that Zic3 and Tcf7l1 share expression domains during gastrulation, it is proposed 
ZIC3 acts with TCF7L1 as a co-repressor. There is, however, no evidence of this interaction occurring 
in published studies. Notably, there is no single method that is universally used in molecular biology 
to demonstrate protein-protein interactions. Each available technique offer advantages over others, 
therefore the use of orthogonal repeats provides greater support of the interaction. As such, four 
different methods were used to investigate the interaction between ZIC3 and TCF7L1: co-
immunoprecipitation, yeast two-hybrid, proximity ligation assay and BiFC. Overall, I have shown 
through multiple molecular assays that ZIC3 is capable of interacting with TCF7L1, in a context specific 
manner, when overexpressed in cell lines, consistent with the role of ZIC3 as a canonical Wnt co-
repressor during gastrulation and providing a precursor for this interaction occurring in vivo.  
3.3.1 ZIC3 and TCF7L1 demonstrate a positive interaction in multiple molecular assays  
Protein-protein interactions are commonly investigated using biochemical co-immunoprecipitation 
experiments, however the attempts presented in this thesis could not confirm an interaction via this 
method. A co-immunoprecipitation between ZIC3 and TCF7L1 was successfully conducted by our 
collaborators, indicating the two proteins can physically interact, however data was not made 
available in time for this thesis submission. There are several alternative molecular techniques such 
as proximity assays that are widely used and increasing in popularity, which I have used to show a 
positive interaction between ZIC3 and TCF7L1. For example, a PLA successfully demonstrated ZIC3 and 
TCF7L1 interact following transient transfection in HEK293T cells. Ideally, this assay would be 
performed on endogenous proteins, however due to the lack of reliable ZIC3 primary antibodies, 
coupled with the low expression of ZIC3 in HEK293T cells (Genevestigator, Appendix B), 
overexpression studies were utilised for this primary experiment. This assay will be useful to test 
future ZIC3-TCF7L1 interaction studies, particularly when screening for mutations that disrupt this 
protein interaction. Furthermore, a PLA experiment could be performed on embryo sections to 
demonstrate the in vivo interaction of these two proteins following production and optimisation of 
suitable ZIC3 antibodies. Alternatively, to aid in protein detection, a cell line or mouse model can be 
created in which a V5 epitope tag is introduced (via CRISPR/Cas9 mutagenesis) into endogenously 
expressed ZIC3 and a different tag (such as FLAG) can be introduced into endogenous TCF7L1. This 
would allow the use of the reliable V5/FLAG-antibodies in downstream experiments.  
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BiFC analysis was also able to confirm the interaction between ZIC3 and TCF7L1 when over expressed 
in HEK293T cells. BiFC assays offer a significant advantage over co-immunoprecipitation or yeast two-
hybrid experiments as quantitative data can be produced easily. Indeed, signal emitted from 
interacting proteins can be imaged with a fluorescent microscope to visualise the interaction at a 
cellular level, or with a fluorescent plate reader to determine the average fluorescent intensity from 
a large collection of cells (Kerppola 2009). The latter method can evaluate vastly greater cell numbers 
than would be able to be individually photographed and scored. Similar to the PLA, BiFC will be useful 
for screening mutations that disrupt the ZIC3-TCF7L1 interaction and quantitative measurements will 
be particularly useful for identifying hypomorphic variants.  
Overexpression studies are often criticised for not accurately representing the physiological 
environment in which they are being tested. To address this, a suite of single-molecule tracking 
techniques are being developed to visualise the movement and molecular dynamics of transcription 
factors. Single-molecule tracking utilises tags such as EGFP, mEOS or HaloTag and, coupled with the 
use of high resolution microscopy and robust computational and statistical algorithms such as pair 
correlation analysis, allows the researcher to track movement and interactions of single proteins in 
live cells (Hinde et al. 2010; Presman et al. 2017). This technique is considered suitable to assess 
molecular mechanisms using overexpressed protein while overcoming potential artefacts associated 
with exogenous protein studies (Hinde et al. 2016). As such, it could be used to validate the protein 
interactions between ZIC3 and TCF7L1.  
3.3.2 Yeast two-hybrid assays showed weak, but not absent, interaction between ZIC3 and TCF7L1 
Yeast two-hybrid experiments are often used to screen for novel protein interactions and can confirm 
protein-protein interactions in living yeast cells. ZIC3 and TCF7L1 proteins were assessed for their 
ability to interact using a yeast two-hybrid experiment, however, data produced from the assay did 
not detect a convincing interaction between the two proteins. Performing this protein interaction 
assay in isolation may suggest that the proteins are not binding partners or that there is only a 
relatively weak protein interaction occurring. Indeed, the importance of orthogonal repeats is 
emphasised as a positive interaction between the two proteins was detected using other methods, 
and this technique likely produced a false negative result.  
Positive interactions in yeast two-hybrid are dependent on a number of factors including protein 
expression in the yeast cells, correct protein folding and post-translational modifications needed for 
the interaction (Brückner et al. 2009). For example, the ZIC3 and TCF7L1 proteins may have low or 
absent protein expression in the heterologous system (i.e. mammalian protein expression in yeast). 
However due to the lack of epitope tags within the vector backbone of bait and prey constructs, and 
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the lack of ZIC specific antibodies, it was not possible investigate protein expression in this system. 
Additionally, expression of mammalian protein in yeast cells may not provide the necessary post 
translational modifications necessary for the proteins to interact. For example, it has been 
documented that ZIC proteins are subject to the post translational modification SUMOylation (Chen 
et al. 2013; Bellchambers 2015). It is possible that the proteins require this modification (or others) 
for normal interaction or expression, and yet are not subject to the modifications in the yeast cells 
resulting in a false negative interaction. Lastly, the configuration of the protein fusion (i.e. the 
attachment of the GAL4 DNA binding or activation domain to the target protein) may physically block 
the interaction binding site of the target protein, thereby unintentionally inhibiting reporter gene 
activation. Indeed, to minimise this artefact, both proteins were made as both bait and prey proteins 
using the ProQuest vectors. There were observable differences between the two confirmations, with 
confirmation 1 (ZIC3 as the bait and TCF7L1 as the prey) having a slightly greater interaction (Figure 
3.5), confirming the arrangement of the fusion proteins can influence the strength of detecting protein 
interactions. The ProQuest vectors, however, attach the GAL4DNA binding or activating domain to the 
N-terminal of the target proteins. Future studies could investigate whether attaching the GAL4 
domains to the C- terminus of the target proteins influences the strength of the protein interaction or 
include additional positive control plasmids such as ZIC2 and TCF7L2. Overall, the ProQuest yeast two-
hybrid method was not deemed appropriate to measure the protein interaction between ZIC3 and 
TCF7L1.  
3.3.3 Data lends support to ZIC3 acting as a Wnt co-repressor.  
Negative regulation of the Wnt signalling pathway is essential for normal embryo development. It is 
suggested that one role of the ZIC3 transcription factor is to function as a co-repressor of Wnt/β-
catenin mediated transcription. I have successfully confirmed that ZIC3 and TCF7L1 are capable of 
direct protein-protein interaction supporting a molecular mechanism of how ZIC3 and TCF7L1 can 
function together to inhibit canonical Wnt signalling during specific stages of development (Figure 
3.12). Given that these proteins are capable of interacting in vitro, it is now practical to investigate this 
interaction in vivo. Furthermore, in vivo analysis of a variant in which the ZIC3-TCF7L1 binding is lost 
would also provide evidence of the functional consequence of this interaction.  
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Figure 3.12: Simplified model of ZIC3-TCF7L1 dependent Wnt repression. ZIC3 can physically interact 
with a well characterised repressor of canonical Wnt signalling, TCF7L1. Both Zic3 and Tcf7l1 mutate 
to give similar phenotypes representing an elevated Wnt phenotype. As such, it is proposed ZIC3 
directly interacts with TCF7L1 during gastrulation to prevent transcription of Wnt target genes.  
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Chapter 4: Do ZIC3 Heterotaxy-associated variant proteins have 
altered Wnt pathway function? 
4.1 Introduction  
ZIC3 is commonly thought to function as a classical transcription factor to influence transcription of 
target genes and can activate several reporters in cell-based assays (Chhin et al. 2007; Li et al. 2018). 
It is becoming apparent, however, that researchers must also consider the function of ZIC3 in the Wnt 
pathway. As discussed in Chapter 1 (section 1.5.4.2), two independent studies using both animal 
models (Xenopus and Zebrafish) and cell based reporter assays demonstrated ZIC proteins can 
function as canonical Wnt co-repressors (Pourebrahim et al. 2011; Fujimi et al. 2012). The Arkell 
laboratory has also demonstrated that all five human ZIC proteins (ZIC1-5) inhibit Wnt signalling in a 
HEK293T cell-based TOPflash assay (Chapter 1, Figure 1.7) and shown that mouse models of Zic3 loss-
of-function not only present with L-R axis defects, but also phenocopy characteristic elevated 
canonical Wnt phenotypes, including anterior truncation and axis duplication (Arkell Laboratory, 
unpublished). Furthermore, both Zic3 and Tcf7l1 exhibit overlapping expression domains in 
gastrulating mouse embryos, and I have demonstrated that these two proteins can physically interact 
in various cell-based assays (Chapter 3), suggesting ZIC3 transects the Wnt pathway via TCF7L1. Based 
on this evidence, if ZIC3 mediated repression of Wnt activity is required to prevent Heterotaxy in 
human probands, it would then be expected that ZIC3 Heterotaxy-associated protein variants have 
altered Wnt inhibition activity. Currently, however, the functional consequence of the reported 
human ZIC3 variants in the Wnt pathway is not known.  
4.1.1 Characterising genetic variants as pathogenic  
Advances in DNA sequencing technologies have fuelled a vast expansion in the number of genetic 
variants being identified in human patients. In the case of ZIC3, more than 40 allelic variants have been 
associated with human Heterotaxy thus far. It is, however, difficult to determine a priori whether 
sequence variants found in probands are causative or are simply naturally occurring sequence 
variation present in the population (i.e. a polymorphism). Studies investigating previously reported 
disease causing variants (from other genes in the genome) established that many of the variants were 
either common polymorphisms, present in population control samples or did not have sufficient 
evidence to be classified as causative (Bell et al. 2011; Norton et al. 2012; Xue et al. 2012). This 
distinction is essential to functional genomic research as falsely assigning causation to a genetic 
variant can have negative consequences regarding downstream analysis, genomic research and 
medical treatments (Macarthur et al. 2014). One issue caused by the increase in variant identification 
is the inconsistent use of terms used to describe genetic variants. Macarthur et al. 2014 have outlined 
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definitions of commonly used terms (outlined in Table 4.1) and these will be used in this thesis. Of 
particular importance is the idea of pathogenicity regarding human variants. A variant is termed 
pathogenic only if there is strong evidence that it contributes mechanistically to the disease. This 
evidence is often a combination of family history, allelic frequency in the population, bioinformatics 
approaches and in vitro or in vivo functional studies demonstrating a damaging effect on the gene or 
gene product.  
Computational (in silico) online prediction tools including Polyphen, SIFT, Align GVGD and Mutation 
Taster have been used to predict the effect on protein function of all previously identified human 
Heterotaxy-associated ZIC3 missense mutations (Paulussen et al. 2016). These commonly used tools 
employ algorithms (which can differ between each program) to determine the effect of a particular 
amino acid change to overall protein function. All 16 ZIC3 missense mutations so far assessed are 
predicted to be either damaging, deleterious or disease causing (Paulussen et al. 2016). Online tools 
such as these have an accuracy of 65-80% when predicting protein function (Thusberg et al. 2011) but 
cannot be used as the only evidence to determine whether a sequence variant is pathogenic (Richards 
et al. 2015). Instead they should be supported with rigorous experimental evidence to demonstrate 
causality. Currently there are gaps in our understanding of ZIC3 variants associated with Heterotaxy, 
particularly with respect to functional studies. For example, the functional effects of only 3/42 known 
Heterotaxy-associated ZIC3 variants have been investigated via an in vivo model organism (Paulussen 
et al. 2016).  
Functional assays are widely used to assess protein function when determining whether a genetic 
variant is disease causing. These assays, however, vary in their supportive strength depending upon 
how well they represent the biological environment (Richards et al. 2015). The strongest support 
comes from animal models that directly mimic the variant. Such models (called avatars) are 
increasingly popular due to the relative ease of introducing precise genome alterations via CRISPR 
technology (Adli 2018; Gurumurthy and Lloyd 2019). It is, however, still impractical to produce and 
analyse all human variants via the avatar approach. Another method that lends strong support is the 
analysis of protein function from patient tissue. This often requires primary cells or the 
reprogramming of post-natal/adult cells. In some cases, CRISPR technology can be used to correct the 
mutation in the cell line and produce isogenic control cells. This method, however, also suffers the 
disadvantage of requiring a large amount of work for each mutant. Additionally, due to limitations 
regarding access to prospectively collected patient tissue, other methods generally must be adopted 
when studying rare congenital disorders. In regards to ZIC protein function, overexpression assays in 
easily transfectable and immortalised cell lines (eg HEK, NIH3T3 etc) are commonly used to overcome  
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Table 4.1: Definitions of terms used to describe sequence variants. The following terms have been 
taken in their entirety from Macarthur et al 2014. 
Term Definition 
Pathogenic Contributes mechanistically to disease, but is not necessarily fully penetrant 
(i.e., may not be sufficient in isolation to cause disease). 
Implicated Possesses evidence consistent with a pathogenic role, with a defined level of 
confidence. 
Associated Significantly enriched in disease cases compared to matched controls. 
Damaging alters the normal levels or biochemical function of a gene or gene product 
Deleterious Reduces the reproductive fitness of carriers, and would thus be targeted by 
purifying natural selection. 
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these problems. It must be noted, however, that these cell lines may not express all the potential co-
factors present in individual tissues where ZIC3 functions in vivo.  
4.1.2 Cell-based assays for assessing ZIC3 function 
TOPflash assays are routinely used to measure TCF-β-catenin mediated transcription (Korinek et al. 
1997). Of the Heterotaxy-associated ZIC3 variants identified so far, only two mutant proteins (W255G 
and P217A) have been assayed for their Wnt repressive function through the use of a Xenopus 
TOPflash assay (Fujimi et al. 2012). ZIC3-W255G, when tested had reduced repressive function, whilst 
ZIC3-P217A repressed transcription as strongly as wildtype ZIC3. It is unknown whether any of the 
other ZIC3 Heterotaxy-associated mutations can still inhibit Wnt signalling. To investigate this, a 
TOPflash reporter construct which consists of 3 tandem copies of a TCF binding motif (AGA TCA AAG 
GG) upstream of a β-globin minimal promoter and a luciferase CDS was created by the Arkell 
laboratory (Helen Bellchambers). This reporter can be transfected into HEK293T cells along with an 
expression construct for β-catenin and ZIC3. The exogenous β-catenin protein interacts with 
endogenous TCF proteins to drive luciferase expression from the reporter, which can then be 
measured. Wildtype ZIC3 has been shown to inhibit this β-catenin-mediated transcription (Chapter 1, 
Figure 1.7).  
As this assay is optimised within the Arkell laboratory, it will be used to investigate whether ZIC3 
Heterotaxy associated variants affect ZIC3 dependent Wnt repression. Importantly, published studies 
have primarily focused on the transcription factor role of ZIC3 when investigating how mutation of 
ZIC3 alters protein function. As the ZIC proteins are capable of both transcription factor and co-factor 
functions, it remains possible that the Heterotaxy phenotype in the human patients arises due to a 
loss of ZIC3’s role as a classical transcription factor. Alternatively, the pathology associated with these 
variants could arise due to the loss of both of these functions or due to a separate unidentified 
mechanism. Therefore, both functions of ZIC3 (co-factor and transcription factor) must be 
investigated.  
Transactivation assays are a useful tool when analysing the effect of a transcription factor on a specific 
DNA element due to their high sensitivity and ease of signal detection. These assays generally contain 
a DNA motif that can be bound by the protein of interest cloned upstream of a reporter protein coding 
sequence (CDS) such as green fluorescent protein (GFP), lacZ or luciferase (Nierode et al. 2016). Of the 
human ZIC3 Heterotaxy-associated variants that have been studied in cell-based assays, many had 
reduced ability to initiate transcription (Ware et al. 2004; Chhin et al. 2007; D’Alessandro et al. 2013b; 
Cowan et al. 2014). However, experimental conditions (such as reporter and expression construct 
concentrations) were not always reported and cell types varied between experiments (Ware et al. 
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2004; D’Alessandro et al. 2013b; Cowan et al. 2014; Li et al. 2018). Moreover, many transactivation 
studies investigating ZIC3 function use either a reporter containing the herpes simplex thymidine 
kinase (TK) or the simian virus 40 (SV40) promoter, yet there is no evidence these are true ZIC 
responsive elements (ZREs) in vivo.  
To accurately study ZIC transactivation ability, target DNA sequences must be known. Two 
independent studies have attempted to find such motifs and identified the same consensus sequence, 
utilising different experimental techniques. The first was a universal protein binding microarray (PBM), 
which was used to identify DNA sequences to which different transcription factors can bind in an in 
vitro study (Badis et al. 2009). In brief, 109 known mouse transcription factors were purified and 
tagged with a detectable epitope. In the case of the ZIC proteins investigated, only fragments 
containing the ZFD were purified. Computational analysis was conducted using an algorithm to 
determine the nucleotide sequence that best interacts with the protein and then generates a variety 
of 8-10 nucleotide sequences (motifs) to determine which sequence combination is most ideal for 
protein binding. This experiment identified a motif able to be bound by purified ZIC1, ZIC2 and ZIC3 
ZFD (Badis et al. 2009). The motif, shown in Figure 4.1, is highly similar to that identified in an 
independent experiment with ZIC3 (Lim et al. 2010). These researchers performed a ChIP-chip 
experiment on mouse embryonic stem cells and found three sequences to be overrepresented in the 
presence of ZIC3, one of which showed high similarity to that identified in the PBM (Figure 4.1). Using 
this sequence, a highly reliable and robust ZIC reporter assay was developed in the Arkell laboratory 
(Ahmed 2015). The reporter construct contains a short stretch of DNA with six tandem copies of the 
consensus motif (with the same five bp spacer between each motif) and placed upstream of a β-globin 
minimal promoter and a luciferase CDS (the final construct is known as p[ZM2]6-β-gl-luc2; see Section 
2.1.1). 
4.1.3 ZIC3-Heterotaxy associated variants selected for functional analysis 
Currently, there are 42 mutations (described in Chapter 1, section 1.3) associated with Heterotaxy in 
humans (Gebbia et al. 1997; Mégarbané et al. 2000; Ware et al. 2004; Chhin et al. 2007; Wessels et al. 
2010; De Luca et al. 2010; Ma et al. 2012; D’Alessandro et al. 2013a, b; Cowan et al. 2014; Paulussen 
et al. 2016; El Malti et al. 2016; Li et al. 2018). The mutational spectrum (summarised in Figure 4.2), 
as well as current knowledge, all point to the importance of the ZFD, and so mutations within this 
domain were prioritised for functional analysis, namely nonsense mutations and missense mutations 
affecting key residues (such as cysteine or histidine) that make up individual zinc fingers.  
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Figure 4.1 Putative ZIC3 DNA-binding sites. (A) Sequence identified by Badis et al. 2009 after 
performing a universal PBM. (B) Sequence identified by Lim et al., (2010) after performing ChIP-chip 
on mouse embryonic stem cells. 
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Figure 4.2: Mutation of ZIC3 is associated with human cases of Heterotaxy. Currently there are 42 
known human mutations in ZIC3 that are associated with human Heterotaxy. These include 18 (42.9 
%) missense, 9 (21.4%) frameshift, 8 (19%) nonsense, 6 in-frame expansions or deletions and 1 intron 
mutation (16.6%). Of these mutations, 22 (52%) occur within the highly conserved zinc finger domain 
of the ZIC3 protein. Experimental analysis is needed to determine if all 42 mutations are pathogenic. 
Seventeen variants (red) were selected for functional analysis and included missense and truncating 
variants both within and outside the zinc finger domain. C: Cysteine, H: Histidine, N’: N-terminus, C’: 
C-terminus.  
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Generally, it would be expected that nonsense and frameshift variants that produce a premature 
termination codon (PTC) would be subject to the cell surveillance mechanism known as nonsense 
mediated decay (NMD). The NMD pathway serves to remove mRNA transcripts containing PTCs before 
they are translated to avoid truncated proteins having damaging effects to the organism (Brogna and 
Wen 2009). The efficiency of NMD is however extremely variable (between tissues and developmental 
stages) and the factors that determine success not fully understood (Huang and Wilkinson 2012). One 
factor that is important in NMD is the splicing events that occur at each intron/exon boundary. NMD 
is typically triggered in transcripts containing nonsense mutations if the PTC is situated 50-55 
nucleotides upstream of the last exon-exon junction, and therefore would presumably affect the 
nonsense mutations investigated here (Maquat 2005). There is evidence, however, of a Zic3 PTC 
variant that evades NMD. The Arkell laboratory identified a Zic3 nonsense mutation (truncated before 
the ZFD; 1283G >T, E249X) that produces a transcript that is not subjected to NMD during murine 
embryogenesis and instead generates a truncated ZIC3 protein (Ahmed et al. 2013). Therefore, it is 
also possible that some, if not all, of the human ZIC3 PTC variants also evade NMD and produce 
detectable protein in vivo. As NMD relies on the presence of introns to determine whether the protein 
is degraded, human ZIC3 variants were introduced into ZIC3 cDNA (which lacks introns), to ensure the 
transcript is not subject to NMD. This allows for protein function to be assessed under the assumption 
the protein is made in vivo. Nonsense mutations that create an N-terminal PTC (<150 amino acids) 
were excluded from analysis due to predicted instability. For example, the ZIC3-S43X variant would 
generate a protein <50 amino acids in length; previous subcellular localisation assays could not detect 
the truncated protein after transfection of the ZIC3-variant plasmids into HeLa cells (Ware et al. 2004). 
Of the 42 known ZIC3 Heterotaxy associated variants, 17 were selected for study (Figure 4.2, Table 
4.2).  
4.1.4 Chapter Aims 
The overall aim of this Chapter is to investigate the functional consequences of 17 Heterotaxy-
associated ZIC3 variants to determine if the mutations affect the ability of ZIC3 to repress Wnt activity 
in vitro. Additionally, as ZIC3 can function as a classical transcription factor, it is possible this function 
is altered by the mutations. As such, the ZIC3 variants will also be assessed for their ability to activate 
transcription at a ZRE. Specifically, this chapter aims to screen human variants to determine whether 
they alter: 
i. ZIC3 dependent Wnt repression (measured by TOPflash assay) 
ii. The interaction with TCF7L1 through a Bimolecular Fluorescence Complementation (BiFC) 
assay  
iii. Transactivation at a ZRE using a reliable and robust ZIC responsive assay  
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Table 4.2: Characteristics of selected ZIC3 Heterotaxy-associated mutations. Clinical symptoms: ASD: 
atrial septal defect, CAVC: complete atrioventricular canal, CHD: congenital heart disease, DORV: 
double outlet right ventricle, d-TGA: dextro-transposition of the great arteries, DILV: double inlet left 
ventricle, HLHS: hypoplastic left heart syndrome, I-TGA: levo-transposition of the great arteries, LV: left 
ventricle, MV: mitral valve, PA: pulmonary atresia, PS: pulmonic stenosis, TA: tricuspid atresia, TAPVR: 
total anomalous pulmonary venous return, VSD: ventricular septal defect. In silico prediction: D: 
probably Damaging or B: Benign as tested by Polyphen, De: Deleterious or T: Tolerated as tested by 
SIFT, DC: Disease causing or P: polymorphism as tested by Mutation Taster 
 
  
Amino acid 
alteration 
Inheritance Clinical symptoms 
In silico 
pathogenicity 
prediction 
G17C 
Isolated, 
familial 
Isolated CHD/Heterotaxy, HLHS, PS, l-
TGA, DILV, ASD, DORV, Heterotaxy, 
dextrocardia, d-TGA, TA 
D/De/DC 
S109C Sporadic Isolated CHD, d-TGA, PDA D/De/P 
E155X Sporadic 
Heterotaxy, Midline liver, dextrocardia, 
CAVC, PA, DORV, TAPVR 
 
Y199delfsX19 Sporadic 
Heterotaxy, dextrocardia, VSD, 
ventriculomegaly, no stomach 
 
P217A 
Sporadic, 
familial 
Heterotaxy, Hypoplastic LV and MV, d-
TGA, DORV, VSD, ventricular inversion, 
Heterotaxy, gut malrotation, polysplenia, 
midline liver 
B/T/DC 
Q249X Familial 
Single ventricle, PS, DORV, asplenia, 
horseshoe kidney, low-set ears, abnormal 
situs 
 
S252X Familial 
Unaffected carrier mother, Asplenia, 
CAVC, PA 
 
C253S Familial 
HLHS, right atrial isomerism, TGA, 
aplenia, malrotation webbed neck, 
abnormal liver lobation 
D/De/DC 
W255G Familial d-TGA, single ventricle, PA, polysplenia D/De/DC 
C268X Familial Situs ambiguous, sacral agenesis  
H286R Unknown Unknown D/De/DC 
E291GfsX53 Familial 
Heterotaxy, Abdominal situs inversus, 
asplenia, CAVC, PA, d-TGA 
 
Q292X Familial 
Two male brothers with situs ambiguous 
and anal malformations 
 
H318N Familial Heterotaxy, VSD, L hip dysplasia  D/T/DC 
E325Lfs*84 Familial Two male deaths with Heterotaxy  
K408X Familial TGA  
A447G Sporadic Isolated CHD, PA, VSD, ASD D/De/DC 
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4.2 Results 
4.2.1 Generation of ZIC3 variant expression constructs 
The 17 human Heterotaxy-associated mutations selected for analysis (Figure 4.2, Table 4.2) included 
6 PTC mutations (4 of which were constructed previously in the Arkell lab), 8 missense mutations and 
3 frameshift mutations. Each corresponding human mutation was introduced into the pENTR-ZIC3-wt 
vector backbone via site-directed mutagenesis. For TOPflash and transactivation assays, all ZIC3 
expression constructs were then introduced into the pcDNA3.1-nV5-DEST (V5-Dest) expression 
plasmid via a Gateway recombination reaction (Life Technologies), which attaches a V5 epitope tag to 
the N-terminus of the ZIC3 protein. The V5 tag allows for easy protein detection when overexpressed 
in mammalian cells due to readily available antibodies for the V5 epitope. Each mutant ZIC3 cDNA was 
also transferred to the V1-ORF destination plasmid for BiFC protein-protein interaction analysis. 
Overall, 34 ZIC3 expression plasmids were generated for functional analysis.  
4.2.2 ZIC3 variants produce detectable protein that localise to the nucleus 
Alteration to DNA sequences (missense, nonsense, frameshift mutations, etc.) may alter protein 
stability or subcellular localisation. For example, there are documented cases for both ZIC2 and ZIC3 
in which transfection of mutant expression plasmids into cells lines does not result in the production 
of detectable protein, or which the protein has impaired nuclear localisation (Ware et al. 2004; Brown 
et al. 2005). Moreover, all documented ZIC functions are nuclear; in such cases where protein is not 
detected in the nucleus, it would not be practical to perform further functional studies. Each ZIC3 
variant expression construct used in this chapter was transfected into HEK293T cells and subcellular 
localisation and stability assessed using standard immunofluorescence techniques. Past members of 
the Arkell laboratory assisted with the analysis of a subset of the immunofluorescence images. For 
each of the human ZIC3 variant proteins investigated, all produced detectable protein that localised 
to the nucleus, although not always to the same degree as the wildtype protein (Figure 4.3). Mutant 
proteins E155X, Y199delfsX19, Q249X, S252X, C253S, W255G, C268X, H286R, E291GfsX53, Q292X, 
H318N, G325Lfs*84, K408X exhibited significantly reduced (p<0.05 one-way ANOVA) nuclear 
localisation compared to wildtype ZIC3 protein, however mean nuclear localisation was always above 
65%. Due to this, it was decided that all variant proteins would be further analysed via functional 
studies.  
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Figure 4.3: ZIC3 Heterotaxy-associated mutants localise to the nucleus. HEK293T cells were 
transfected with the V5-tagged ZIC3 expression constructs shown. 24 hours post-transfection, cells 
were prepared for immunofluorescence microscopy and stained with α-V5 antibody to detect the 
transfected V5-ZIC3 proteins, as well as α-LaminB1 to mark the nuclear membrane. Images of cells 
were captured with a fluorescent microscope. ImageJ software was used to determine the relative 
nuclear and cytoplasmic fluorescence intensity, which was converted to a percentage of total cell 
fluorescence. *: p<0.05; one-way ANOVA.   
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4.2.3 Human ZIC3 variants have altered Wnt repression ability 
To test the ability of the ZIC3-variant proteins to repress β-catenin mediated transcription, a cell-based 
TOPflash reporter assay was used. HEK239T cells were co-transfected with V5-β-catenin, the TOP-β-
gl-luc2 reporter construct and either V5-Dest (to detect background luciferase), V5-hZIC3-wt or a V5-
hZIC3-variant expression construct. Cells were lysed and assessed for protein expression by SDS-PAGE 
and western blot, and luciferase activity was measured in a corresponding aliquot of cells 24 hours 
post-transfection. The data was expressed as relative luciferase activity (with respect to background 
luminescence). In each case, transfection of β-catenin in the absence of exogenous ZIC3 resulted in a 
~25-30 fold increase in luciferase activity, whilst luciferase activity decreased to less than 10 fold with 
the addition of wildtype ZIC3, indicating that wildtype ZIC3 can repress transcription in this assay.  
The ZIC3 variant proteins exhibited a range of repressive abilities. Variants affecting the ZIC3 ZFD, 
including both nonsense and frameshift mutations, had the greatest effect on Wnt inhibition. ZIC3 
variants Q292X, K408X, E155X, E325LfsX84, Q249X, S252X and E291GfsX53 either lost all repressive 
ability or had severely reduced levels of repression (as indicated by high levels of luciferase expression) 
(p<0.05) (Figure 4.4 A-C). Comparatively, ZIC3 protein variants that alter critical amino acids within the 
first zinc finger (C253S, W255G, C268X) demonstrated decreased Wnt inhibition at varying degrees, 
indicated by increased luciferase values compared to wildtype protein. None of these proteins, 
however, completely lost the ability to repress Wnt signalling (Figure 4.4 A, C). Finally, missense 
mutations located outside the ZIC3 ZFD (G17S, S109C, P217A, A447G) were the only variant proteins, 
with the exception of H318N, that could repress Wnt signalling at a similar level to wildtype ZIC3 
(p>0.05; Figure 4.4 D) suggesting these mutations will not result in an elevated Wnt phenotype in vivo. 
Overall, all ZIC3 variant proteins had varied ability to inhibit Wnt signalling, with missense mutations 
outside the ZFD retaining normal ZIC3 function. 
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Figure 4.4: ZIC3 Heterotaxy-associated mutations have altered ability to repress Wnt signalling. 
HEK293T cells were transfected with a TOPflash reporter (TOP-β-gl-luc2), V5-tagged β-catenin-wt and 
a V5-tagged ZIC3 expression plasmid as shown. Luminescence was measured 24 hours post-
transfection in each of three internal replicate samples. (A-D) One representative experiment with 
error bars representing the SD between the three internal replicates. A western blot was performed 
to confirm expression of transfected proteins with anti-TBP as a loading control. (A’-D’) Pooled data 
from three independent repeats. Values depict the mean relative luciferase values. Error bars depict 
SEM. Different letters denote statistical differences of p<0.05 calculated via a two-way ANOVA with 
Fischer’s unprotected post hoc test, where a is statistically significant to b etc. 
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4.2.4 Human ZIC3 variants have altered TCF7L1 interaction 
The absent or relatively mild effect some ZIC3 missense mutant proteins exhibited on ZIC3 repressor 
activity in the TOPflash assay suggests that the ability of the variant proteins to interact with TCF7L1 
may be intact. Conversely, missense mutations within the first zinc finger and several nonsense 
mutations displayed reduced repressor activity, suggesting either the ability of these proteins to 
interact with TCF proteins is affected, or the mutation affects the interaction with other repressor 
machinery involved in transcriptional repression with ZIC3. 
To directly assess whether the ZIC3-variant proteins can still interact with TCF7L1, a BiFC assay was 
performed. For the BiFC assay, several ZIC3 variant expression constructs needed to be generated. 
Expression plasmid V1-hZIC3-wt was already available in the Arkell laboratory, whilst all 17 ZIC3 
variant cDNAs were cloned into the V1-ORF expression plasmid via Gateway recombination 
technology (section 2.2.5). Variant ZIC3-H318N was not made until after the assay was conducted and 
was therefore excluded from downstream analysis.  
To test the relative ability of the ZIC3-variant proteins to interact with TCF7L1 protein, HEK239T cells 
were co-transfected with V2-mTcf7l1 and either V1-hZIC3-wt or a V1-hZIC3-variant expression 
plasmid. Fluorescence intensity was measured 48 hours post-transfection and cells were lysed and 
assessed by SDS-PAGE and western blot (Figure 4.5). Wildtype ZIC3 resulted in approximately a 3-4 
fold increase in fluorescence relative to background levels. All ZIC3 variants tested interacted with 
TCF7L1 either at similar levels to wildtype ZIC3, or displayed an increase in fluorescence intensity, 
suggesting an increased interaction between the two proteins. Unexpectedly, the truncation 
mutations resulted in significantly higher fluorescence compared to wildtype ZIC3. ZIC3-Q249X was 
the only mutant to have a significantly reduced, but not absent, interaction with TCF7L1 (Figure 4.5 
B). Interestingly, Q249X and S252X differ by only 3 amino acids yet produce contrasting BiFC results: 
Q249X exhibits reduced fluorescence compared to wildtype ZIC3 whilst S252X produced increased 
fluorescence. This suggests that the ZIC3-TCF7L1 interaction site may encompass amino acids within 
this region.  
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Figure 4.5: ZIC3 Heterotaxy-associated mutants have altered interaction with TCF7L1. HEK239T cells 
were co-transfected with V2-mTcf7l1 and either V1-hZIC3-wt or a V1-hZIC3-variant expression 
plasmid. The mean fluorescence intensity emitted from each of three internal replicate samples was 
detected 48 hours post-transfection. Three independent experiments were performed. (A-D) Mean 
fluorescence intensity of three internal replicates from one representative experiment. Error bars 
represent the SD between the three internal replicates. A western blot was performed to confirm 
expression of transfected proteins. The primary antibody α-Tcf7l1 was used to detect V2-Tcf7l1, α-
GFP was used to detect V1-ZIC3 and α-TBP was used as a loading control. (A’-D’) Pooled data from 
three independent repeats. Values depict the mean relative luciferase values. Error bars depict SEM. 
Different letters denote statistical differences of p<0.05 calculated via a two-way ANOVA with 
Fischer’s unprotected post hoc test, where a is statistically significant to b etc. 
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4.2.5 Human ZIC3 variants have altered transactivation at a ZRE 
Several of the human ZIC3 variant proteins were able to inhibit Wnt signalling at a level comparable 
to wildtype ZIC3. Similarly, all variant proteins were able to interact with TCF7L1 through a BiFC assay, 
suggesting the mutations do not disrupt this protein-protein interaction and that the Wnt repressive 
function of some of these mutant proteins is likely still intact. In addition to this co-factor (repressor) 
function of the ZIC proteins, another more common function associated with the ZICs is to act as a 
transcriptional activator. Studies have demonstrated that the transcription and co-factor function of 
the ZICs can be separated as shown by the ZIC2 mutation C270S (Brown et al. 2005; Pourebrahim et 
al. 2011). This mutation lies within the second cysteine of the fourth zinc finger of ZIC2 and can no 
longer bind DNA. Consequently, ZIC2 C270S protein cannot activate transcription of target genes, yet 
the same mutant protein is still able to repress Wnt signalling in a cell based TOPflash assay, indicating 
these two functions of the ZICs can, in some instances, be mutually exclusive (i.e. a mutation affecting 
DNA dependent transcriptional activation may not affect the repressive function though protein-
protein interactions). It remains to be seen whether ZIC3s transcriptional activation ability is also 
impaired by the human Heterotaxy-associated mutations.  
To assess the transcription factor function of the ZIC3 mutant proteins, a ZIC luciferase assay was 
utilised. HEK293T cells were co-transfected with the p(Z3M2)6-β-gl-luc2 reporter construct and either 
the V5-Dest vector (to detect background luciferase), V5-hZIC3-wt or a V5-hZIC3-variant expression 
construct. Luciferase activity was measured 24 hours post-transfection and cells were lysed and 
assessed by SDS-PAGE and western blot (Figure 4.6). Compared to wildtype ZIC3, the mutant proteins 
had variable abilities to transactivate the reporter. All truncated proteins failed to stimulate reporter 
transcription, confirming the necessity of the ZFD in DNA dependent transcription. A similar result was 
seen with each missense mutation within the first zinc finger (C253S, W255G and H286R). Missense 
mutations G17C and S109C were the only two mutations able to elicit transcription at the same level 
as the wildtype protein, whilst mutants P217A and A447G had mildly reduced transactivation ability 
(Figure 4.6 B, p<0.05).  
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Figure 4.6: Heterotaxy-associated ZIC3 mutants have reduced ability to transactivate gene 
expression at a ZRE. HEK293T cells were transfected with the reporter construct p(Z3M2)6-β-gl-luc2 
(containing a ZRE) and a V5-tagged ZIC3 expression plasmid as shown. Luminescence was measured 
24 hours post-transfection in each of three internal replicate samples. (A-D) One representative 
experiment with error bars representing the SD between the three internal replicates. A western blot 
was performed to confirm expression of transfected proteins shown below. Anti V5 antibody was used 
to detect ZIC protein, while anti-TBP was used as a loading control. (A’-D’) Pooled data from three 
independent repeats. Values depict the mean relative luciferase values. Error bars depict SEM. 
Different letters denote statistical differences of p<0.05 calculated via a two-way ANOVA with 
Fischer’s unprotected post hoc test, where a is statistically significant to b etc. Assay from panel A and 
western blot from panel A and C performed by J. Ahmed, Arkell laboratory. 
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4.3 Discussion  
Mutation of ZIC3 is associated with Heterotaxy, a congenital abnormality that results in the abnormal 
arrangement of the internal thoraco-abdominal organs. There are currently 42 documented 
Heterotaxy-associated variants in human ZIC3. It is, however, unclear whether the reported variants 
are all pathogenic, and (if so) what the underlying molecular mechanism is. Given that ZIC3 has been 
shown to inhibit β-catenin mediated Wnt signalling in both in vivo and in vitro studies to prevent L-R 
axis defects (Fujimi et al. 2012; Cast et al. 2012; Ahmed et al. 2013) and that ZIC3 physically interacts 
with a known repressor of Wnt signalling, TCF7L1, when overexpressed in HEK293T cells (Chapter 3), 
it is possible that altered Wnt signalling underlies human cases of Heterotaxy. To test this hypothesis, 
17 of the reported Heterotaxy-associated ZIC3 variants were functionally assessed in cell based assays 
of Wnt activity and ZIC-TCF interaction. Additionally, to evaluate the alternative hypothesis (that ZIC3-
associated Heterotaxy arises due to a loss of ZIC3 transactivation factor activity), each ZIC3 variant 
was simultaneously assessed for the ability to transactivate gene expression at a ZRE. These analyses 
highlight the importance of the ZIC3 ZFD for both Wnt repression and transactivation. In most cases, 
mutation of ZIC3 leads to severely reduced transactivation ability and reduced Wnt repression. 
Missense mutations within the ZFD and truncating ZIC3 variants had the greatest effect on ZIC3 
function, while missense mutations outside the ZFD failed to substantially alter protein function, 
suggesting some identified variants may not be pathogenic. The data are consistent with altered Wnt 
signalling contributing to Heterotaxy, but do not rule out a critical role for ZIC3 as a classical 
transcription factor during establishment of the L-R embryonic axis. 
4.3.1 Functional analysis corroborates and extends previous work 
To date, only a subset of the 42 human ZIC3 variants have been functionally assessed, primarily in cell 
based nuclear localisation and transactivation assays using overexpressed proteins. Analyses in these 
studies of the transcription factor function of ZIC3 alone correlates with ZIC3 predominately being 
considered a DNA binding transcriptional regulator and not a cofactor. As shown in Table 4.3, the 
results presented here largely align with previously published studies. For example, all of the proteins 
examined in this Chapter were able to accumulate in the nucleus at an appreciable level. Wildtype 
ZIC3 is 85% nuclear. Comparatively, 13 (75%) of the variant proteins tested have a significant decrease 
in nuclear localisation. However, in most cases this was a small decrease, with only two proteins 
(E155X; 65% and Q292X; 66%) falling below 70% nuclear localisation. In contrast to the results 
presented here, two of the proteins that alter the first two zinc fingers (W255G and C253S) failed to 
substantially accumulate in the nucleus when examined in previous publications using NIH3T3 cells 
(Chhin et al. 2007; Hatayama et al. 2008).  
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Table 4.3: Summary of ZIC3 functional analysis from published and current data.  In silico prediction: D: probably Damaging or B: Benign as tested by 
Polyphen, De: Deleterious or T: Tolerated as tested by SIFT, DC: Disease causing or P: polymorphism as tested by Mutation Taster. 
Amino 
acid 
alteration 
In silico 
pathogenicity 
prediction 
Nuclear localisation Transactivation Wnt inhibition (TOPflash) 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
G17C D/De/DC Normal 
 
(Cowan et al. 
2014) 
Normal (88%) Normal 
 
(Cowan et al. 
2014) 
Normal  Normal 
Normal  (D’Alessandro 
et al. 2013b) 
S109C D/De/P Small 
decrease 
(Cowan et al. 
2014) 
Normal (86%) Normal  (Cowan et al. 
2014) 
Normal  Normal 
E155X  Large 
decrease 
(Cowan et al. 
2014) 
Decreased (65%) Decreased  (Cowan et al. 
2014) 
Ablated  Decreased 
Y199delfsX
19 
 Small 
decrease   
(Cowan et al. 
2014) 
Small decrease 
(73%) 
Decreased  (Cowan et al. 
2014) 
Ablated  Decreased 
P217A B/T/DC Small 
decrease 
(Cowan et al. 
2014) 
Normal (88%) Normal  (Cowan et al. 
2014) 
Decreased Normal (Fujimi et 
al. 2012) 
Normal 
Normal 
 
(Ware et al. 
2004) 
Increased  
 
(Ware et al. 
2004) 
Normal  
 
(D’Alessandro 
et al. 2013b) 
Q249X  No 
protein 
detected  
(Ware et al. 
2004) 
Small decrease 
(78%) 
Decreased  (Ware et al. 
2004) 
Ablated  Decreased 
S252X  Large 
decrease 
(Cowan et al. 
2014) 
Small decrease 
(76%) 
Decreased (Cowan et al. 
2014) 
Ablated  Decreased 
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Amino 
acid 
alteration 
In silico 
pathogenicity 
prediction 
Nuclear localisation Transactivation Wnt inhibition (TOPflash) 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
C253S D/De/DC Large 
decrease 
(Chhin et al. 
2007) 
Small decrease 
(79%) 
Decreased 
 
(Chhin et al. 
2007) 
 
Ablated  Decreased 
Small 
decrease 
(Ware et al. 
2004) 
Decreased  
 
(Ware et al. 
2004) 
Large 
decrease 
(Hatayama et 
al. 2008) 
Decreased (D’Alessandro 
et al. 2013b) 
W255G D/De/DC Large 
decrease 
(Chhin et al. 
2007) 
Small decrease 
(73%) 
Decreased  (Chhin et al. 
2007) 
Ablated Reduced Fujimi et 
al. 2012) 
Decreased 
Large 
decrease 
(Hatayama et 
al. 2008) 
C268X  Large 
decrease 
(Ware et al. 
2004) 
Small decrease 
(74%) 
Decreased Ware et al. 
2004) 
Ablated  Decreased 
H286R D/De/DC Large 
decrease  
(Chhin et al. 
2007) 
Small decrease 
(70%) 
Decreased  
 
(Chhin et al. 
2007) 
Ablated  Decreased 
Large 
decrease 
(Ware et al. 
2004) 
Decreased  (Ware et al. 
2004) 
Large 
decrease 
(Hatayama et 
al. 2008) 
E291GfsX53  Large 
decrease 
(Cowan et al. 
2014) 
Small decrease 
(77%) 
Decreased (Cowan et al. 
2014) 
Ablated  Decreased 
Q292X  Large 
decrease 
(Ware et al. 
2004) 
Decrease (66%) Decreased  (Ware et al. 
2004) 
Ablated  Decreased 
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Amino 
acid 
alteration 
In silico 
pathogenicity 
prediction 
Nuclear localisation Transactivation Wnt inhibition (TOPflash) 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
Published results Results from this 
thesis 
H318N D/T/DC Large 
decrease 
(Cowan et al. 
2014) 
Small decrease 
(82%) 
Decreased  (Cowan et al. 
2014) 
N/A  Normal 
E325Kfs*84    Small decrease 
(82%) 
  Ablated  Decreased 
K408X  Small 
decrease 
(Ware et al. 
2004) 
Small decrease 
(82%) 
Decreased  (Ware et al. 
2004) 
Ablated  Decreased 
A447G D/De/DC Small 
decrease 
(Cowan et al. 
2014) 
Normal (84%) Increased (Cowan et al. 
2014) 
Decreased  Normal 
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In another publication, however, Ware et al. 2004 found that the C253S variant protein did indeed 
accumulate in the nucleus to near wildtype levels, mirroring the results in this Chapter (Table 4.3). 
Given the differences in experimental protocols between each study (cell lines and level of 
overexpression), these proteins appear to have context dependent ability to accumulate within the 
nucleus. As the ZIC3 protein contains a cryptic NLS within the ZFD (Bedard et al. 2007; Hatayama et al. 
2008), it may be expected that the PTC containing variants which produce proteins that lack the entire 
ZFD (such as E155X, Y199delfsX19, Q249X and S252X) would be unable to localise to the nucleus. 
Despite this, it was found that each of these variants were able to accumulate within the nucleus at 
appreciable levels (Figure 4.3). It is likely that (as for the murine katun variant protein [Ahmed et al. 
2013]) these truncated proteins enter the nucleus via passive diffusion, since small proteins (less than 
~40 kDa) are known to do so (Wei et al. 2003). Whether these proteins use passive transport could be 
assessed by attaching a tag (such as eGFP) that will artificially increase the size of the ZIC3 protein and 
prevent diffusion through the nuclear membrane. 
The transactivation studies conducted here also confirm previous studies using either the herpes 
simplex thymidine kinase (TK) or the simian virus 40 (SV40) promoters (Koyabu et al. 2001a; Ware et 
al. 2004; Chhin et al. 2007; D’Alessandro et al. 2013a, b; Cowan et al. 2014). Although ZICs1-3 are able 
to stimulate transcription with either promoter (Mizugishi et al. 2001), neither promotor contains 
known ZIC DNA binding sequences nor are they considered in vivo ZIC protein targets. To test the ZIC3 
variant proteins ability to transactivate a ZRE, the transactivation assays conducted here utilised a 
synthetic enhancer developed in the Arkell laboratory, containing a consensus DNA binding sequence 
for ZIC3. In all but one case, the transactivation ability of the ZIC3 variants aligned with previously 
results; variant A447G exhibited a small decrease in TA ability here, whereas in a previous study 
(Cowan et al. 2014) it exhibited increased transactivation function (Table 4.3 and Table 4.4). 
Of the ZIC3 variants examined in this Chapter, only two had been previously examined for their ability 
to inhibit Wnt signalling (Table 4.3). Mutant proteins ZIC3-P217A and ZIC3-W255G were analysed by 
Fujimi et al. 2012 using a Xenopus TOPflash assay. The data presented here corroborates their finding 
that variant P217A is still able to repress reporter activation, while W255G has reduced repressor 
function. It should be noted, however, that the W255G variant failed to localise to the nucleus in the 
cell-based studies of Chhin et al. 2007 and Hatayama et al. 2008, and subcellular localisation was not 
assessed in the whole animal Xenopus TOPflash assay (Fujimi et al. 2012). In the cell-based assays 
presented here, the W255G protein did enter the nucleus but exhibited reduced inhibition of Wnt 
mediated transcription than the wildtype ZIC3 protein, suggesting that the decreased inhibition results 
from a change in the protein itself, rather than altered subcellular localisation. The tryptophan (W)  
 
143 
 
Table 4.4: Summary of functional properties of ZIC3 variants assessed in this Chapter 
 
 
Function assessed 
Transcription 
factor 
Co-factor 
Transactivation  TOPflash  BiFC  
ZIC3 
variant 
Empty vector - +++++ - 
wt ++++ + ++ 
G17C ++++ + ++ 
S109C ++++ + ++ 
E155X - +++++ +++++ 
Y199delfsX19 - +++ +++++ 
P217A +++ + ++ 
Q249X - +++ + 
S252X - +++ ++++ 
C253S - +++ +++ 
W255G - +++ +++ 
C268X - ++ ++++ 
H286R - ++ ++ 
E291Gfs53X - +++ +++ 
Q292X - ++++ ++++ 
H318N n/a + n/a 
E325LfsX84 - +++ ++++ 
K408X - ++++ ++++ 
A447G +++ + ++ 
1 For Transactivation and BiFC, ‘-’ denotes baseline activity and ‘+’ to ‘+++++’ indicates increasing activity, based 
on relative luminescence or fluorescence intensity within that assay.  
2 For TOPflash, ‘+’ indicates an inhibitory effect compared to ‘+++++’, which indicates no inhibition. 
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residue, affected in the W255G human variant, forms part of the CWCH2 motif in the first zinc finger 
of the ZIC3 protein. Although the ZFD is made of five tandem zinc fingers, the first two zinc fingers of 
the ZIC proteins form a single structural unit and share a hydrophobic core (Hatayama and Aruga 
2010). These zinc fingers don’t follow the standard Cys-Xn-Cys-Xn-His-Xn-His (C2H2) pattern of zinc 
finger composition seen in zinc fingers 3-5. Instead, the first two zinc fingers follow the pattern Cys-X-
Trp-Xn-Cys-Xn-His-Xn-His-Xn-Cys-X-Trp-Xn-Cys-Xn-His-Xn-His and hence termed the CWCH2 motif. It 
has been suggested that these zinc fingers do not directly bind DNA, but facilitate DNA binding by the 
other zinc fingers and have a more important role in protein-protein interactions (Hatayama and 
Aruga 2010; Houtmeyers et al. 2013). In the experiments conducted here, the W255G variant entered 
the nucleus but was not able to stimulate any transcription from the ZRE reporter construct, could still 
bind TCF7L1 and lost some (but not all) Wnt inhibition ability (Table 4.3 and Table 4.4). Taken together, 
this variant exhibits similar properties to other ZFD missense mutants and the data does not confirm 
a unique role for zinc fingers 1 and 2 versus zinc fingers 3-5 of ZIC3.
4.3.2 Some reported ZIC3 variants do not appear pathogenic 
All missense mutations outside the ZFD (ZIC3-G17C, -S109C, -P217A and -A447G) were able to inhibit 
Wnt signalling to the same degree as wildtype ZIC3 in the TOPflash assay. Similarly, the transactivation 
ability of variants G17C and S109C was indistinguishable from wildtype, whilst P217A and A447G 
showed a small but significant reduction in transactivation ability. The data suggests these four ZIC3 
variants are unlikely to be damaging mutations as they did not substantially alter ZIC protein function 
in the cell assays conducted. 
ZIC3 variant G17C was identified in a screen for mutations in 10 genes associated with L-R defects (De 
Luca et al. 2010). Two patients from the same family were identified as heterozygous for the ZIC3 
G17C variant, however both patients also harboured a secondary mutation either affecting the FOXH1 
or NKX2.5 genes. It was suggested the cardiac defects identified in these patients could be a result of 
either the second mutation alone or due to a compounded effect of both mutations. The same ZIC3 
variant was identified in two independent screens, and functional studies by both groups determined 
it did not alter transactivation compared to wildtype ZIC3 in overexpression reporter assays 
(D’Alessandro et al. 2013b; Cowan et al. 2014). I confirm and extend this data to show Wnt dependent 
inhibition is not altered, strongly suggesting this variant is neither damaging nor pathogenic.  
ZIC3 variant P217A was identified by Ware et al. 2004 as a sporadic mutation in a male patient with a 
cardiac defect. The variant has since been identified in five other Heterotaxy patients via two different 
studies (D’Alessandro et al. 2013b; Cowan et al. 2014). Notably, this variant has appeared in various 
control groups, including that of D’Alessandro et al. 2013 and in the 1000 Genomes project with a 
frequency of 0.0082. Similar to the G17C variant, prediction software suggests a deleterious effect of 
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the mutation, however the functional analyisis presented here suggests the variant retains normal 
ZIC3 function. Moreover, functional studies by D’Alessandro et al. 2013 also demonstrated the 
mutation does not alter transactivation (in NIH3T3 cells), nor does it alter protein interaction of ZIC3 
with GLI3 (Zhu et al. 2008).  
Finally, variants S109C and A447G were identified by Cowan et al. 2014 in a screen of 440 unrelated 
indviduals with Heterotaxy. Published data shows that both mutants exhibit a mild reduction of 
nuclear localisation and A447G exhibits increased transactivation at a SV40 luciferase reporter (Table 
4.3). Both mutations, however, displayed relatively minor functional deviation to wildtype ZIC3 in the 
assays described here and therefore there is only weak evidence to suggest these would be classified 
as damaging mutations.  
4.3.3 All PTC variants appear pathogenic 
It is generally predicted that transcripts containing a PTC (in a location that adheres to particular rules) 
will undergo NMD, thereby preventing accumulation of the truncated protein and ensuring a null 
allele. However, as previously stated, a murine Zic3 nonsense mutation (katun; in which the PTC meets 
the rule for NMD) is known to evade NMD at gastrulation and instead is predicted to encode a stable, 
truncated protein which lacks both transcription factor and co-factor function (Ahmed et al. 2013). It 
is therefore possible that some of the human ZIC3 nonsense alleles may also escape NMD. To 
understand whether the reported variants encode null alleles, each mutation was introduced into the 
ZIC3 cDNA, a strategy which prevents targeting of the PTC containing transcript for NMD due to the 
absence of intron/exon junctions. Each of the PTC variants tested here lack most (C268X, Q292X, 
K408X, E325LeufsX84, E291GlyfsX53), if not all (Q249X, S252X), of the ZFD. Despite this, they encode 
stable and nuclear localised truncated proteins. Consistent with the lack of the ZFD, the transactivation 
ability of each protein is abolished. Based on results from the closely related ZIC2 protein (in which 
the ZFD and C-terminus are required for Wnt inhibition; Pourebrahim et al. 2011) it was predicted 
each truncated ZIC3 protein would also lose the ability to inhibit Wnt signalling in the TOPflash assay. 
It was, however, found that the majority of truncated ZIC3 proteins have reduced (but not ablated) 
ability to inhibit TCF-dependent transcription. The only ZIC3 variant to lose all repressive function is 
ZIC3-E155X (Table 4.4) suggesting the first 155 amino acids of ZIC3 are not necessary for repression at 
WREs. Collectively, this analysis suggests that the ZIC3 nonsense alleles are pathogenic, regardless of 
the extent of NMD. Additionally, the data suggest that the ZIC3 N-terminus contains regions that 
contribute to transcriptional repression at WREs. There are several conserved domains located in the 
N-terminal region of ZIC3 that have yet to be assigned a definitive function, including conserved 
regions such as the ZOC and ZFNC domains. Moreover, although located within the first 50 amino acids 
(and thus present in the E155X protein), low complexity regions such as the alanine repeat have 
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previously been associated with Heterotaxy in humans (Brown et al. 2005) and could possess TCF-
dependent repressive function. 
4.3.4 Many Heterotaxy-associated variants stabilised the ZIC-TCF interaction 
In addition to the functional assays to examine transcription factor versus co-factor function, each 
variant protein was also assessed for interaction with TCF7L1. As can be seen in Table 4.4, a notable 
trend emerged from these experiments. Of the ten variant proteins that were substantially less able 
than wildtype ZIC3 to inhibit TCF-mediated transcription, nine exhibited increased relative 
fluorescence in a BiFC assay (indicating a stronger affinity for TCF7L1). This result was especially 
noteworthy because each of these variant proteins were either missing the ZFD or contained a 
missense mutation at a key ZFD residue, indicating the ZIC3 ZFD is dispensable for interaction. A 
previous study that mapped the ZIC2-TCF7L2 interacting domains showed the ZIC2 ZFD is necessary 
for this interaction (Pourebrahim et al. 2011). By analogy, it seemed likely that the highly homologous 
ZIC3 ZFD would also be essential for the ZIC3-TCF7L1 interaction. The increase in fluorescence seen in 
the BiFC assay conducted here could indicate several things. First, the ZIC3-TCF7L1 protein binding 
domain could potentially be located in the N-terminus of the ZIC3 protein, rather than the ZFD. 
Alternatively, the tertiary structure of the variant ZIC3 proteins could be altered in such a way that 
makes the TCF binding site on ZIC3 more accessible to the TCF7L1 compared to wildtype ZIC3 protein 
or allows the two Venus tags (V1 and V2) to interact with greater affinity. 
The only ZIC3 variant protein that displayed reduced fluorescence/interaction in the BiFC assay was 
Q249X which truncates immediately prior to the ZFD. In the functional assays this variant has reduced 
ability to inhibit TCF-dependent transcription and ablated transactivation ability relative to wildtype 
ZIC3. Comparatively, mutant S252X truncates just 3 amino acids after Q249X, yet has increased ZIC3-
TCF7L1 interaction relative to wildtype ZIC3. This could be interpreted to mean that the glutamine 
residue and/or the following two amino acids have a key role in TCF7L1 interaction. Indeed, the 
glutamine residue (Q), but not the serine (S), is located within the highly conserved ZIC3 ZFNC domain, 
potentially identifying a role for this domain in the ZIC3-TCF7L1 protein interaction. For example, the 
ZIC3 lysine residue K248, within the ZFNC, is targeted by the post-translational modification 
SUMOylation (Chen et al. 2013). In this process SUMO protein is covalently attached to the lysine 
amino acid and influences protein stability and subcellular localisation of the ZIC3 protein (Chen et al. 
2013). Due to the proximity of Q249 to K248, it is possible that variants within this domain may alter 
the SUMOylation process. Whether SUMOylation or the ZFNC domain are involved in the ZIC3-TCF7L1 
interaction will need to be further investigated, perhaps by altering the lysine residue to prevent 
SUMOylation or by deleting the ZFNC to investigate how this domain influences TCF7L1 interaction. 
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4.3.5 Additional molecules may be required for ZIC-TCF repression at WREs 
Given that ZIC and TCF co-expression consistently leads to inhibition of transcription at WREs, that ZIC 
and TCF proteins can bind one another, and that they can be co-immunoprecipitated with DNA at 
WREs in cell-based assays (Pourebrahim et al. 2011), a model has emerged in which the ZIC-TCF 
binding is associated with transcriptional repression (and conversely a lack of binding with enhanced 
transcription at WREs). Assuming the BiFC data presented in this Chapter is an accurate representation 
of the ZIC3-TCF7L1 interaction, based on the molecular model proposed, it may be expected that a 
stronger ZIC3-TCF7L1 interaction results in stronger transcriptional repression. In most cases 
examined here, however, increased ZIC3-TCF7L1 interaction correlated with increased transcription 
(i.e. less repression) in the TOPflash assay (Table 4.4). One explanation consistent with this is that the 
ZIC3 protein variants in these assays are unable to interact with one or more additional proteins that 
are also critical for transcriptional repression. 
Chromatin structure plays a large role in both transcriptional activation and repression, and when in 
a restrictive state prevents the access of RNA polymerase or other transcriptional regulators binding 
to DNA (Thiel et al. 2004). Published data suggests that ZIC proteins may be involved in chromatin 
modification. For example, in embryonic stem cells ZIC2 has been shown to interact with the Mbd3-
NuRD complex which has nucleosome remodelling and histone deacetylase activities (Luo et al. 2015). 
Furthermore, knockdown of ZIC2 was shown to affect expression of known Mbd3-NuRD targets. 
Whether these interactions are required for ZIC function in vivo, however, has not yet been examined. 
It is therefore possible that ZIC3 similarly interacts with NuRD complexes or other similar protein 
complexes to regulate nucleosome remodelling and gene expression. Additionally, TCF7L1 has been 
shown to recruit C-terminal binding protein (CtBP) and histone deacetylase 1 (HDAC1) proteins to 
repress transcription by stabilising chromatin in cell lines (Brannon et al. 1999; Eshelman et al. 2017). 
ZIC3 could perhaps provide a bridge between TCF proteins and these proteins. If the ZIC3 variant 
proteins retain TCF7L1 binding ability but are less able to recruit repressive machinery, increased 
expression at WREs would be observed. 
4.3.6 Increased ZIC3-TCF7L1 interaction correlates with decreased transactivation 
In every case in which the ZIC3 variant proteins exhibited increased TCF7L1 interaction compared to 
wildtype ZIC3, the variant protein was unable to stimulate transcription in the transactivation assay 
(Table 4.4). It is possible that this stronger affinity for TCF7L1 protein prevents ZIC3 from acting upon 
ZREs to function as a classical transcription factor. Indeed, the transactivation assay experiments 
presented here were conducted in a Wnt unstimulated state (similar to the BiFC experiments), and a 
lack of transcriptional activation could reflect ZIC3 proteins being sequestered by endogenous TCF7L1 
protein. To test this theory, the same transactivation assay can be conducted in a Wnt stimulated state 
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(which biases against ZIC-TCF interaction). This can be achieved by co-transfecting in a form of β-
catenin that drives high levels of Wnt signalling (such as the stabilised β-catenin delta N89 variant). 
Alternatively, Wnt signalling can be stimulated by using Wnt conditioned media (e.g. by the addition 
of a Wnt activator such as Wnt3A or by addition of CHIR99021, an inhibitor of GSK3) to drive high, yet 
controlled levels of Wnt activity. If ZIC3 is in fact sequestered by TCF protein, the sequestration will 
presumably be alleviated in a high Wnt state and result in increased transactivation ability by these 
ZIC3 protein variants. 
In summary, I have investigated the functional effects of 17 ZIC3 Heterotaxy-associated variants in 
well-established molecular cell-based assays. Based on the variants investigated, four human variants 
located outside the ZIC3 ZFD do not alter protein function in the assays examined, implying these 
variants are not pathogenic. Of those that do exhibit pathogenic qualities, it was not possible to 
distinguish whether the pathology associated with these variants is due to a loss of transcription factor 
function or due to a loss of ZIC3 as a Wnt co-repressor as both functions were altered. ZIC3 is likely to 
interact with other co-repressors/chromatin complexes to mediate its activity, and the variants 
examined in this Chapter suggest these interactions are also affected.  
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Chapter 5: Can the transcription factor and co-factor functions of 
ZIC3 be separated? 
5.1 Introduction 
ZIC proteins are unusual in that they can influence transcription in both a DNA binding and protein 
binding manner, however, it is not well understood how the ZICs can alternate between these two 
molecular functions or when each role is necessary during embryonic development. Molecular 
analysis of human Heterotaxy associated variants in Chapter 4 could not definitively determine which 
of the two functions of ZIC3 (transcription factor or co-factor) is the underlying mechanism responsible 
for the ZIC3-associated Heterotaxy phenotype, as no mutant protein affected one function without 
altering the other. This may suggest that both functions of ZIC3 are needed to prevent Heterotaxy. In 
order to determine whether only one function underlies ZIC3-associated Heterotaxy, two alleles are 
needed, that each affect one, but not the other, function of ZIC3. Once such mutations are identified, 
a detailed comparison of the respective mouse strains could reveal when and where these distinct 
functions are required during embryonic development. Whether these functions of ZIC3 can be 
separated, however, remains to be elucidated.  
5.1.1 Can these functions be separated? 
Evidence that the transcription factor and co-factor functions of ZIC proteins can be isolated comes 
from a Zic2 mouse allele. A variant of Zic2, that alters the second cysteine of the fourth zinc finger to 
a serine, can no longer bind DNA (Brown et al. 2005) and exhibits in vivo loss-of-function (Elms et al. 
2003). This mutant is still able to repress β-catenin mediated transcription in a TOPflash assay and 
bind TCF7L2 when overexpressed in cells (Pourebrahim et al. 2011), providing the first evidence that 
these two distinct functions of the ZICs and the location of these domains within the gene are 
independent of each other. This indicates that the resulting Zic2 mouse mutant phenotype produced 
is a consequence of the loss of DNA binding only and not due to a loss of a co-factor role (such as 
interaction with TCF proteins or a loss of Wnt inhibition). The same mutation is yet to be identified 
within the other ZIC family members, and the inverse mutation has not been identified in any ZIC 
protein, i.e. a mutation that results in a loss of Wnt inhibition but retains DNA binding/transactivation 
activity. Understanding the role of ZIC3 during development would be greatly heightened by 
identification of both of these mutations within the ZIC3 gene.  
5.1.2 A screen for mutations that separate function 
Identification of these mutations will be accelerated by understanding the specific functional domains 
within ZIC3. Currently, however, there is limited knowledge surrounding where the functional 
domains within the ZIC proteins lie and often large regions of the protein are assigned overlapping 
150 
 
functions. For example, the ZIC ZFD has been implicated in both DNA binding and protein binding 
activities (Brown et al. 2005; Pourebrahim et al. 2011). Badis et al. 2009 conducted a protein binding 
microarray using the purified ZIC3 ZFD and identified a DNA motif bound by the ZFD. Additionally, 
mutations within the ZFD of ZIC proteins can result in a loss of DNA binding as demonstrated by EMSA 
assays and, consequently, alter transcriptional activation in cell based overexpression assays (Brown 
et al. 2005). Published data also suggests that the ZIC ZFD is necessary for protein-protein interactions, 
particularly in terms of TCF binding and Wnt transcriptional repression. ZIC2 deletion constructs 
lacking the ZFD and C-terminus could no longer bind TCF7L2 protein or repress TOPflash reporter 
activity (Pourebrahim et al. 2011). This study, however, used large deletion mutants of ZIC2 without 
confirming nuclear localisation of the truncated proteins (the site within the cell the ZIC-TCF 
interaction occurs). However, given the ZFD of ZIC2 and ZIC3 differ by only 14 amino acids, the ZFD is 
also predicted to be the site where ZIC3 binds TCF proteins, and necessary for Wnt repression. 
One difficulty in interpreting these results is evidence suggesting there are ‘subdomains’ within each 
identified functional domain, or that multiple regions are necessary for protein function. For example, 
as mentioned previously, there is some evidence to suggest that not all five zinc fingers participate in 
DNA binding. The first two zinc fingers of the ZFD share a hydrophobic core and form a single structural 
unit termed the CWCH2 motif. This motif is characterised by the presence of a tryptophan (W) residue 
between the two canonical cysteines of each zinc finger (Aruga et al. 2006) as well as an increased 
linker sequence between the two zinc fingers. Due to these features it is suggested that this motif may 
not contain canonical (i.e. DNA binding) zinc fingers but instead may facilitate DNA binding by zinc 
fingers 3-5, however further analysis is required to confirm these findings (Hatayama and Aruga 2010; 
Houtmeyers et al. 2013). Nevertheless, as a Zic2 variant affecting the fourth zinc finger (described 
above) affects the transcription factor, but not co-factor, function of ZIC2, perhaps not all zinc fingers 
are required for each role and a similar mutation affecting the ZIC3 ZFD may also separate these 
functions. Similarly, as the ZFD was found to be necessary for TCF interaction, it would be expected 
that proteins lacking the ZFD would no longer interact with TCF proteins. Despite this, ZIC3 human 
nonsense and frameshift mutations (investigated in Chapter 4) that truncate within or prior to the ZFD 
could interact with TCF7L1 in a BiFC assay and were still able to inhibit Wnt signalling in the cell based 
TOPflash assays (albeit at lower levels to wildtype), suggesting that there are N-terminal regions of 
the ZIC3 protein that are involved in repressing Wnt dependent transcription. Further domain 
mapping experiments are therefore necessary to determine if the ZIC3 Wnt repressor domain can be 
focused to a more isolated area within the ZFD, or to another region outside the ZFD of the ZIC3 
protein.  
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In mapping these domains, it would be logical to assume that the domains required for each function 
of ZIC3 be localised to a conserved region. There are several evolutionary conserved regions in the ZIC 
proteins including the ZOC, ZFNC, SANC, SACC and also several low complexity regions that have not 
been assigned a functional role despite their strong conservation. It is possible that some of these 
domains contribute, at least in part, to the transcription factor or co-factor function of the ZIC 
proteins. Indeed, low complexity regions such as those found in the ZIC proteins are characteristic of 
intrinsic disorder, a term used to describe proteins or regions of proteins that lack a conventional, 
well-defined tertiary structure in their native state. Instead, disordered proteins, or regions of 
disorder, are unstructured but will fold into a more structured conformation upon binding to their 
target or in response to post-translational modifications (Mészáros et al. 2007; Dyson 2016). This 
flexibility in structure appears to confer multiple advantages including the ability to interact with 
numerous binding partners. Additionally, it enables interactions with high specificity, but low affinity, 
which facilitates the rapid disassembly of the protein complex (Dyson and Wright 2005; Dyson 2016). 
This structural polymorphism allows disordered proteins to be involved in a vast array of biological 
processes and protein functions, such as accessibility to post translational modifications, involvement 
in cell signalling, control of the cell cycle and transcriptional activation (Mészáros et al. 2007). 
Consequently, identification of disordered regions within ZIC3 may indicate regions important for one 
specific function. 
5.1.3 Chapter Aims 
The ZIC3 protein contains many conserved domains but not all have a well characterised function. This 
chapter will investigate putative functional domains of the ZIC3 protein via TOPflash, BiFC and 
transactivation assays. The goal of this chapter is to identify a mutation in ZIC3 that ablates only one 
ZIC3 protein function (i.e. either the transcription factor function or the co-factor function), but not 
both. Specifically, this chapter will investigate whether: 
i) Evolutionary conserved domains within ZIC3 are required for Wnt inhibition 
ii) Individual zinc fingers within ZIC3 contribute differently to Wnt inhibition 
iii) Evolutionary conserved domain within ZIC3 are required for transactivation 
iv) Individual zinc fingers within ZIC3 contribute differently to transactivation 
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5.2 Results 
5.2.1 ZIC proteins contain intrinsically disordered regions 
As protein-protein interaction domains and transactivation domains can be associated with intrinsic 
disorder (Liu et al. 2006; Shammas 2017), the ZIC proteins were screened for disordered regions 
outside of the ZFD. Computer algorithms can predict disordered proteins or regions of disorder from 
sequence composition since disorder is characterised by a high concentration of charged and polar 
amino acids and a low prevalence of hydrophilic residues (Dyson and Wright 2005; Mészáros et al. 
2018). There are several online bioinformatics prediction tools available to determine the tendency of 
a protein to be disordered. One of these, IUPred2A, was used to assess the level of disorder predicted 
to occupy the protein sequence of the human ZIC proteins (ZIC1-5) (Mészáros et al. 2018). The 
program provides intrinsic disorder predictions using both IUPred2 and ANCHOR2 algorithms. The 
output from the analysis is a graph showing the disorder tendency of each residue of the protein. 
Higher values indicate predicted disordered regions, while lower values suggest protein order. 
Analysis of the human ZICs identifies intrinsically disordered regions in the residues adjacent to the 
ZFD, with only minimal disorder predicted within the ZFD itself for each of the five proteins (Figure 
5.1). For example, in all human ZIC proteins, the C-terminus is predicted to be almost completely 
disordered as are multiple regions of the N-terminal regions. ZIC3 contains several predicted regions 
of disorder within the N-terminal region some of which overlap with conserved domains. For example, 
the ZIC3 ZOC, SANC, SACC domains and histidine repeat were predicted to be disordered regions by 
both algorithms, while the alanine repeat was predicted to be a disordered region by the ANCHOR2 
algorithm but not IUPred2 (Figure 5.1). 
In addition to exhibiting intrinsic disorder, domains directly involved in protein function, such as a 
transactivation domain or other protein binding domains are likely to be conserved. Given that 
annotated domains such as the ZOC, ZFNC, SANC, SACC and low complexity regions are conserved 
both across species and within the ZIC protein family, it is likely these domains contribute somewhat 
to protein function. Taken together, it is possible these conserved regions play a currently 
unrecognised role in ZIC protein function.  
To investigate whether these conserved regions contribute to the function of ZIC3, each region was 
selectively deleted from wildtype ZIC3 (Figure 5.2). The N’ terminal region of the ZIC proteins has not 
yet been assigned a particular function and truncation mutations lacking part or all of the ZFD 
(assessed in Chapter 4) did not lose all inhibitory function, suggesting there is some N-terminal regions 
of ZIC3 that play a role in Wnt inhibition. Overall, seven deletion constructs were generated to study  
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Figure 5.1: ZIC proteins are predicted to have intrinsically disordered regions. IUPred2 was used to 
predict disorder within each of the five human ZIC proteins and displays outputs from IUPred and 
ANCHOR2 algorithms (red and blue output, respectively). A score between 0-0.5 (threshold line) 
indicates predicted order for each residue, whilst a score of 0.5-1 indicates a predicted disordered 
region of the protein. ZOC: Zic-opa conserved, ZFNC; zinc finger N-terminus conserved, SANC: Subclass 
A N terminally conserved, SACC: Subclass A C terminally conserved. 
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Figure 5.2: Schematic representation of the protein structure of ZIC3 deletion mutations. Seven 
evolutionary conserved domains within the ZIC3 protein were selectively deleted from the ZIC3 coding 
sequence via site directed mutagenesis to produce expression constructs lacking the specific domains. 
Additionally, the entire N-terminal domain prior to the ZIC3 zinc finger domain (ZFD) was deleted to 
produce a ZIC3 protein with the ZFD and C-terminus only (termed N’-del). ZOC: Zic-opa conserved, 
ZFNC; zinc finger N-terminus conserved, SANC: Subclass A N terminally conserved, SACC: Subclass A C 
terminally conserved. 
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the function of evolutionary conserved domains within the ZIC3 protein. The ZOC, ZFNC, SANC, SACC 
domains, as well as the alanine repeat, histidine repeat and the entire N ’domain prior to the ZFD was 
deleted from ZIC3 (producing a protein that contains only the ZFD and C-terminal region) via site-
directed mutagenesis to generate seven expression constructs to study protein function. 
Additionally, individual zinc fingers were targeted for mutation to determine whether each zinc finger 
contributes differently to ZIC3 function. The importance of the ZIC ZFD has been well documented for 
both DNA binding and protein interaction (Lim et al. 2007; Pourebrahim et al. 2011). Published data 
on the CWCH2 motif suggests that the zinc fingers do not undertake the same role. To investigate 
whether individual zinc fingers contributes more or less to Wnt inhibition, and to localise the ZIC3-
TCF7L1 interaction to a more specific region within the ZFD, each zinc finger was selectively targeted 
by a single amino acid substitution. A missense mutation was introduced into ZIC3 that altered the 
second cysteine of each zinc finger to a serine, generating five mutant constructs affecting the ZFD 
(C268S, C302S, C335S, C365S and C393S) (Figure 5.3). The cysteine residue is directly involved in 
complexing the zinc ion that makes each C2H2 zinc finger. Alteration of the cysteine residue results in 
the amino acid residue unable to chelate the zinc ion which ultimately destroys the zinc finger 
complex. It is predicted that this single amino acid substitution would disrupt each individual zinc 
finger, allowing for functional roles to be mapped to specific zinc fingers within this domain.  
Overall, 12 new ZIC3 variant proteins were generated. Each of the variant constructs were transferred 
to both the V5-Dest expression vector (to attach a V5-epitope tag to the N-terminus of the protein) 
for use in immunofluorescence, transactivation and TOPflash assays as well as the V1-ORF expression 
vector (to attach the N-terminal half of the Venus fluorescent tag to the N-terminus of the ZIC3 
protein) to be used in BiFC analysis, thereby generating 24 new ZIC3 expression constructs.  
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Figure 5.3: Schematic representation of the ZIC3 protein structure of targeted missense mutations.  
The second cysteine of each zinc finger was converted to serine through site directed mutagenesis. 
Position of each mutation (cysteine to serine) is outlined above and the amino acid change on each 
zinc finger is shown in red. ZOC: Zic-opa conserved, ZFNC; zinc finger N-terminus conserved, SANC: 
Subclass A N terminally conserved, SACC: Subclass A C terminally conserved, C: cysteine, H: histidine, 
S: serine 
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5.2.2 ZIC3 variants produce detectable protein that localise to the nucleus. 
Each of the 12 V5-ZIC3 variant expression constructs were transfected into HEK293T cells and 
subcellular localisation of the protein was assessed using standard immunofluorescence techniques. 
Each of the ZIC3 deletion mutations investigated produced detectable protein that localised to the 
nucleus (Figure 5.4). The N-terminal deletion had a small but significant increase in nuclear localisation 
while the deletion of the ZFNC and missense mutations C302S, C335S, C365S had slightly reduced, but 
significant, nuclear localisation compared to wildtype ZIC3. In all cases however, nuclear protein was 
above 80% and thus were deemed appropriate to use in downstream functional studies.  
5.2.3 Analysis of ZIC3 domains in Wnt repression and TCF7L1 protein interaction 
5.2.3.1 Deletion of well characterised ZIC3 domains alter WNT repression ability, but still interact 
with TCF7L1 
To determine which regions of the ZIC3 protein are required for Wnt inhibition, ZIC3 deletion proteins 
lacking specific conserved domains were assayed in the established TOPflash assay described in 
Chapter 4 (section 4.1.2). Additionally, a BiFC assay was used to determine whether the mutant 
proteins could still interact with TCF7L1. Deletion of the ZOC domain or the ZFNC domain did not 
significantly alter the repression ability of ZIC3 in the TOPflash assay, as these mutations inhibit 
transcription at the same level as wildtype ZIC3 (Figure 5.5). Similarly, the ZOC deletion could interact 
with TCF7L1 at a similar level to wildtype protein in the BiFC assay, but deletion of the ZFNC region 
reduced the ZIC3-TCF7L1 interaction. The reduced protein-protein interaction however does not 
produce a noticeable functional consequence in the TOPflash assay, as the ZFNC deletion did not 
significantly alter transcriptional inhibition compared to wildtype protein. The N-terminal deletion 
drove overstimulation at the TOPflash reporter as luciferase values were higher than when β-catenin 
was transfected alone, suggesting that despite the presence of the ZFD this mutant has lost all 
repression ability and instead adopts an activator role. Interestingly, even though this mutant protein 
lost its repressive function, it was still able to interact with TCF7L1 protein at stronger levels than 
wildtype ZIC3. This result suggests that the ZFD alone is not sufficient to inhibit β-catenin mediated 
transcription and that the N-terminus possesses regions necessary for ZIC3-mediated repression 
and/or correct protein conformation.  
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Figure 5.4: ZIC3 variant proteins localise to the nucleus.  HEK293T cells were transfected with the V5-
tagged ZIC3 expression constructs shown. 24 hours post-transfection, cells were prepared for 
immunofluorescence microscopy and stained with α-V5 antibody to detect the transfected V5-ZIC3 
proteins as well as α-LaminB1 to mark the nuclear membrane. Images of cells were captured with a 
fluorescent microscope and ImageJ software was used to determine the relative nuclear and 
cytoplasmic fluorescence intensity. Error bars represent standard error *: p<0.05 one-way ANOVA.  
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Figure 5.5: ZIC3 N-terminal regions have a role in Wnt inhibition.  (A) HEK293T cells were transfected 
with a TOPflash reporter, V5-tagged β-catenin-wt and a V5-tagged ZIC3 expression construct as 
shown. Luminescence was measured 24 hours post-transfection in each of three internal replicate 
samples. (B) HEK239T cells were co-transfected with pV2-TCF7L1 and either pV1-ZIC3-wt or a pV1-
ZIC3-variant expression plasmid. The mean fluorescence intensity emitted from each of three internal 
replicate samples was detected at 48 hours post-transfection. Three independent experiments were 
performed. (A, B) One representative experiment with error bars representing the SD between the 
three internal replicates. A western blot was performed to confirm expression of transfected proteins. 
For BiFC experiments α-GFP was used to detect V1-ZIC3 protein and α-TBP was used as a loading 
control for both experiments. (A’, B’) Pooled data from three independent repeats. Values depict the 
mean relative luciferase or fluorescent values. Error bars depict SEM. Different letters denote 
statistical differences of p<0.05 calculated via a two-way ANOVA with Fischer’s unprotected post hoc 
test, where a is statistically significant to b etc. 
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5.2.3.2 Subclass A conserved domains in Wnt signalling  
To investigate whether the subclass A conserved domains SANC and SACC also have a role in Wnt 
repression, ZIC3 constructs were generated that delete these two conserved domains from the 
protein. Following transfection in HEK293T cells for analysis in the TOPflash assay, both the SANC and 
SACC deletion mutants were able to inhibit Wnt signalling at the same level as wildtype ZIC3 
suggesting these regions do not have a role in the repression of β-catenin-mediated transcription 
(Figure 5.6). When assessed in the BiFC assay, the SANC deletion was able to interact with TCF7L1 at 
a similar level to wildtype ZIC3. Conversely, the SACC deletion mutant was able to interact with TCF7L1 
at a significantly stronger level than wildtype ZIC3. These results suggest that these two evolutionary 
conserved domains do not play a role in Wnt inhibition, however the SACC domain is required for 
normal protein-protein interactions.  
5.2.3.3 Low complexity regions in Wnt signalling 
Deletion of both the alanine and histidine repeat from ZIC3 did not significantly alter the ability to 
repress Wnt signalling compared to wildtype ZIC3 (Figure 5.7). Thereby suggesting the alanine and 
histidine repeat do not contribute to the repression of β-catenin-mediated transcription. Additionally, 
both the alanine and histidine deletions had a small but significant decrease in fluorescence in the 
BiFC assay (Figure 5.7), suggesting these mutants have decreased TCF7L1 interaction. Similar to the 
ZFNC deletion, the removal of these domains and consequent reduced TCF7L1 interaction does not 
impact the proteins ability to repress Wnt signalling in the TOPflash assay conditions used here. 
5.2.3.4 Zinc finger mutants in Wnt signalling 
When assessed in the cell based TOPflash assay, each of the five ZIC3 zinc finger mutant protein did 
not completely lose their Wnt repressive ability (Figure 5.8). Zinc finger variants C268S (ZF1), C302S 
(ZF2), C335S (ZF3), and C393S (ZF5) could inhibit at levels similar to wildtype ZIC3, whereas ZF4 (C365S) 
mutant protein had a small but significant decrease in repression ability compared to wildtype protein. 
Together, this would suggest that the ZFD does not play as big of a role in Wnt repression as previously 
thought and that, as expected, not all the zinc fingers have an equal role in Wnt inhibition. To confirm 
whether the relatively minor effect on Wnt repressive ability of the ZIC3 zinc finger variants is 
associated with normal TCF7L1 interaction, a BiFC assay was conducted. It was found that all zinc 
finger mutant proteins were able to interact with TCF7L1 at varying degrees (Figure 5.8). Only variant 
C302S, which affects the second zinc finger, interacts with TCF7L1 at the same level as wildtype ZIC3. 
ZIC3 variants C268S, C335S and C393S had a small but significant increase in TCF7L1 interaction, while 
C356S had a slight decrease in fluorescence, supporting the partial loss of repression in the TOPflash  
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Figure 5.6: ZIC3 subclass A conserved domains do not play a role in Wnt inhibition. (A) HEK293T cells 
were transfected with a TOPflash reporter, V5-tagged β-catenin-wt and a V5-tagged ZIC3 expression 
plasmid shown. Luminescence was measured 24 hours post transfection in each of three internal 
replicate samples. (B) HEK239T cells were co-transfected with pV2-TCF7L1 and either pV1-ZIC3-wt or 
pV1-ZIC3-variant expression plasmid. The mean fluorescence intensity emitted from each of three 
internal replicate samples was detected at 48 hours post transfection. Three independent 
experiments were performed. (A, B) One representative experiment with error bars representing the 
SD between the three internal replicates. A western blot was performed to confirm expression of 
transfected proteins. For BiFC experiments α-GFP was used to detect V1-ZIC3 protein and α-TBP was 
used as a loading control for both experiments. (A’, B’) Pooled data from three independent repeats. 
Values depict the mean relative luciferase or fluorescent values. Error bars depict SEM. a Different 
letters denote statistical differences of p<0.05 calculated via a two-way ANOVA with Fischer’s 
unprotected post hoc test, where a is statistically significant to b etc. 
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Figure 5.7: ZIC3 low complexity regions are required for normal protein interaction but are not 
needed for Wnt inhibition. (A) HEK293T cells were transfected with a TOPflash reporter, V5-tagged 
β-catenin-wt and a V5-tagged ZIC3 expression plasmid shown. Luminescence was measured 24 hours 
post-transfection in each of three internal replicate samples. (B) HEK239T cells were co-transfected 
with pV2-TCF7L1 and either pV1-ZIC3-wt or a pV1-ZIC3-variant expression plasmid. The mean 
fluorescence intensity emitted from each of three internal replicate samples was detected at 48 hours 
post transfection. Three independent experiments were performed. (A, B) One representative 
experiment with error bars representing the SD between the three internal replicates. A western blot 
was performed to confirm expression of transfected proteins. For BiFC experiments α-GFP was used 
to detect V1-ZIC3 protein and α-TBP was used as a loading control for both experiments. (A’, B’) 
Pooled data from three independent repeats. Values depict the mean relative luciferase or fluorescent 
values. Error bars depict SEM. Different letters denote statistical differences of p<0.05 calculated via 
a two-way ANOVA with Fischer’s unprotected post hoc test, where a is statistically significant to b etc.  
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Figure 5.8: ZIC3 zinc finger mutant proteins can still repress Wnt signalling and interact with TCF7L1.  
(A) HEK293T cells were transfected with a TOPflash reporter, V5-tagged β-catenin-wt and a V5-tagged 
ZIC3 expression plasmid shown. Luminescence was measured 24 hours post-transfection in each of 
three internal replicate samples. (B) HEK239T cells were co-transfected with pV2-TCF7L1 and either 
pV1-ZIC3-wt or a pV1-ZIC3-variant expression plasmid. The mean fluorescence intensity emitted from 
each of three internal replicate samples was detected at 48 hours post transfection. Three 
independent experiments were performed. (A, B) One representative experiment with error bars 
representing the SD between the three internal replicates. A western blot was performed to confirm 
expression of transfected proteins. For BiFC experiments α-GFP was used to detect V1-ZIC3 protein 
and α-TBP was used as a loading control for both experiments. (A’, B’) Pooled data from three 
independent repeats. Values depict the mean relative luciferase or fluorescent values. Error bars 
depict SEM. Different letters denote statistical differences of p<0.05 calculated via a two-way ANOVA 
with Fischer’s unprotected post hoc test, where a is statistically significant to b etc. 
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assay. Together this indicated that this zinc finger has a larger role in TCF7L1 mediated Wnt repression 
than the other zinc fingers. 
5.2.4 ZIC3 conserved domains are required for transactivation 
In addition to acting as a co-factor to inhibit Wnt signalling, ZIC proteins also act as transcription factors 
to regulate gene expression. Isolation of these protein functions would allow great insight into when 
and which ZIC3 function is necessary during development. Transcription factors require a DNA binding 
domain but also a transactivation domain, a region of the protein that interacts with transcriptional 
machinery to regulate target gene transcription. The ZFD of ZIC proteins has been implicated in DNA 
binding, but the transactivation domain is yet to be identified within the protein. Transactivation 
assays are routinely used to determine which regions of the protein are necessary for or sufficient to 
drive gene expression. To determine which regions of the ZIC3 protein are required for transactivation, 
the 12 structural ZIC3 deletion mutant proteins were assessed in the ZIC transactivation assay 
described in Chapter 4 (section 4.1.3). This work was performed in conjunction with Jerry Ahmed from 
the Arkell laboratory. 
HEK293T cells were transfected with a V5-tagged ZIC3 variant and the Z3M2:β-globin reporter 
construct to determine whether the transactivation ability is altered. Deletion of the ZOC or the ZFNC 
domain led to significantly increased stimulation of the Z3M2:β-globin reporter compared to wildtype 
ZIC3 (Figure 5.9), suggesting these domains contain repressive functions at this isolated DNA element. 
Conversely, when the entire N-terminal region prior to the ZFD was deleted, the protein could no 
longer stimulate a transcriptional response at the reporter (Figure 5.9). This suggests that the ZFD is 
not sufficient to elicit a transcriptional response in isolation at this reporter element and that there 
are N-terminal regions that are necessary for normal transcriptional activation.  
The SANC and SACC deletions could still activate transcription at the Z3M2:β-globin reporter, however 
this was at a reduced level compared to wildtype ZIC3 (Figure 5.9). Both these regions are therefore 
implicated in transactivation. Removal of these domains, however, does not completely abolish 
transcriptional activation, suggesting the transactivation domain is not restricted to one region of the 
protein. Removal of the alanine repeat did not significantly alter the proteins ability to activate 
transcription, however deletion of the Histidine repeat drove overstimulation at the Z3M2:β-globin 
reporter suggesting the Histidine also has a repressive role (Figure 5.9). Missense mutations affecting 
the second cysteine of each zinc finger were also assessed for their transactivation abilities. Each zinc 
finger mutant was unable to elicit a transcriptional response at the reporter, confirming the 
importance of the ZFD in transactivation.   
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Figure 5.9: Evolutionary conserved ZIC3 mutants have reduced ability to transactivate gene 
expression at a ZRE.  HEK293T cells were transfected with the reporter construct B:luc2:Z3M2- β-glo 
(containing a ZRE) and a V5-tagged ZIC3 expression plasmid shown. Luminescence was measured 24 
hours post-transfection in each of three internal replicate samples. (A-D) One representative 
experiment with error bars representing the SD between the three internal replicates. A western blot 
was performed to confirm expression of transfected proteins shown below and α-TBP was used as a 
loading control. (A’-D’) Pooled data from three independent repeats. Values depict the mean relative 
luciferase values. Error bars depict SEM. a Different letters denote statistical differences of p<0.05 
calculated via a two-way ANOVA with Fischer’s unprotected post hoc test, where a is statistically 
significant to b etc. Transactivation experiments performed by (Panel A) or in conjunction with (Panel 
C, D) J. Ahmed, Arkell laboratory.  
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5.3 Discussion  
The ZIC3 transcription factor is required at early embryogenesis to establish the L-R axis and prevent 
Heterotaxy in man and mouse. Recent advances in understanding ZIC3 molecular function 
demonstrate that ZIC3 can act as a classical transcription factor as well as a Wnt co-repressor (Ali et 
al. 2012; Houtmeyers et al. 2013). Consistent with this latter role, the murine Zic3 null phenotype can 
be interpreted as a Wnt gain-of-function effect. The ZIC3 Heterotaxy-associated variant proteins 
(investigated in Chapter 4), however, appear to alter both transcription factor and co-factor functions. 
One way to clarify whether one or the other molecular function is critical to prevent Heterotaxy is to 
produce a murine allele that disrupts one but leaves the other intact. To further the development of 
such an allele, in this Chapter I undertook a directed search for mutations in ZIC3 that may compromise 
one function but not the other. Several conserved domains were selectively deleted from the ZIC3 
protein and point mutations were introduced into the ZIC3 ZFD. Molecular assays were used to assess 
the role of these domains in each function, including their ability to inhibit Wnt signalling in a cell 
based TOPflash assay, interact with TCF7L1 via a BiFC assay and activate transcription at a ZRE. From 
this functional analysis, I identified several point mutations within the ZIC3 ZFD that abolish 
transactivation activity but retain Wnt repressive function. These variants affect a key cysteine residue 
of each zinc finger and are comparable to a missense mutation affecting the fourth zinc finger of ZIC2 
that similarly affects the transcription factor but not co-factor role of the protein (Brown et al. 2005). 
Overall, these mutations will be useful for determining whether the transactivation function of ZIC3 is 
necessary to prevent Heterotaxy by creating mouse models containing these variants and assessing 
the resulting phenotype.  
5.3.1 Separating transcription factor and co-factor functions of ZIC3 
Analysis of protein variants in this chapter showed that transcription factor and co-factor functions 
can indeed be separated within the ZIC3 protein. Several ZIC3 variant proteins were found to abolish 
transactivation ability, yet retain Wnt repressive function and TCF7L1 interaction (Table 5.1). For 
example, transactivation function alone was disrupted when single missense mutations were 
introduced that affect key residues within the ZFD. Most notably, when the second cysteine (C) of ZF2 
(C302) was substituted for a serine (S) residue, the ZIC3 protein was not able to transactivate at the 
ZRE, yet retained Wnt inhibition in the TOPflash assay and normal affinity for TCF7L1 in the BiFC assay. 
Therefore, the only function affected by this mutation was the ability to function as a transcription 
factor. Similarly, substituting the second cysteine of ZF1 (C268), ZF3 (C335) or ZF5 (C393) for a serine 
residue also abolished transactivation ability while retaining Wnt inhibition with very minor increased 
affinity for TCF7L1 protein (Table 5.1). Given the aim of understanding which of these functions  
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Table 5.1: Summary of functional properties of targeted ZIC3 variants 
 
1 For Transactivation and BiFC ‘-’ denotes baseline activity and ‘+’ to ‘+++++’ indicates increasing activity, based 
on relative luminescence or fluorescence intensity within that assay.  
2 For TOPflash ‘+’ indicates an inhibitory effect compared to ‘+++++’, which indicates no inhibition. 
 
 Function assessed 
Transcription 
factor 
Cofactor 
Transactivation 
(Z3M2) 
TOPflash  BiFC  
ZIC3 
variant 
Empty vector - +++++ - 
wt ++++ + ++ 
ZOCdel ++++++ + ++ 
ZFNCdel +++++ + + 
N’del - ++++++ ++++ 
SANCdel +++ + ++ 
SACCdel +++ + ++++ 
Aladel ++++ + + 
Hisdel +++++ + + 
C268S (ZF1) - + +++ 
C302S (ZF2) - + ++ 
C335S (ZF3) - + +++ 
C365S (ZF4) - ++ + 
C393S (ZF5) - + +++ 
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prevents Heterotaxy, it is now imperative that a mouse model be created that contains one of these 
ZIC3 variants, preferably C302S (ZF2), as the only function altered was the transactivation function. 
Analysis of this mouse phenotype (eg identification of laterality defects in developing embryos) would 
allow insight into whether transactivation ability is required to prevent Heterotaxy as no current Zic3 
mouse allele exists that separates these functions. 
In all cases, it is not known whether the amino acid deletions or alterations change the 3-dimentional 
structure of the protein and/or result in a loss of DNA binding. An equivalent mutation affecting the 
second cysteine of the fourth zinc finger of the ZIC2 protein was shown to ablate DNA binding (Brown 
et al. 2005). Due to the homology of the ZIC ZFDs, it is presumed that the cysteine-to-serine mutations 
would also affect DNA binding of ZIC3. Therefore the loss of reporter activation could be due to a loss 
of DNA binding and not due to alteration to the transactivation domain. This can be confirmed through 
DNA binding assays such as ChIP or EMSA experiments. These DNA binding experiments could similarly 
be used to assess all the other mutations to determine whether it is DNA binding or the transactivation 
domain that is affected by the mutation. 
Ideally, the mouse studies proposed above would be augmented by the production of a mouse in 
which transactivation is intact but Wnt inhibition is lost. However, such a mutation was not found via 
this study. Similar to all of the ZIC3 variants investigated in Chapter 4, loss of Wnt inhibition was always 
accompanied by loss of transactivation. All deletion mutations in this Chapter, with the exception of 
the N-terminal deletion, were able to inhibit β-catenin mediated Wnt signalling, albeit with different 
interaction levels with TCF7L1. In fact, in the majority of cases, any change to the TCF7L1 interaction 
(with either increased or reduced affinity) did not significantly influence the inhibition ability in the 
TOPflash assay (Table 5.1). The N-terminal deletion was the only ZIC3 variant investigated in this 
Chapter to lose Wnt repressive function, implicating regions outside the ZFD for Wnt inhibition. 
Interestingly, this protein could still interact with TCF7L1 in the BiFC assay, suggesting that the 
interaction between ZIC3 and TCF7L1 is not sufficient for Wnt repression. Instead, it is possible that 
the N-terminal region of ZIC3 contains uncharacterised domains necessary for repression independent 
of TCF7L1 binding. Under this scenario, the N-terminal region would contain domains necessary for 
interaction with one or more unidentified repressor molecules or repressive chromatin complexes. 
Given that the N-terminally deleted protein also lost transactivation ability, it is possible that the 
transactivation domain structures are co-located in this region. If these domains (i.e. co-repressor 
interaction and transactivation domain) overlap, it is possible this influences the molecular role of ZIC3 
(as a transcription factor or co-factor) in a given situation. For example, the co-expression of the 
repressive molecule(s) could bias against ZIC3 functioning as a classical transcription factor. 
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5.3.2 How does ZIC3 bind TCF7L1? 
Published domain mapping experiments by Pourebrahim et al. 2011, determined that the ZIC2 ZFD is 
necessary for binding to TCF7L2 protein. Due to the high conservation of the ZIC ZFDs, it was expected 
that the ZFD of ZIC3 would be necessary for the interaction between TCF7L1. However, a ZIC3 
nonsense variant associated with human Heterotaxy (investigated in Chapter 4: ZIC3-S252X) truncates 
just prior to the ZIC3 ZFD and is still able to interact with TCF7L1 in the BiFC assay despite lacking the 
entire ZFD (Chapter 4, Table 4.4). In contrast, a ZIC2 deletion protein lacking the ZFD and C-terminus 
can no longer interact with TCF7L2 in a co-immunoprecipitation assay when overexpressed in 
HEK293T cells (Pourebrahim et al. 2011). This results suggests the ZIC3 ZFD is not necessary for this 
protein-protein interaction and is consistent with TCF7L1 binding occurring via the N-terminus of ZIC3. 
To investigate this further, an inverse protein was generated that lacks the N-terminal domain of ZIC3 
(i.e. contains the ZFD and C-terminus only), however, it was found that this N-terminal deletion (ZIC3-
N’del) could still interact with TCF7L1 in the BiFC assay (Table 5.1). While this might suggest that both 
the ZFD and N-terminal regions are sufficient for TCF7L1 interaction, it may be an artefact due to an 
extreme effect on the structure of one or both proteins.  
Alanine tract expansions are associated with pathology in ZIC genes (Brown et al. 2005; Cowan et al. 
2014), however it is not clear what the functional role of the domain is. Removal of the alanine or 
histidine repeats suggests these low complexity regions are needed for correct TCF7L1 interaction 
(Figure 5.7). Similarly, the deletion of the ZFNC domain reduced ZIC3-TCF7L1 interaction (Figure 5.6). 
Coupled with the fact that loss of all three of these domains not only results in a reduced affinity of 
ZIC3 for the TCF7L1 protein but also drives higher reporter gene activation at a ZRE (Table 5.1), it 
suggests these domains either contain some repressor properties (where loss of repressor domains 
lead to increased gene transactivation), but also provide further support to the model where reduced 
affinity for the TCF7L1 protein allows ZIC3 to function at an increased rate/greater capacity as a 
transcription factor. Overall, further domain mapping experiments are needed to isolate the ZIC3-
TCF7L1 binding domain, potentially through smaller deletions of ZIC3 protein regions or more targeted 
and specific amino acid substitutions. Furthermore, mutations directly targeting TCF7L1 should be 
assessed to identify the domain within TCF7L1 that interacts with ZIC3. 
5.3.3 These studies inform the search for the transactivation domain of ZIC3 
The ZFD of the ZIC proteins has been well characterised as the DNA binding domain of the protein. It 
is not known, however, where the transactivation domain is within the ZIC proteins. Analysis of 
variants investigated in this Chapter affecting domains outside of the ZFD suggest these regions are 
necessary for normal transactivation. For example, removal of the SANC domain, a region conserved 
in Subclass A ZIC proteins (ZIC1-3), could function as well as wildtype protein in both TOPflash and 
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BiFC assays, while had significantly reduced transactivation ability at the ZRE, suggesting this domain 
is necessary for reporter activation and may form part of the transactivation domain for ZIC3. Similarly, 
removal of the SACC domain significantly reduced reporter activation which also implicates this region 
in transactivation. Future studies should create a double mutant construct that lacks both the SANC 
and SACC domains and put it through these established cell-based assays to determine whether the 
loss of both these domains compounds the loss of transactivation at this reporter. This will identify 
whether they play a co-operative role in ZIC3 transactivation. Alternatively, as the SANC domain 
appears to play a greater role in transactivation at the ZRE tested in this study, this region could be 
further analysed by introducing missense mutations into the SANC domain, or by rearranging the 
domain to effectively scramble the amino acid sequence. This will assess function without deleting 
several amino acids and, presumably, result in a less severe protein conformational change. The 
function of this domain could also be tested in isolation using an artificial system such as the GAL4-
UAS fusion reporter system, a common method for identifying transcriptional regulatory domains 
(Weston and Bishop 1989; Pan and Pei 2003; Mizugishi et al. 2004). In this gain-of-function system, 
specific protein regions are fused to the DNA binding domain of the yeast transcription factor GAL4 
and transfected into mammalian cells along with a luciferase reporter (Ma 2018). The GAL4-DNA 
binding domain interacts with the luciferase reporter and if the transfected fusion protein contains 
sufficient transcriptional regulatory domains, the reporter will be activated and gene expression 
quantified.  
In summary, I have shown that mutations outside of the ZFD either reduce or increase transactivation 
ability of ZIC3, suggesting multiple regions combine to form the transactivation domain. Conversely, 
Wnt inhibition was relatively refractory to mutation and the experiments conducted here did not 
localise this function to a specific protein region. Importantly, these assays demonstrate the 
transcription factor and co-factor functions of ZIC3 can be separated and identifies mutations within 
the ZIC3 ZFD that affect transactivation but not Wnt repression. Therefore, a murine allele can be 
created to investigate whether the transactivation function of ZIC3 is required to prevent the 
Heterotaxy disorder, whilst further functional studies are required to identify a mutation that disrupts 
Wnt repression without affecting transactivation.  
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Chapter 6: Conclusion and Future Perspectives  
The overall aim of this project was to investigate the molecular mechanism underlying ZIC3-associated 
Heterotaxy, with the hypothesis that ZIC3 interacts with TCF7L1 to repress canonical Wnt signalling 
during mammalian gastrulation to enable correct development of the L-R axis. At the onset of this 
project, there was evidence to suggest ZIC3 has a role in restricting Wnt target gene expression in the 
developing embryo, as loss-of-function alleles of Zic3 resemble Wnt gain-of-function phenotypes in 
mouse studies. However, there was a lack of understanding regarding the molecular mechanism 
required for ZIC3 inhibition of this signalling pathway, and if (and how) elevated canonical Wnt 
signalling underlies human cases of Heterotaxy.  
The data presented in this thesis significantly advances our understanding of ZIC3’s molecular role in 
the Wnt pathway and identifies molecular functions affected by the ZIC3 Heterotaxy-associated 
protein variants. In Chapter 3, a variety of molecular assays were used to show that ZIC3 and TCF7L1 
proteins are capable of direct protein-protein interaction when overexpressed in HEK293T cells. 
Coupled with the fact that these genes, when mutated, give rise to the same phenotype and that both 
genes have overlapping expression patterns during mammalian gastrulation, I present a model in 
which ZIC3 interacts with TCF7L1 during gastrulation to inhibit Wnt signalling and ultimately prevent 
L-R axis defects. Overall, the analysis conducted in this thesis provides a prime opportunity for further 
study of ZIC3 function in the Wnt pathway and establishes a new understanding of ZIC3-associated 
Heterotaxy phenotypes.  
6.1 Future experiments to identify the ZIC3-TCF7L1 repressive complex 
Combined analysis from Chapter 4 and 5 suggests that ZIC3 must form a repressive complex not only 
with TCF7L1, but with additional protein(s) or repressive chromatin complexes to inhibit the 
transcription of Wnt target genes (Figure 6.1). Whether this additional repressive machinery interacts 
solely with ZIC3, or with both ZIC3 and TCF7L1 (i.e. has both ZIC3 and TCF7L1 binding domains) remains 
unknown, however, the experiments presented here warrant the search for this protein complex. One 
way this complex can be identified is through a CRISPR mutagenesis screen. For example, a CRISPR 
guide library can be employed to target and knockout HEK293T genes (such as the commercially 
available Brunello library, which targets 19,114 genes in the human genome via 76,441 guide RNAs; 
Doench et al. 2016) under traceable conditions. These screens are well-established means for 
identifying currently unknown interactions, as long as good reporter systems are in place. In such an 
assay, the TOPflash system, described and used in this thesis (along with transiently transfected ZIC3 
protein), can be used as the reporter to determine which genes/proteins are required for ZIC3  
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Figure 6.1 Final model for ZIC3 dependent repression of Wnt target genes. Molecular analysis 
strongly suggests that ZIC3 interacts with the TCF7L1 transcription factor to repress the transcription 
of Wnt target genes. Gene repression is likely accompanied by additional unknown repressor 
complexes that interact with the N-terminus of ZIC3.  
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dependent repression (with the aim to identify a mutation that directly disrupts the ZIC3 dependent 
inhibition). Once a target(s) is identified, a secondary screen can be performed to validate the gene(s) 
of interest and further protein binding assays to confirm an interaction between ZIC3 and/or TCF7L1.  
6.2 Canonical Wnt inhibition is a key player in the prevention of human Heterotaxy 
All ZIC3 Heterotaxy-associated protein variants investigated in this thesis displayed altered Wnt 
repression, yet the proteins also displayed absent or reduced transcription factor function. 
Consequently, it remains unknown which function is required to prevent Heterotaxy, and remains 
possible both functions are necessary to prevent the disorder. A key detail remains, however, in which 
transactivation is never solely affected in the Heterotaxy variants. Zinc finger variants investigated in 
Chapter 5, such as C302S, result in loss of transactivation and retain Wnt repression, demonstrating 
protein function can be separated. On the other hand, human variants assessed in Chapter 4 impair 
both functions and lead to Heterotaxy. Logically, one would have to assume that if the loss of 
transactivation alone was enough to cause Heterotaxy in humans, then ZIC3 variants that affect 
transactivation but retain Wnt repression (such as C302S), would appear in the Heterotaxy cohort. 
However, this is not the case as all the human variants have altered Wnt inhibition in parallel with 
transactivation function. This ultimately makes ZIC3’s role in the Wnt pathway the limiting factor and 
highly implicates it in Heterotaxy over the transcription factor role. Alternatively, Heterotaxy may only 
result as a combined effect when both functions are impaired. Although these molecular functions 
can be separated by mutating individual zinc fingers of the ZFD, a ZIC3 variant has not yet been 
identified that alters Wnt repression whilst keeping transactivation intact and indeed, it is unknown 
whether such a variant will exist. If this mutation (or a variant of TCF7L1 that disrupts the ZIC3-TCF7L1 
interaction) is identified, comparison of each allele individually as well as a double mutant (a cross 
with both alleles) mouse strain will identify whether the transactivation role, the cofactor role, or both 
functions are required for the correct development of the L-R axis.  
6.3 Effect of node development (and impact of L-R axis formation) in ZIC3 Heterotaxy 
variants 
Despite Zic3 being linked to Heterotaxy more than 20 years ago, the underlying cellular mechanisms 
relating to the correct development of cardiac structures and establishment of the L-R axis still remain 
unsolved. The work presented here, however, in combination with work from other members of the 
Arkell laboratory, extends our knowledge of ZIC3 function during gastrulation and supports a model 
for ZIC3’s role in the correct establishment of the L-R axis via inhibition of Wnt signalling through the 
following steps: 1) ZIC3 and TCF7L1 interact to inhibit Wnt signalling during gastrulation. 2) This leads 
to the correct formation of the embryonic node (via an unresolved mechanism) followed by 3) the 
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correct establishment of the L-R axis. The Arkell laboratory’s work using mouse models and cell-based 
assays, in conjunction with Xenopus gain-of-function studies suggesting that Zic3 regulates organiser 
and notochord formation by repressing β-catenin mediated Wnt signalling (Fujimi et al. 2012), leads 
us to propose a model underlying ZIC3 Heterotaxy associated cases. Firstly, elevated canonical Wnt 
signalling results from a lack of ZIC3-TCF7L1 dependent repression during gastrulation. This elevated 
Wnt signalling results in downstream effects such as node abnormalities. Consequently, it is assumed 
that the dysmorphic node disrupts the leftward flow of node fluid required for L-R determination and 
subsequently, the L-R axis is not correctly established resulting in CHDs and Heterotaxy. Importantly 
the work presented here is one of the first to link elevated Wnt signalling to human cases of 
Heterotaxy and this model not only supports the role of ZIC3 in the prevention on Heterotaxy, but also 
implicates Wnt genes and Wnt regulators in the development of Heterotaxy and therefore provides 
new directions for screening patients and explaining unsolved cases. 
To complement my molecular analysis regarding ZIC3 protein function, this study provides support for 
several areas of future in vivo work regarding L-R defects and the Wnt pathway. For example, although 
there is evidence that Zic3 loss-of-function alleles and Wnt gain-of-function alleles produce abnormal 
shaped nodes during gastrulation, it is unknown what molecular events result in the irregular node 
shape, nor is it known if these dysmorphic nodes are able to support a leftward flow of extracellular 
fluid and ultimately cause L-R defects. Future analysis could investigate whether the ZIC3 Heterotaxy 
variants that alter ZIC3 function also result in abnormal node development and if so, determine 
whether this node dysmorphology results in defective fluid flow across the node causing the 
Heterotaxy phenotype.  
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Appendix A: Plasmid Maps 
1. P(ZM2)6-β-gl-luc2 reporter plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. pTOP-β-gl-luc2 
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3. pENTR-3C  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. V5-Dest 
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5. V1-ORF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. ORF-V1 
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7. V2-ORF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. V2-Tcf7l1 
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9. Myc-Tcf7l1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. pENT3C-Tcf7l1 
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11. V5-β-catenin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12. pΔN89- β-catenin 
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13. V1-ZIC3-wt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14. V5-ZIC3-wt 
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Appendix B: ZIC expression is low in HEK cell lines  
 
 
 
 
Genevestigator was used to investigate the level of ZIC gene expression in cell lines. ZIC1, ZIC3, ZIC4 
and ZIC5 have low-medium expression in HEK cell lines, whilst ZIC2 expression is in the high range. 
  
185 
 
References 
Adli M (2018) The CRISPR tool kit for genome editing and beyond. Nat. Commun.  
Ahmed J (2015) Mapping Domains for ZIC3 Molecular Function.  
Ahmed JN, Ali RG, Warr N, et al (2013) A murine Zic3 transcript with a premature termination codon 
evades nonsense-mediated decay during axis formation. Dis Model Mech 6:755–767. doi: 
10.1242/dmm.011668\rdmm.011668 [pii] 
Ali RG, Bellchambers HM, Arkell RM (2012) Zinc fingers of the cerebellum (Zic): Transcription factors 
and co-factors. Int. J. Biochem. Cell Biol. 44:2065–2068. 
Alzahrani A (2017) Identification and Characterisation of Genes which are Critical for Murine 
Gastrulation.  
Arce L, Yokoyama NN, Waterman ML (2006) Diversity of LEF/TCF action in development and disease. 
Oncogene 25:7492–7504. doi: 10.1038/sj.onc.1210056 
Arkell RM, Fossat N, Tam PPLP (2013) Wnt signalling in mouse gastrulation and anterior 
development: new players in the pathway and signal output.  
Aruga J (2004) The role of Zic genes in neural development. Mol Cell Neurosci 26:205–221. doi: 
10.1016/j.mcn.2004.01.004 
Aruga J, Kamiya A, Takahashi H, et al (2006) A wide-range phylogenetic analysis of Zic proteins: 
Implications for correlations between protein structure conservation and body plan complexity. 
Genomics 87:783–792. doi: 10.1016/j.ygeno.2006.02.011 
Aruga J, Minowa O, Yaginuma H, et al (1998) Mouse Zic1 Is Involved in Cerebellar Development.  
Aruga J, Mizugishi K, Koseki H, et al (1999) Zic1 regulates the patterning of vertebral arches in 
cooperation with Gli3. Mech Dev 89:141–50. 
Aruga J, Nagai T, Tokuyama T, et al (1996a) The Mouse Zic Gene Family: Homologues of the 
Drosophila pair-rule gene odd- paired. J Biol Chem 271:1043–1047. 
Aruga J, Tohmonda T, Homma S, Mikoshiba K (2002) Zic1 Promotes the Expansion of Dorsal Neural 
Progenitors in Spinal Cord by Inhibiting Neuronal Differentiation. Dev Biol 244:329–341. doi: 
10.1006/dbio.2002.0598 
186 
 
Aruga J, Yokota N, Hashimoto M, et al (1994) A novel zinc finger protein, zic, is involved in 
neurogenesis, especially in the cell lineage of cerebellar granule cells. J Neurochem 63:1880–
1890. doi: 10.1046/j.1471-4159.1994.63051880.x 
Aruga J, Yozu  a, Hayashizaki Y, et al (1996b) Identification and characterization Zic gene family of 
Zic4 , a new member of the mouse. Gene 172:291–294. 
Badis G, Berger MF, Philippakis AA, et al (2009) Diversity and complexity in DNA recognition by 
transcription factors. Science 324:1720–3. doi: 10.1126/science.1162327 
Barratt K (2018) New aspects of ZIC2-associated Holoprosencephaly.  
Barratt KS, Glanville-Jones HC, Arkell RM (2014) The Zic2 gene directs the formation and function of 
node cilia to control cardiac situs. Genesis 52:626–35. doi: 10.1002/dvg.22767 
Bedard JEJ, Purnell JD, Ware SM (2007) Nuclear import and export signals are essential for proper 
cellular trafficking and function of ZIC3. Hum Mol Genet 16:187–198. doi: 10.1093/hmg/ddl461 
Behrens J, Jerchow BA, Würtele M, et al (1998) Functional interaction of an axin homolog, conductin, 
with β-catenin, APC, and GSK3β. Science (80- ). doi: 10.1126/science.280.5363.596 
Bell CJ, Dinwiddie DL, Miller NA, et al (2011) Carrier testing for severe childhood recessive diseases 
by next-generation sequencing. Sci Transl Med. doi: 10.1126/scitranslmed.3001756 
Bellchambers H (2015) Wnt responsive SUMOylation regulates ZIC protein activity to promote 
murine neural crest specification.  
Bellchambers HM, Ware SM (2018) ZIC3 in heterotaxy. In: Advances in Experimental Medicine and 
Biology.  
Belmont JW, Mohapatra B, Towbin JA, Ware SM (2004) Molecular genetics of heterotaxy syndromes. 
Curr Opin Cardiol 19:216–20. 
Benedyk MJ, Mullen JR, DiNardo S (1994) odd-paired: a zinc finger pair-rule protein required for the 
timely activation of engrailed and wingless in Drosophila embryos. Genes Dev 8:105–17. 
Blank MC, Grinberg I, Aryee E, et al (2011) Multiple developmental programs are altered by loss of 
Zic1 and Zic4 to cause Dandy-Walker malformation cerebellar pathogenesis. Development 
138:1207–16. doi: 10.1242/dev.054114 
187 
 
Bogani D, Warr N, Elms P, et al (2004) New semidominant mutations that affect mouse 
development. Genesis 40:109–117. doi: 10.1002/gene.20071 
Bonnafe E, Touka M, AitLounis A, et al (2004) The transcription factor RFX3 directs nodal cilium 
development and left-right asymmetry specification. Mol Cell Biol 24:4417–27. 
Brannon M, Brown JD, Bates R, et al (1999) XCtBP is a XTcf-3 co-repressor with roles throughout 
Xenopus development. Development 126:3159–70. 
Brantjes H (2001) All Tcf HMG box transcription factors interact with Groucho-related co-repressors. 
Nucleic Acids Res. doi: 10.1093/nar/29.7.1410 
Brayer KJ, Segal DJ (2008) Keep Your Fingers Off My DNA: Protein–Protein Interactions Mediated by 
C2H2 Zinc Finger Domains. Cell Biochem Biophys 50:111–131. doi: 10.1007/s12013-008-9008-5 
Brogna S, Wen J (2009) Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol.  
Brown L, Paraso M, Arkell R, Brown S (2005) In vitro analysis of partial loss-of-function ZIC2 
mutations in holoprosencephaly: alanine tract expansion modulates DNA binding and 
transactivation. doi: 10.1093/hmg/ddi037 
Brown LY, Odent S, David V, et al (2001) Holoprosencephaly due to mutations in ZIC2: alanine tract 
expansion mutations may be caused by parental somatic recombination. Hum Mol Genet 
10:791–796. 
Brückner A, Polge C, Lentze N, et al (2009) Yeast Two-Hybrid, a Powerful Tool for Systems Biology. 
Int J Mol Sci 10:2763–2788. doi: 10.3390/ijms10062763 
Cadigan KM, Peifer M (2009) Wnt signaling from development to disease: insights from model 
systems. Cold Spring Harb. Perspect. Biol.  
Carrel T, Purandare SM, Harrison W, et al (2000) The X-linked mouse mutation Bent tail is associated 
with a deletion of the Zic3 locus. Hum Mol Genet 9:1937–1942. 
Carvalho LR, Brinkmeier ML, Castinetti F, et al (2010) Corepressors TLE1 and TLE3 Interact with 
HESX1 and PROP1. Mol Endocrinol. doi: 10.1210/me.2008-0359 
Cast AE, Gao C, Amack JD, Ware SM (2012) An essential and highly conserved role for Zic3 in left–
right patterning, gastrulation and convergent extension morphogenesis. Dev Biol 364:22–31. 
188 
 
doi: 10.1016/J.YDBIO.2012.01.011 
Catana A, Apostu AP (2017) The determination factors of left-right asymmetry disorders- a short 
review. Clujul Med 90:139–146. doi: 10.15386/cjmed-701 
Cavallo RA, Cox RT, Moline MM, et al (1998) Drosophila Tcf and Groucho interact to repress Wingless 
signalling activity. Nature 395:604–608. doi: 10.1038/26982 
Chen L, Ma Y, Qian L, Wang J (2013) Sumoylation regulates nuclear localization and function of zinc 
finger transcription factor ZIC3. Biochim Biophys Acta - Mol Cell Res 1833:2725–2733. doi: 
10.1016/j.bbamcr.2013.07.009 
Chhin B, Hatayama M, Bozon D, et al (2007) Elucidation of penetrance variability of a ZIC3 mutation 
in a family with complex heart defects and functional analysis of ZIC3 mutations in the first zinc 
finger domain. Hum Mutat 28:563–570. doi: 10.1002/humu.20480 
Chinnadurai G (2002) CtBP, an unconventional transcriptional torepressor in development and 
oncogenesis. Mol. Cell  
Cimbora DM, Sakonju S (1995) Drosophila midgut morphogenesis requires the function of the 
segmentation gene odd-paired. Dev Biol. doi: 10.1006/dbio.1995.1171 
Conlon FL, Lyons KM, Takaesu N, et al (1994) A primary requirement for nodal in the formation and 
maintenance of the primitive streak in the mouse. Development 120:1919–28. 
Costello I, Nowotschin S, Sun X, et al (2015) Lhx1 functions together with Otx2, Foxa2, and Ldb1 to 
govern anterior mesendoderm, node, and midline development. Genes Dev 29:2108–22. doi: 
10.1101/gad.268979.115 
Cowan J, Tariq M, Ware SM (2014) Genetic and functional analyses of ZIC3 variants in congenital 
heart disease. Hum Mutat 35:66–75. doi: 10.1002/humu.22457 
Craig NL, Nash HA (1984) E. coli integration host factor binds to specific sites in DNA. Cell. doi: 
10.1016/0092-8674(84)90478-1 
Croce JC, McClay DR (2008) Evolution of the Wnt pathways. Methods Mol Biol 469:3–18. doi: 
10.1007/978-1-60327-469-2_1 
D’Alessandro LCA, Casey B, Siu VM (2013a) Situs Inversus Totalis and a Novel ZIC3 Mutation in a 
189 
 
Family with X-linked Heterotaxy. Congenit Heart Dis 8:E36–E40. doi: 10.1111/j.1747-
0803.2011.00602.x 
D’Alessandro LCA, Latney BC, Paluru PC, Goldmuntz E (2013b) The phenotypic spectrum of ZIC3 
mutations includes isolated d-transposition of the great arteries and double outlet right 
ventricle. Am J Med Genet A 161A:792–802. doi: 10.1002/ajmg.a.35849 
De Luca A, Sarkozy A, Consoli F, et al (2010) Familial transposition of the great arteries caused by 
multiple mutations in laterality genes. Heart 96:673–7. doi: 10.1136/hrt.2009.181685 
Delling M, Indzhykulian AA, Liu X, et al (2016) Primary cilia are not calcium-responsive 
mechanosensors. Nature. doi: 10.1038/nature17426 
Diamand KEM, Barratt KS, Arkell RM (2018) Overview of Rodent Zic Genes. In: Advances in 
experimental medicine and biology. pp 179–207 
Doench JG, Fusi N, Sullender M, et al (2016) Optimized sgRNA design to maximize activity and 
minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. doi: 10.1038/nbt.3437 
Dyson HJ (2016) Making Sense of Intrinsically Disordered Proteins. doi: 10.1016/j.bpj.2016.01.030 
Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell 
Biol 6:197–208. doi: 10.1038/nrm1589 
El Malti R, Liu H, Doray B, et al (2016) A systematic variant screening in familial cases of congenital 
heart defects demonstrates the usefulness of molecular genetics in this field. Eur J Hum Genet 
24:228–36. doi: 10.1038/ejhg.2015.105 
Elms P, Scurry A, Davies J, et al (2004) Overlapping and distinct expression domains of Zic2 and Zic3 
during mouse gastrulation. Gene Expr Patterns 4:505–511. doi: 10.1016/j.modgep.2004.03.003 
Elms P, Siggers P, Napper D, et al (2003) Zic2 is required for neural crest formation and hindbrain 
patterning during mouse development. Dev Biol 264:391–406. 
Eshelman MA, Shah M, Raup-Konsavage WM, et al (2017) TCF7L1 recruits CtBP and HDAC1 to 
repress DICKKOPF4 gene expression in human colorectal cancer cells. Biochem Biophys Res 
Commun 487:716–722. doi: 10.1016/j.bbrc.2017.04.123 
Field S, Riley K-L, Grimes DT, et al (2011) Pkd1l1 establishes left-right asymmetry and physically 
190 
 
interacts with Pkd2. Development. doi: 10.1242/dev.058149 
Fields S, Song OK (1989) A novel genetic system to detect protein-protein interactions. Nature. doi: 
10.1038/340245a0 
Fossat N, Jones V, Khoo P-L, et al (2011) Stringent requirement of a proper level of canonical WNT 
signalling activity for head formation in mouse embryo. Development 138:667–76. doi: 
10.1242/dev.052803 
Frank CL, Liu F, Wijayatunge R, et al (2015) Regulation of chromatin accessibility and Zic binding at 
enhancers in the developing cerebellum. Nat Neurosci 1–13. doi: 10.1038/nn.3995 
Fredriksson S, Gullberg M, Jarvius J, et al (2002) Protein detection using proximity-dependent DNA 
ligation assays. Nat Biotechnol. doi: 10.1038/nbt0502-473 
Fujimi TJ, Hatayama M, Aruga J (2012) Xenopus Zic3 controls notochord and organizer development 
through suppression of the Wnt/β-catenin signaling pathway. doi: 10.1016/j.ydbio.2011.10.026 
Funayama N, Fagotto F, McCrea P, Gumbiner BM (1995) Embryonic axis induction by the armadillo 
repeat domain of β-catenin: Evidence for intracellular signaling. J Cell Biol. doi: 
10.1083/jcb.128.5.959 
Furushima K, Murata T, Kiyonari H, Aizawa S (2005) Characterization ofOpr deficiency in mouse 
brain: Subtle defects in dorsomedial telencephalon and medioventral forebrain. Dev Dyn 
232:1056–1061. doi: 10.1002/dvdy.20253 
Furushima K, Murata T, Matsuo I, Aizawa S (2000) A new murine zinc finger gene, Opr. Mech Dev 
98:161–4. 
Garber ED (1952) “Bent-Tail,” A Dominant, Sex-Linked Mutation in the mouse.  
Gebbia M, Ferrero GB, Pilia G, et al (1997) X-linked situs abnormalities result from mutations in ZIC3. 
Nat Genet 17:305–308. doi: 10.1038/ng1197-305 
Gó Mez-Orte E, Sá Enz-Narciso B, Moreno S, Cabello J (2013) Multiple functions of the noncanonical 
Wnt pathway. Trends Genet 29:545–553. doi: 10.1016/j.tig.2013.06.003 
Grinberg I, Northrup H, Ardinger H, et al (2004) Heterozygous deletion of the linked genes ZIC1 and 
ZIC4 is involved in Dandy-Walker malformation. Nat Genet 36:1053–5. doi: 10.1038/ng1420 
191 
 
GrüNeberg H (1963) The pathology of development: a study of inherited skeletal disorders in 
animals.  
Gurumurthy CB, Lloyd KCK (2019) Generating mouse models for biomedical research: technological 
advances. Dis Model Mech. doi: 10.1242/dmm.029462 
Haegel H, Larue L, Ohsugi M, et al (1995) Lack of beta-catenin affects mouse development at 
gastrulation. Development 121:3529–37. 
Hamada F, Bienz M (2004) The APC tumor suppressor binds to C-terminal binding protein to divert 
nuclear β-catenin from TCF. Dev Cell. doi: 10.1016/j.devcel.2004.08.022 
Hatayama M, Aruga J (2010) Characterization of the tandem CWCH2 sequence motif: a hallmark of 
inter-zinc finger interactions.  
Hatayama M, Tomizawa T, Sakai-Kato K, et al (2008) Functional and structural basis of the nuclear 
localization signal in the ZIC3 zinc finger domain. Hum Mol Genet 17:3459–3473. doi: 
10.1093/hmg/ddn239 
He TC, Sparks AB, Rago C, et al (1998) Identification of c-MYC as a target of the APC pathway. Science 
281:1509–12. 
Herrera E, Brown L, Aruga J, et al (2003) Zic2 patterns binocular vision by specifying the uncrossed 
retinal projection. Cell 114:545–57. 
Herrmann C, Horn G, Spaargaren M, Wittinghofer A (1996) Differential interaction of the Ras family 
GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase 
and Ral-Guanine nucleotide exchange factor. J Biol Chem. doi: 10.1074/jbc.271.12.6794 
Hicks GR, Raikhel N V. (2003) Protein Import into the Nucleus: An Integrated View. Annu Rev Cell Dev 
Biol. doi: 10.1146/annurev.cb.11.110195.001103 
Hikasa H, Sokol SY (2013) Wnt signaling in vertebrate axis specification. Cold Spring Harb Perspect 
Biol 5:a007955. doi: 10.1101/cshperspect.a007955 
Hinde E, Cardarelli F, Digman MA, Gratton E (2010) In vivo pair correlation analysis of EGFP 
intranuclear diffusion reveals DNA-dependent molecular flow. Proc Natl Acad Sci. doi: 
10.1073/pnas.1006731107 
192 
 
Hinde E, Pandžić E, Yang Z, et al (2016) Quantifying the dynamics of the oligomeric transcription 
factor STAT3 by pair correlation of molecular brightness. Nat Commun 7:11047. doi: 
10.1038/ncomms11047 
Hirokawa N, Tanaka Y, Okada Y, Takeda S (2006) Nodal Flow and the Generation of Left-Right 
Asymmetry. Cell 125:33–45. doi: 10.1016/J.CELL.2006.03.002 
Houtmeyers R, Gainkam OT, Glanville-Jones HA, et al (2016) Zic2 mutation causes 
holoprosencephaly via disruption of NODAL signalling. Hum Mol Genet 25:3946–3959. doi: 
10.1093/hmg/ddw235 
Houtmeyers R, Souopgui J, Tejpar S, Arkell R (2013) The ZIC gene family encodes multi-functional 
proteins essential for patterning and morphogenesis. Cell Mol Life Sci 70:3791–811. doi: 
10.1007/s00018-013-1285-5 
Hrckulak D, Kolar M, Strnad H, Korinek V (2016) TCF/LEF Transcription Factors: An Update from the 
Internet Resources. Cancers (Basel). doi: 10.3390/cancers8070070 
Hruz T, Laule O, Szabo G, et al (2008) Genevestigator v3: a reference expression database for the 
meta-analysis of transcriptomes. Adv Bioinformatics. doi: 10.1155/2008/420747 
Huang L, Wilkinson MF (2012) Regulation of nonsense-mediated mRNA decay. Wiley Interdiscip. Rev. 
RNA  
Huelsken J, Vogel R, Brinkmann V, et al (2000) Requirement for β-catenin in anterior-posterior axis 
formation in mice. J Cell Biol. doi: 10.1083/jcb.148.3.567 
Inoue T, Hatayama M, Tohmonda T, et al (2004) Mouse Zic5 deficiency results in neural tube defects 
and hypoplasia of cephalic neural crest derivatives. Dev Biol 270:146–162. doi: 
10.1016/j.ydbio.2004.02.017 
Inoue T, Ota M, Mikoshiba K, Aruga J (2007) Zic2 and Zic3 synergistically control neurulation and 
segmentation of paraxial mesoderm in mouse embryo. Dev Biol 306:669–684. doi: 
10.1016/j.ydbio.2007.04.003 
Invitrogen (2005) ProQuest TM Two-Hybrid System A sensitive method for detecting protein-protein 
interactions.  
Iuchi S (2001) Three classes of C2H2 zinc finger proteins. Cell. Mol. Life Sci.  
193 
 
Jans DA, Xiao CY, Lam MHC (2000) Nuclear targeting signal recognition: A key control point in 
nuclear transport? BioEssays  
Jiang Z, Zhu L, Hu L, et al (2013) Zic3 is required in the extra-cardiac perinodal region of the lateral 
plate mesoderm for left-right patterning and heart development. Hum Mol Genet 22:879–89. 
doi: 10.1093/hmg/dds494 
Kelly OG (2004) The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. 
Development. doi: 10.1242/dev.01137 
Kerppola TK (2009) Visualization of molecular interactions using bimolecular fluorescence 
complementation analysis: Characteristics of protein fragment complementationw. doi: 
10.1039/b909638h 
Klootwijk R, Franke B, van der Zee CE, et al (2000) A deletion encompassing Zic3 in bent tail, a mouse 
model for X-linked neural tube defects. Hum Mol Genet 9:1615–22. 
Kodama Y, Hu C-D (2012) Bimolecular fluorescence complementation (BiFC): A 5-year update and 
future perspectives. Biotechniques. doi: 10.2144/000113943 
Komiya Y, Habas R (2008) Wnt signal transduction pathways. Organogenesis 4:68–75. 
Korinek V, Barker N, Moerer P, et al (1998) Depletion of epithelial stem-cell compartments in the 
small intestine of mice lacking Tcf-4. Nat Genet. doi: 10.1038/1270 
Korinek V, Barker N, Morin PJ, et al (1997) Constitutive transcriptional activation by a β-catenin-Tcf 
complex in APC(-/-) colon carcinoma. Science (80- ). doi: 10.1126/science.275.5307.1784 
Koyabu Y, Nakata K, Mizugishi K, et al (2001a) Physical and functional interactions between Zic and 
Gli proteins. J Biol Chem 276:6889–92. doi: 10.1074/jbc.C000773200 
Koyabu Y, Nakata K, Mizugishi K, et al (2001b) Physical and functional interactions between Zic and 
Gli proteins. doi: 10.1074/jbc.C000773200 
Lacks S, Greenberg B (1975) A deoxyribonuclease of Diplococcus pneumoniae specific for methylated 
DNA.  
Layden MJ, Meyer NP, Pang K, et al (2010) Expression and phylogenetic analysis of the zic gene 
family in the evolution and development of metazoans. Evodevo 1:12. doi: 10.1186/2041-9139-
194 
 
1-12 
Lee JD, Anderson K V. (2008) Morphogenesis of the node and notochord: The cellular basis for the 
establishment and maintenance of left-right asymmetry in the mouse. Dev. Dyn.  
Leuchowius K-J, Weibrecht I, Söderberg O (2011) In Situ Proximity Ligation Assay for Microscopy and 
Flow Cytometry. Curr Protoc Cytom 56:9.36.1-9.36.15. doi: 10.1002/0471142956.cy0936s56 
Li S, Liu S, Chen W, et al (2018) A novel ZIC3 gene mutation identified in patients with heterotaxy and 
congenital heart disease. Sci Rep 8:12386. doi: 10.1038/s41598-018-30204-3 
Lim LS, Hong FH, Kunarso G, Stanton LW (2010) The pluripotency regulator Zic3 is a direct activator 
of the Nanog promoter in ESCs. Stem Cells 28:1961–1969. doi: 10.1002/stem.527 
Lim LS, Loh Y-H, Zhang W, et al (2007) Zic3 is required for maintenance of pluripotency in embryonic 
stem cells. Mol Biol Cell 18:1348–58. doi: 10.1091/mbc.E06-07-0624 
Lin AE, Ticho BS, Houde K, et al (2000) Heterotaxy: Associated conditions and hospital-based 
prevalence in newborns.  
Liu C, Li Y, Semenov M, et al (2002) Control of β-catenin phosphorylation/degradation by a dual-
kinase mechanism. Cell. doi: 10.1016/S0092-8674(02)00685-2 
Liu J, Perumal NB, Oldfield CJ, et al (2006) Intrinsic disorder in transcription factors. Biochemistry. 
doi: 10.1021/bi0602718 
Lu F-I, Thisse C, Thisse B (2011) Identification and mechanism of regulation of the zebrafish dorsal 
determinant. Proc Natl Acad Sci. doi: 10.1073/pnas.1106801108 
Luo Z, Gao X, Lin C, et al (2015) Zic2 is an enhancer-binding factor required for embryonic stem cell 
specification. Mol Cell 57:685–694. doi: 10.1016/j.molcel.2015.01.007 
Ma J (2018) Promoter Fusions to Study Gene Expression. In: eLS.  
Ma L, Selamet Tierney ES, Lee T, et al (2012) Mutations in ZIC3 and ACVR2B are a common cause of 
heterotaxy and associated cardiovascular anomalies. Cardiol Young 22:194–201. doi: 
10.1017/S1047951111001181 
Macarthur DG, Manolio TA, Dimmock DP, et al (2014) Guidelines for investigating causality of 
sequence variants in human disease. Nature 508:469–476. doi: 10.1038/nature13127 
195 
 
MacDonald BT (2004) Hypomorphic expression of Dkk1 in the doubleridge mouse: dose dependence 
and compensatory interactions with Lrp6. Development. doi: 10.1242/dev.01126 
Maquat LE (2005) Nonsense-mediated mRNA decay in mammals. J Cell Sci. doi: 10.1242/jcs.01701 
McGrath J, Somlo S, Makova S, et al (2003) Two Populations of Node Monocilia Initiate Left-Right 
Asymmetry in the Mouse. Cell 114:61–73. doi: 10.1016/S0092-8674(03)00511-7 
Mégarbané A, Salem N, Stephan E, et al (2000) X-linked transposition of the great arteries and 
incomplete penetrance among males with a nonsense mutation in ZIC3. Eur J Hum Genet 
8:704–708. 
Mehla J, Caufield JH, Uetz P (2015) The yeast two-hybrid system: a tool for mapping protein-protein 
interactions. Cold Spring Harb Protoc 2015:425–30. doi: 10.1101/pdb.top083345 
Merrill BJ, Pasolli HA, Polak L, et al (2004) Tcf3: a transcriptional regulator of axis induction in the 
early embryo. Development 131:263–74. doi: 10.1242/dev.00935 
Mészáros B, Erdös G, Dosztányi Z (2018) IUPred2A: Context-dependent prediction of protein 
disorder as a function of redox state and protein binding. Nucleic Acids Res. doi: 
10.1093/nar/gky384 
Mészáros B, Tompa P, Simon I, Dosztányi Z (2007) Molecular Principles of the Interactions of 
Disordered Proteins. J Mol Biol. doi: 10.1016/j.jmb.2007.07.004 
Miller KE, Kim Y, Huh W-K, Park H-O (2015) Bimolecular Fluorescence Complementation (BiFC) 
Analysis: Advances and Recent Applications for Genome-Wide Interaction Studies. J Mol Biol 
427:2039–2055. doi: 10.1016/j.jmb.2015.03.005 
Mizugishi K, Aruga J, Nakata K, Mikoshiba K (2001) Molecular properties of Zic proteins as 
transcriptional regulators and their relationship to GLI proteins. J Biol Chem 276:2180–2188. 
doi: 10.1074/jbc.M004430200 
Mizugishi K, Hatayama M, Tohmonda T, et al (2004) Myogenic repressor I-mfa interferes with the 
function of Zic family proteins. Biochem Biophys Res Commun 320:233–240. doi: 
10.1016/j.bbrc.2004.05.158 
Morkel M, Huelsken J, Wakamiya M, et al (2003) -Catenin regulates Cripto- and Wnt3-dependent 
gene expression programs in mouse axis and mesoderm formation. Development 130:6283–
196 
 
6294. doi: 10.1242/dev.00859 
Mosimann C, Hausmann G, Basler K (2009) β-Catenin hits chromatin: regulation of Wnt target gene 
activation. Nat Rev Mol Cell Biol 10:276–286. doi: 10.1038/nrm2654 
Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al (2001) Dickkopf1 Is Required for Embryonic 
Head Induction and Limb Morphogenesis in the Mouse. Dev Cell 1:423–434. doi: 
10.1016/S1534-5807(01)00041-7 
Munemitsu S, Albert I, Rubinfeld B, Polakis P (1996) Deletion of an amino-terminal sequence beta-
catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor 
suppressor protein. Mol Cell Biol. doi: 10.1128/MCB.16.8.4088 
Murcia NS, Richards WG, Yoder BK, et al (2000) The Oak Ridge Polycystic Kidney (orpk) disease gene 
is required for left-right axis determination. Development 127:2347–55. 
Nagai T, Aruga J, Minowa O, et al (2000) Zic2 regulates the kinetics of neurulation. Proc Natl Acad Sci 
U S A 97:1618–23. 
Nagai T, Aruga J, Takada S, et al (1997) The expression of the mouse Zic1, Zic2, and Zic3 gene 
suggests an essential role for Zic genes in body pattern formation. Dev Biol 182:299–313. doi: 
10.1006/dbio.1996.8449 
Nagai T, Ibata K, Park ES, et al (2002) A variant of yellow fluorescent protein with fast and efficient 
maturation for cell-biological applications. Nat Biotechnol. doi: 10.1038/nbt0102-87 
Nakamura T, Saito D, Kawasumi A, et al (2012) Fluid flow and interlinked feedback loops establish 
left-right asymmetric decay of Cerl2 mRNA. Nat Commun. doi: 10.1038/ncomms2319 
Nauli SM, Alenghat FJ, Luo Y, et al (2003) Polycystins 1 and 2 mediate mechanosensation in the 
primary cilium of kidney cells. Nat Genet. doi: 10.1038/ng1076 
Nierode G, Kwon PS, Dordick JS, Kwon S-J (2016) Cell-Based Assay Design for High-Content Screening 
of Drug Candidates. J Microbiol Biotechnol 26:213–25. doi: 10.4014/jmb.1508.08007 
Nonaka S, Shiratori H, Saijoh Y, Hamada H (2002) Determination of left-right patterning of the mouse 
embryo by artificial nodal flow. Nature. doi: 10.1038/nature00849 
Nonaka S, Tanaka Y, Okada Y, et al (1998) Randomization of left-right asymmetry due to loss of nodal 
197 
 
cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. Cell 
95:829–37. 
Nonaka S, Yoshiba S, Watanabe D, et al (2005) De novo formation of left-right asymmetry by 
posterior tilt of nodal cilia. PLoS Biol 3:e268. doi: 10.1371/journal.pbio.0030268 
Norris DP (2012) Cilia, calcium and the basis of left-right asymmetry. BMC Biol. doi: 10.1186/1741-
7007-10-102 
Norton N, Robertson PD, Rieder MJ, et al (2012) Evaluating pathogenicity of rare variants from 
dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet. doi: 
10.1161/CIRCGENETICS.111.961805 
Norum JH, Bergström Å, Andersson AB, et al (2015) A conditional transgenic mouse line for targeted 
expression of the stem cell marker LGR5. Dev Biol. doi: 10.1016/j.ydbio.2015.05.002 
Nüsslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in 
Drosophila. Nature 287:795–801. doi: 10.1038/287795a0 
Ogura H, Aruga J, Mikoshiba K (2001) Behavioral abnormalities of Zic1 and Zic2 mutant mice: 
Implications as models for human neurological disorders. Behav Genet 31:317–324. doi: 
10.1023/A:1012235510600 
Okada Y, Takeda S, Tanaka Y, et al (2005) Mechanism of Nodal Flow: A Conserved Symmetry 
Breaking Event in Left-Right Axis Determination. Cell 121:633–644. doi: 
10.1016/j.cell.2005.04.008 
Pan GJ, Pei DQ (2003) Identification of two distinct transactivation domains in the pluripotency 
sustaining factor nanog. Cell Res. doi: 10.1038/sj.cr.7290193 
Paulussen ADC, Steyls A, Vanoevelen J, et al (2016) Rare novel variants in the ZIC3 gene cause X-
linked heterotaxy. Eur J Hum Genet 1–9. doi: 10.1038/ejhg.2016.91 
Pennekamp P, Karcher C, Fischer A, et al (2002) The ion channel polycystin-2 is required for left-right 
axis determination in mice. Curr Biol. doi: 10.1016/S0960-9822(02)00869-2 
Perantoni AO (2005) Inactivation of FGF8 in early mesoderm reveals an essential role in kidney 
development. Development. doi: 10.1242/dev.01945 
198 
 
Pérez-Pinera P, Menéndez-González M, Vega JA (2006) Deletion of DNA sequences of using a 
polymerase chain reaction based approach. Electron J Biotechnol. doi: 10.2225/vol9-issue5-
fulltext-10 
Pöpperl H, Schmidt C, Wilson V, et al (1997) Misexpression of Cwnt8C in the mouse induces an 
ectopic embryonic axis and causes a truncation of the anterior neuroectoderm. Development. 
doi: 7588062 
Pourebrahim R, Houtmeyers R, Ghogomu S, et al (2011) Transcription factor Zic2 inhibits Wnt/Beta-
catenin protein signaling. J Biol Chem 286:37732–37740. doi: 10.1074/jbc.M111.242826 
Presman DM, Ball DA, Paakinaho V, et al (2017) Quantifying transcription factor binding dynamics at 
the single-molecule level in live cells. Methods 123:76–88. doi: 10.1016/j.ymeth.2017.03.014 
Purandare SM (2002) Zic3 null mice model X-linked heterotaxy.  
Purandare SM, Ware SM, Kwan KM, et al (2002) A complex syndrome of left-right axis, central 
nervous system and axial skeleton defects in Zic3 mutant mice. Development 129:2293–2302. 
Quinn ME, Haaning A, Ware SM (2012) Preaxial polydactyly caused by Gli3 haploinsufficiency is 
rescued by Zic3 loss of function in mice. Hum Mol Genet 21:1888–96. doi: 
10.1093/hmg/dds002 
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